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Plasmodium falciparum malaria is an infectious disease considered to have great impact on public
health due to its associated high mortality rates especially in sub Saharan Africa. Falciparum drug-
resistant strains, notably, to chloroquine and sulfadoxine-pyrimethamine in Africa is traced mainly to
Southeast Asia where artemisinin resistance rate is increasing. Although careful surveillance to mon-
itor the emergence and spread of artemisinin-resistant parasite strains in Africa is on-going, research
into new drugs, particularly, for African populations, is critical since there is no replaceable drug for
artemisinin combination therapies (ACTs) yet.
Objective:
The overall objective of this study is to identify potential protein targets through host–pathogen
protein–protein functional interaction network analysis to understand the underlying mechanisms of
drug failure and identify those essential targets that can play their role in predicting potential drug
candidates specific to the African populations through a protein-based approach of both host and
Plasmodium falciparum genomic analysis.
Methods:
We leveraged malaria-specific genome wide association study summary statistics data obtained from
Gambia, Kenya and Malawi populations, Plasmodium falciparum selective pressure variants and
functional datasets (protein sequences, interologs, host-pathogen intra-organism and host-pathogen
inter-organism protein-protein interactions (PPIs)) from various sources (STRING, Reactome, HPID,
Uniprot, IntAct and literature) to construct overlapping functional network for both host and pathogen.
Developed algorithms and a large-scale data-driven computational framework were used in this study
to analyze the datasets and the constructed networks to identify densely connected subnetworks or
hubs essential for network stability and integrity. The host-pathogen network was analyzed to eluci-
date the influence of parasite candidate key proteins within the network and predict possible resistant
pathways due to host-pathogen candidate key protein interactions. We performed biological and path-
way enrichment analysis on critical proteins identified to elucidate their functions. In order to leverage
disease-target-drug relationships to identify potential repurposable already approved drug candidates
that could be used to treat malaria, pharmaceutical datasets from drug bank were explored using se-
mantic similarity approach based of target–associated biological processes
Results:
About 600,000 significant SNPs (p-value<0.05) from the summary statistics data were mapped to
their associated genes, and we identified 79 human-associated malaria genes. The assembled parasite
network comprised of 8 clusters containing 799 functional interactions between 155 reviewed proteins
of which 5 clusters contained 43 key proteins (selective variants) and 2 clusters contained 2 candidate
key proteins(key proteins characterized by high centrality measure), C6KTB7 and C6KTD2.
The human network comprised of 32 clusters containing 4,133,136 interactions between 20,329
unique reviewed proteins of which 7 clusters contained 760 key proteins and 2 clusters contained 6
significant human malaria-associated candidate key proteins or genes P22301 (IL10), P05362 (ICAM1),
P01375 (TNF), P30480 (HLA-B), P16284 (PECAM1), O00206 (TLR4).
The generated host-pathogen network comprised of 31,512 functional interactions between 8,023 host
and pathogen proteins. We also explored the association of pfk13 gene within the host-pathogen. We
observed that pfk13 cluster with host kelch–like proteins and other regulatory genes but no direct
association with our identified host candidate key malaria targets.
We implemented semantic similarity based approach complemented by Kappa and Jaccard statistical
measure to identify 115 malaria–similar diseases and 26 potential repurposable drug hits that can be
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appropriated experimentally for malaria treatment.
Conclusion:
In this study, we reviewed existing antimalarial drugs and resistance–associated variants contributing
to the diminished sensitivity of antimalarials, especially chloroquine, sulfadoxine-pyrimethamine and
artemisinin combination therapy within the African population. We also described various compu-
tational techniques implemented in predicting drug targets and leads in drug research. In our data
analysis, we showed that possible mechanisms of resistance to artemisinin in Africa may arise from
the combinatorial effects of many resistant genes to chloroquine and sulfadoxine–pyrimethamine. We
investigated the role of pfk13 within the host–pathogen network. We predicted key targets that have
been proposed to be essential for malaria drug and vaccine development through structural and func-
tional analysis of host and pathogen function networks. Based on our analysis, we propose these
targets as essential co-targets for combinatorial malaria drug discovery.
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CHAPTER 1
1 Introduction and background
1.1 Overview
Malaria is a life-threatening mosquito-borne blood disease which is considered to have the greatest
impact on public health. This parasitic disease is one of the leading worldwide infectious diseases
with a devastating mortality rate especially in developing countries [1]. It is caused by Plasmodium,
a protozoan parasite of phylum Apicomplexa.
Malaria aetiology is attributed to environmental factors, parasite virulence as well as the level of
immunity by host (human) genetics [2]. The disease is primarily transmitted to humans through the
bite of an infective female mosquito from the genus Anopheles. However, because the malaria parasite
is found in erythrocytes of infected peoples, secondary transmission is through blood transfusion,
organ transplant and transmission from a mother to her unborn baby prior or during delivery. The
global effects and distribution (Figure 1) of this disease is vast and as such, threatens public health and
productivity on a broad scale. It also impedes the progress of many countries especially endemic ones
characterized by high poverty indices. This public health problem is aggravated by the emergence
and widespread of drug-resistant parasites.
It is hypothesized that death from malaria heightened with the development of the agriculture and
human habitation about 5,000 to 10,000 years ago [2]. These factors are thought to have increased
human population density and also mosquitoes, the malaria vector promoting transmission. Accord-
ing to World Malaria Report [3], it is estimated that, 3.4 billion people in 92 countries are at risk
of being infected with malaria. The burden is heaviest in the Africa, a continent where the disease
brings about severe morbidity and mortality cases which significantly affects her socio-economic de-
velopment. This continent is characterized by high level of genetic variation, population structure and
naturally acquired immunity.
Figure 1. A diagram showing the global distribution of malaria.
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Between the year 2000 and 2015, malaria occurrence rate reduced significantly by 37% globally
and 42% in Africa with a corresponding decrease in mortality by 60% and 66% globally and in
Africa respectively [4]. However, 2017 World Health Organization (WHO) malaria statistics showed
that there were about 216 million global reported cases and 445,000 related deaths out of which 90%
of both malaria occurrence and death occurred in sub-Saharan Africa (SSA) [5].
Mortality rate of the disease in areas with high transmission is mostly observed among children under
five years and pregnant women [5]. Children are also at high risk of contracting the disease because
they have not yet developed immunity. On the other hand, pregnant women are prone to malaria
infection due to their modulated immune response and the accumulation of parasites in the placenta.
In addition, the fetus is also at high risk because the parasites in the placenta could cause intrauterine
growth restriction, resulting in cases such as low birth weight, congenital malaria and stillbirth [6].
There are five reported species of Plasmodium genus that cause human malaria. The species are
Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmod-
ium knowlesi [5, 7]. Plasmodium falciparum is ubiquitous mostly in the tropical Africa, Southeast
Asia and the Amazon region [8]. It is the most virulent parasite associated with severe clinical symp-
toms and mortality, particularly in SSA, a region with about 3.2 billion people at risk [9]. Studies have
shown that the genetic variation in Plasmodium falciparum (P. falciparum) populations is a function
of geographic distance from SSA [10]. These variations significantly influences the pathogen’s ability
to evade human immune response.
P. falciparum malaria infection is the third most life-threatening infectious disease of humans and
is associated with serious complications. These complications are as a result of parasite-infected red
blood cells sequester in the microvasculature of organs [11]. Plasmodium vivax causes chronic disease
and is the second most harmful human malaria causing species responsible for significant morbidity
outside SSA, particularly in South America and the Asia-Pacific region, contributing about 16 million
cases annually [5]. Plasmodium vivax presents specific biological challenges that make it difficult
to detect its infections. This is because of its ability to remain hidden and dormant in an infected
person’s liver [3]. Plasmodium ovale like Plasmodium vivax have the added deadly complication of
a dormant liver stage, which can be reactivated in the absence of a mosquito bite. It is reported that
Plasmodium ovale and Plasmodium malariae represent only small percentage of malaria infections.
Plasmodium knowlesi, the fifth human malaria parasite infection is prevalent in South-east Asian
countries. Plasmodium knowlesi malaria infection could be transmitted from monkeys to humans as
well as through Anopheles balabacencis [12]. Studies have shown it to be responsible for up to 80%
of malaria infections in Malaysia [12].
Plasmodium falciparum has 23-megabase, (A+T) rich genomic content which encodes about
5,300 genes located on 14 chromosomes, along with 35-kb circular plastid genome and a 6kb mi-
tochondrial genome [13]. The majority of its predicted proteome are cell adhesion and host immune
system evasion proteins whiles enzymes and transporters constitutes the minority [14]. Unique sur-
vival mechanism of this parasite is its ability to evade host immune response by switching its variant
surface antigens. These surface antigens mediate the binding of infected erythrocytes to the vascular
endothelium (cytoadherence) and non-infected erythrocytes (rosetting). This results in the accumula-
tion of infected cells in the vasculature of a variety of organs, blocking the blood flow and reducing
the oxygen supply [15].
With no vaccine available yet in the market, malaria treatment and control is mainly by chemo-
prevention, vector control through the use of mosquito treated nets and insecticide sprays, together
with diagnostic-led case management [16]. However, progress in malaria elimination is threatened by
challenges including, but not limited to: rapid emergence of resistant strains towards chemoprevention
and poor responses of vectors to insecticides and treated nets.
Resistance to antimalarial drugs by P. falciparum due to selective pressures has been a major pub-
lic health burden specifically in SSA since the emergence of chloroquine (CQ) and sulfadoxine-
pyrimethamine (SP) resistance. This challenge hinders the ability to effectively suppress the infection
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due to the significant efficacy decline of antimalarial drugs.
The discovery of antimalarials especially chloroquine, helped to control and eradicate malaria in-
fection globally through the National Malaria Control and Eradication Program in the 1950s until
resistance emerged [17]. Drug resistance remains a major obstacle to malaria control and elimination
globally.
Primarily, antimalarial drug resistance development emerges as a result of variations affecting
the structure and molecular mechanisms of the drug target in the pathogen or affecting the ability
of the drug to access its target to execute the expected biological activity. Substandard medications
and high drug residual levels after treatment is a contributing factor that increases selective pressure
on parasite populations thus enabling a conducive environment for spread of drug-resistant parasites.
Drug efficacy and resistance emergence is determined by, but not limited to: clinical or in vivo efficacy
trials, pharmacological studies, in vitro parasite susceptibility assays, in vitro drug susceptibility test,
molecular studies, genetic cross-linkage and mapping studies of parasites [17]. Drug pressure can be
used to identify loci responsible for drug resistance.
Although significant improvement over the past decade has helped to reduce malaria mortality and
morbidity, resistance to antimalarial drugs have intensified the morbidity and mortality rate thereby
hindering the progress of controlling, eradicating and eliminating the disease. This is because, resis-
tance increases the risk of treatment failure thus resulting in severe malaria, anaemia and recurrent
parasitaemia [18]. These resistances have been reported for Plasmodium falciparum, Plasmodium
vivax and Plasmodium malariae. Among the three, Plasmodium falciparum have developed resis-
tance to most antimalarial drugs and this poses a great threat to controlling and eliminating malaria
globally. As such, identifying and understanding mechanisms of antimalarial drugs would contribute
immensely to elucidate the patterns of emergence and the continuous spread of drug resistance within
particular populations, thus, helping to put up strategic and effective policies to control the effect.
Multiple variations within a gene could result in differential contributions to drug resistance or
susceptibility. Understanding molecular markers associated with malaria drug resistance is of note-
worthy importance and would contribute immensely in monitoring the spread of resistant parasites
by either measuring parasite responses to specific drugs or measuring the prevalence of specific
variants associated with reduced drug efficacy [19]. Among the many molecular markers for drug
resistance, Plasmodium falciparum ATP-binding cassette (ABC) transporters are known to be signif-
icantly involved in malaria drug resistance. Because of their transport mechanism across extra and
intracellular membranes, variations and/or overexpression could result in drug resistance and treat-
ment failure [20].
Extensive adherence and use of monotherapy in the past resulted in rapid resistance development
by the parasite to most available antimalarials (Table 1 shows available antimalarial drugs). After
the development of resistance to quinine, chloroquine, sulfadoxine-pyrimethamine and mefloquine,
artemisinin combination therapies (ACTs) have been adopted as first line treatment for uncompli-
cated malaria in most endemic countries especially SSA since early 2000s. This is because of its
faster clearance rate and high efficacy [21]. Today, it is considered as the defense mechanism for
malaria control. However, the advent of Plasmodium falciparum resistant strains are associated with
reduced sensitivity to artemisinin and all the quinoline partner drugs in use including amodiaquine,
lumefantrine and mefloquine [1]. In addition, evidence abounds concerning the spread of multi-drug
resistance by the parasites from countries of the Greater Mekong Subregion, i.e., Cambodia, Thailand,
Lao People’s Democratic Republic, Myanmar, Viet Nam and Myanmar-China-India border [22]. Be-
cause of that, the drug is seen as a fading hope. Spread of resistant parasite strains is a major factor to
the global resurgence of malaria research. Spread of resistance is linked to the fact that, the presence
of drug within the parasite confers survival advantage which results in the transmission of resistant
parasite [23]. These factors highly correlates with global malaria burden. Tolerance by resistant
strains are characterized by a delayed parasitic clearance and a high rate of parasites recrudescence in
populations under artemisinin selective pressure [9]. It has been reported that antimalarial drug resis-
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tance is also compounded by cross resistance [23], a phenomenon where by one drug maybe selected
for by another in situations where mechanism of resistance is similar.
Emergence of Plasmodium falciparum CQ and SP resistant strains in Africa is traced mainly to
Cambodia where there are several reports of artemisinin resistance [24]. The current rapid spread of
artemisinin resistance in SEA coupled with the gene flow of chloroquine and SP resistant parasites
into SSA and its impact presents a serious concern of the likelihood of emergence and spread of
artemisinin resistant strains in Africa [22].
To date, there is no confirmed report of ACTs resistance in Africa, South America and Oceania [9].
Researchers have proposed that with the rising trend in malaria cases and death in Africa, should
resistance to ACTs (particularly artemisinin) emerge, there would be about 78 million additional
malaria cases which would result in an increase in the morbidity and mortality rate between the year
2016 and 2020 [9].
With the aforementioned challenges faced by malaria treatment and control, the need to under-
stand antimalarial drug resistance in Africa and identify novel, safe and effective antimalarial chemo-
types specific to the African populations will persist until the human pathogenic Plasmodium species
are eventually eradicated. This research proposes to understand the mechanisms and patterns un-
derlying antimalarial drug failure in SSA by investigating functional interactions between malaria
selective variants using bioinformatics pipelines and techniques. The study proposes also to iden-
tify potential protein targets that can play their role in predicting potential drug candidates specific
to the African populations through a comparative approach of both host and Plasmodium falciparum
genomics analysis.
1.2 Life cycle of Plasmodium falciparum
The life cycle of Plasmodium falciparum involves different hosts and tissues as shown in Figure 2.
The cycle comprises of three different developmental stages: the mosquito stage, the human liver and
blood stages.
Malaria parasites alternate between asexual replication in the bloodstream of human host and
reproduction in the vector. Asexual replication causes structural and functional changes which results
in the disease, while reproduction in the vector facilitates transmission to new hosts [25]. Clinical
symptoms of malaria are observed during the parasite’s intra-erythrocytic developmental stage inside
the host’s red blood cell. The life cycle of the parasite is quite complex, and as such the pathogen
establishes molecular mechanisms to ensure its growth and survival within its hosts.
The ability of the parasite to survive and develop within the environments of its hosts is facilitated by
genes and their specialized proteins that interact with the host cell to modulate the host’s response to
it [26]. These interactions help the parasite to invade and grow within multiple cell types as well as
evade the human immune system.
Human infection, termed as blood meal, begins when malaria infected female Anopheles mosquitoes
inoculates sporozoites from their salivary glands into the host. These sporozoites migrate into the
bloodstream and into the liver, where they begin the liver stage [27]. The sporozoites invade hepato-
cytes and mature into schizonts. The schizonts undergo dormancy then after replicating, they rupture
to release merozoites [28].
The merozoites undergo asexual multiplication and then invade human mature red blood cells (RBCs)
to begin the blood stage. They develop inside a parasitophorous vacuole and initiate almost a 48 hour
cycle of asexual blood stage (ABS) parasite growth, egress and re-invasion [29]. The ring stage
trophozoites mature into schizonts, which rupture to release merozoites. Some of the parasites dif-
ferentiate into sexual gametocytes (erythrocytic stage). Blood stage parasites are responsible for
the clinical manifestations of the disease. The gametocytes, male (microgametocytes) and female
(macrogametocytes), are ingested by an Anopheles mosquito during a blood meal. It is estimated that
about 10000–100000 mature gametocytes are taken up during a blood meal. These gametocytes then
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form male and female gametes that undergo sexual recombination to form ookinetes and then oocysts
before completing their life cycle by forming sporozoites that migrate to salivary glands of the vector
ready for further human infection. Inoculation of the sporozoites into a new human host perpetuates
the malaria life cycle.
Figure 2. Schematic diagram of the life cycle of Plasmodium falciparum in both human and
mosquito. Image retrieved from Malaria Site ( https://www.malariasite.com/life-cycle/).
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1.3 Antimalarial drug candidates










Chloroquine Treatment of both falciparum and non-
falciparum malaria infection
Inhibits heam polymerization [30]
Amodiaquine Treatment of non-severe falciparum in-
fection
inhibits heam polymerization [17]







Quinine Treatment of severe falciparum malaria
infection
Accumulates in food vacuoles




Mefloquine Treatment of non severe falciparum





Pyronaridine Treatment of non severe falciparum
malaria infection
[32, 33]
Naphthoquine Used in combination with artemisinin to
treat both P. falciparum and P. vivax







Halofantrine Treatment of non severe falciparum
malaria infection
Causes parasite membrane
damage by forming cytotoxic
complexes
[17]
Continued on next page
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Drug name Use Anti-malarial activity Reference





Primaquine Treatment of P. vivax and P. ovale
malaria infection





Tafenoquine Treatment of P. vivax and P. ovale
malaria infection
inhibits haem polymerization [37]
8-
aminoquinolines
Quinidine Treatment of Plasmodium falciparum
malaria infection
Accumulates in the food vacoule











Antifolate Sulfadoxine Inhibits folates synthesis [39]
Diazines Antifolate Pyrimethamine Treatment of Plasmodium falciparum
malaria infection
Inhibits enzymes within the fo-
late pathway
[16]




Antibiotic Clindamycin Complicated falciparum malaria Inhibits protein synthesis [41, 42]
hydroxy-
naphthoquinone
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Proguanil Inhibit synthesis of folates [43]
Artemisinin
derivatives































1.4 Antimalarial drug Response/Resistance and Plasmodium falci-
parum
The genetics of the parasite constitute a major building block that determines the variations in the
levels of drug susceptibility, particularly having elucidated that antimalarial drug resistance of P.
falciparum involves a single major gene effect [17]. These variants could be either single or multiple
point which arises from a series of linked or unlinked additive variations. This resistance is effectuated
by resistance-associated variants under selection and the geographical spread of resistance alleles
from their origin [17]. Table 2 describes Plasmodium falciparum selective genes and mutations
associated with drug resistance.
Table 2. Description of genes/selective variants associated to various antimalarial drug
resistance.
Drug Gene Variation Reference
Chloroquine pfcrt K76T, K76N, K76I, C72R, S163R [44]
pfmdr1 N86Y, D1246Y, S1034C, N1042D [45]
pfmrp1 F1390I, Y191H, A437S [17]
Pyrimethamine pfdhfr S108N/T, N51I, I164L, A16V, C59R [46, 47]











Artemisinin pfatp6 L263D,L263E, L263K [54, 55]
pfk13 C580Y, Y493H, R539T, I543T [17]
pfcrt [1, 17]
1.4.1 Resistance/response to chloroquine
The discovery of chloroquine, a rapidly-acting schizonticidal drug, in the 1940s served as the pri-
mary chemotherapeutic means of malaria treatment because of its efficacy, safety and low cost. This
tremendous breakthrough helped reduce reported malaria cases and mortality rate.
It’s usage contributed immensely to controlling malaria until the emergence and spread of drug-
resistant Plasmodium falciparum strains two decades after its introduction, with the first reports from
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Thai-Cambodia border and Columbia followed by South America [56, 57]. Resistance to chloroquine
is characterized by diminished accumulation, decreased sensitivity and reduced concentration within
the parasite’s food vacuole. The lack of new antimalarial drugs led to the spread of chloroquine re-
sistant parasites to Africa around 1970s which resulted into about three fold increase in the mortality
rate [17].
Free haem produced from heamoglobin digestion is suggested as target for chloroquine [58]. The
mode of action of this 4-aminoquinoline compound involves accumulation inside the digestive vac-
uole of the intraerythrocytic trophozoite (infected red blood cell) where its concentration increases [8].
It then inhibits haemoglobin degradation and binds to haem moiety to form lethal haem-chloroquine
complexes. The complexes formed inhibits haem polymerization, a process that detoxifies haem, thus,
inhibiting the production of haemazoin pigment catalyzed by Plasmodium falciparum histidine-rich
protein-2 (Pfhrp-2) [58]. This inhibition allows the accumulation of toxic hemoglobin metabolite in
the cell thereby disrupting the biochemical processes of the parasite and leading to cell death [59]. A
study conducted by Tewari and colleagues to investigate the effect of chloroquine on P. falciparum
DNA replication identified significant changes in DNA synthesis related genes during chloroquine
treatment. The study reported continuous accumulation of haem within the parasite’s food vacuole to
be associated with inhibition of redox metabolism, carbon fixation and pyrimidine metabolism which
are contributing factors of DNA synthesis inhibition [60].
Molecular marker analysis, genetic mapping and allelic association studies have shown that chloro-
quine resistant P. falciparum strains emanated from Asia through South America and to Africa due to
variations in P. falciparum chloroquine resistance transporter (pfcrt) gene on chromosome 7 [30, 44].
It is well established that the spread of chloroquine resistant parasite strains through multiple evo-
lutionary pathways is associated with pfcrt K76T variant [56]. However, other variants in the trans-
membrane domains of pfcrt encoded protein, specifically, K76N, K76I and C72R in transmembrane 1,
S163R in transmembrane 4, and Q352K and Q352R in transmembrane 9 have reportedly been linked
to chloroquine resistance in clinical studies and field isolates [19]. The parasite’s ability to remove
chloroquine from its food vacuole is suggested to depend on the K76T variant because it is consistent
in chloroquine resistant isolates studied.
N86Y, D1246Y, S1034C and N1042D variants and copy number variants in the Pfmdr1 gene on chro-
mosome 5, which codes for a homologue of human multi-drug resistance p-glycoprotein (Pgh1) pro-
tein in the digestive vacuole of Plasmodium falciparum, is associated to chloroquine reduced suscep-
tibility and resistance [45]. Also, Pfmrp1 gene variants including F1390I, Y191H and A437S have
been reported to be linked with in vitro susceptibility to chloroquine [17].
Several studies have reported variations in the pfcrt gene in individuals of Asian, African or South
American origin that confer verapamil-reversible chloroquine resistance, cross-resistance, as well
as alter susceptibility to other anti-malarial drugs such as quinine and quinidine which targets the
parasite’s food vacuole [61]. Also, different phenotypic expressions by resistant isolates that carry the
pfcrt and pfmdr1 alleles give an indication that there are other genes responsible for modulating the
pathogen’s response to drugs [13]. These modulators could be molecules involved in drug transport
or transporter genes encoding products like ABC transporters.
The advent of chloroquine resistant parasites with adequate fitness to survive and spread over time
resulted in the decline of its efficacy. This resulted to the abandonment of the drug in early 2000s [17].
It was used for about 50 years in Africa before it was withdrawn from the market.
1.4.2 Resistance/response to sulfadoxine – pyrimethamine (SP)
The widespread of CQ resistance led to the introduction of SP as an alternative antimalarial drug to
treat CQ resistant falciparum malaria. Sulfadoxine and pyrimethamine act with high synergistic effect
when administered together to inhibit dihydrofolate reductase and dihydropteroate synthetase which
are two enzymes important in the parasite’s folate biosynthesis pathway [62, 63]. SP binds to these
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enzymes to inhibit their activity. This inhibition results in significant decrease of tetrahydrofolate pro-
duced which sequentially results in a reduced production of folate precursors such as methionine and
deoxythymidine monophosphate (dTMP). Low production of folate precursors inhibits the parasite’s
life cycle [47]. In the early 1980s, SP was adopted in Africa for treating non-severe malaria. SP is
used either as monotherapy or in combination with other antimalarial agents such as artemisinin-based
derivatives to treat uncomplicated Plasmodium falciparum malaria as well as for intermittent preven-
tive therapy in infants and pregnant women in Africa [17]. Clinical efficacy trials have shown that
SP intermittent preventive therapy confer protection against malaria anemia in children and improve
foetal outcomes from malaria [47].
The extensive use of SP led to a rapid resistance and decrease in efficacy during its year of intro-
duction [17]. The resistance to SP is influenced by the influx of folates and the efflux of antifolates
during the biosynthesis. The prevalence of SP resistant parasite genotypes was first reported in Thai-
land before spreading to other malaria endemic regions. Genetic crosslinking and mapping studies
helped to identify variations involved in SP resistance. Evidence abounds for selective sweep of these
genetic variations into Africa [64].
The resistance to pyrimethamine is linked to variations in the parasite’s dihydrofolate reductase
gene (pfdhfr) on chromosome 4 [65]. Pfdhfr variants S108N/T, N51I, I164L, A16V and C59R results
in an increased parasite clearance [46, 47]. Single nucleotide variants such as S108N expresses low re-
sistance whiles N51I/S108N and C59R/S108N double-variant expresses relatively higher resistances.
S108N, N51I and C59R is the most common triple-variant mutant characterized by increased rates of
treatment failure in high pyrimethamine resistance areas in Africa and Southeast Asia [46, 64]. These
triple-variants increase and diverge rapidly in some parts of Africa as compared to other variants.
Among the variations, N51I /C59R/S108N/I164L, a quadruple-variant, highly prevalent in Southeast
Asia but with low frequency in Africa, is considered to confer high resistance to pyrimethamine such
that it renders the parasite untreatable [46, 66]. Microsatellite analysis have shown that these triple-
variants have shared ancestry with pfdhfr variants in Southeast Asia thus, suggesting the spread of
pyrimethamine resistance from Southeast Asia to Africa just as the emergence of chloroquine re-
sistance [66]. Similarly, the pfdhfr double-variant in Africa emerged from three independent origins
whereas the triple-variant occurred from a single origin thus confirming the spread of single dominant
resistant parasite lineage into Africa [46]. However, there are additional pfdhfr haplotypes present in
Africa at low frequencies particularly in Kenya and Cameroon [67]. The C50R variant of pfdhfr in
South America has been detected in Africa and thought to increase the level of resistance [68].
On the other hand, selection of parasite with variations in dihydropteroate synthetase gene (pfdhps)
on chromosome 8 results in resistance to sulfadoxine [65]. S436A/F, A437G, K540E, A581G and
A613S/T variants in pfdhps confer reduced susceptibility to sulfadoxine and daspone, another an-
tifolate drug [47]. Studies have shown that these variants express reduced affinity for sulfadoxine.
Double-variants A437G and K540E have been shown to be very common in Africa. Studies have
shown that S436A and A437G alone express low resistance level but they act synergistically with
K540E, A581G, and/or A613S to confer an increased level of resistance to sulfadoxine [64]. These
mutations results in a long half-life of the drug. Other studies have shown that selection of parasites
with highly resistant allelic types also confers resistance [63].
The level of SP resistance is determined by the type of variant. Single nucleotide variants result
in about 100-fold lower levels of resistance compared to wild-types, while multiple variations results
in about 225-fold higher level of resistance compared to wild-types.
A study conducted in 31 African countries revealed consistency in the reduced efficacy of SP due to
significant increase in pfdhfr triple-variant and pfdhps double-variant genotypes, with Kenya-Tanzania
border and Malawi recording high prevalence rate [47]. Natural selection and hard selective sweeps
contributes to the gene flow of resistant alleles and genetic hitchhiking across the parasites population
in Africa [69]. Although there is independent segregation of pfdhfr and pfdhps alleles in Africa, there
is lack of variation and significant linkage disequilibrium between codons 51, 59, and 108 in pfdhfr
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and codon 437 of pfdhps due to drug selection [64].
1.4.3 Resistance/response to piperaquine
Piperaquine is characterized mainly by its large distribution volume, ability to bind high number
of plasma proteins and long half-life resulting in low hepatic elimination clearance [70]. The uncon-
trolled use of piperaquine as monotherapy in China in the 1970s and 1980s contributed significantly to
the development of parasite resistance, which were validated through several clinical drug resistance
and in vitro reports [31]. Aside from that, cross-resistance between piperaquine and other antimalarial
agents including artemisinin derivates and chloroquine could be a factor. The long half-life of piper-
aquine causes it to circulate within the body for long, and puts other partner drugs (in combinatorial
therapy) at high risk of selection.
The degree of cross-resistance varies among other antimalarial agents. For instance, an in vitro test
on two piperaquine resistant strains revealed a cross-resistance between piperaquine and hydroxy-
piperaquine which is formed from oxidation of piperaquine. Also, a cross-resistance has been reported
between piperaquine, artesunate and mefloquine [31]. Among other strains, moderate cross-resistance
was observed between piperaquine and pyronaridine. A recent study conducted by Witkowski et
al. [48] in western Cambodia showed that piperaquine resistance in Cambodia is strongly associ-
ated with amplified copy number in the plasmepsin 2–3 gene on chromosome 14, which encodes
haemoglobin-digesting proteases. These enzymes have been shown to modulate parasite susceptibil-
ity to piperaquine [71]. Combined analysis of K13 polymorphisms and plasmepsin 2 copy number
have been identified as signature of selection for dihydroartemisinin–piperaquine failures. A variant
in the pfmrp1 gene is reported to be associated with piperaquine resistance [49]. In a recent study
to determine piperaquine sensitivity and the role played by pfmdr1, it was shown that selection on
pfmdr1 86Y allele was associated with reduced piperaquine sensitivity in an in vitro test using Thai
Plasmodium falciparum isolates [52]. Agrawal and colleagues in a genome-wide association study
identified F145I as a novel variant of the pfcrt gene linked with reduced sensitivity thus resulting in
dihydroartemisinin-piperaquine treatment failure [51]. Duru and colleagues, in a study in Cambodia
confirmed that Pfmdr1, Pfcrt and Pfk13 variants are associated with piperaquine resistance [50].
1.4.4 Resistance/response to mefloquine
Mefloquine monotherapy was mostly used in South-east Asia until the emergence of parasite resis-
tance rendering it ineffective within six years after its introduction as an antimalarial drug in 1984.
However, it is now used in combination with artemisinin and has been shown to be effective. The
exact mechanism of resistance is unknown, however, there are several lines of in vitro and in vivo ex-
perimental evidences that explicitly show that an increase in copy number of multidrug-resistant gene
1 (pfmdr1) is associated with mefloquine resistance [53]. Studies conducted by Price et al. showed
that increased copy number in pfmdr1 is associated with attributable hazard ratio for treatment failure
of 6.3 and 5.4 for monotherapy and combination therapy respectively [72]. In vitro studies showed
an increase in copy number of pfmrd1 was associated with a significant decrease in susceptibility to
mefloquine. In their study on Plasmodium falciparum isolates from Suriname, Labadie-Bracho et al.
showed that an increase in copy number of pfmdr1 is not only associated with mefloquine resistance
but also with resistance artemether-lumefantrine in vitro [53]. Amplification of pfmdr1 was reported
to be associated with an increase in mefloquine IC50 [13]. The gene pfmdr1 has therefore emerged as
a critical determinant associated with many malaria drugs resistance by modulating their sensitivity.
This phenomenon could result from an extensive selection of multiple drugs on the parasite. Also,
Preechapornkul et al. studied the ex-vivo dynamics of pfmdr1 from a Thai Plasmodium falciparum
isolate using multiple genetic markers and concluded that pfmdr1 amplification is obtained as a re-
sult of mefloquine resistance in addition to the decline in the parasite’s survival fitness with no drug
pressure [73].
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1.4.5 Resistance/response to ACTs
Further research helped to implement the policy of using antimalarial drugs as combination therapies
instead of the usual monotherapy. This impelled the introduction of Artemisinin Combination Thera-
pies (ACTs), which has demonstrated tremendous positive therapeutic response. This is because, the
components of the drug have different modes of action that enhance pharmacodynamic synergistic
effect whiles significantly minimizing resistance development of the parasite by decreasing the risk
of selection by resistant parasites compared to a monotherapy setting [31].
In these drugs, artemisinin derivates sesquiterpenes found mainly in plants of the genus Artemesia,
are used as the core component in combination with other antimalarial drug agents thereby preventing
recrudescent malaria [31]. Due to the short half-life of artemisinin, it permits a very sharp reduction
of parasite load in an infected individual. The efficacy of artemisinin is linked to the fact that they
target both the early and late erythrocytic stages of the parasite where it kills the parasite through an
induced proteopathy mechanism or degeneration of parasite’s cytoplasm [74]. Only residual parasites
are then eradicated by the partner drugs which are characterized by relatively increased half-life as
compared to artemisinin [31].
ACTs recommended by WHO are artesunate and mefloquine; artesunate and amodiaquine; artesunate,
sulfadoxine, and pyrimethamine; artemether and lumefantrine; and dihydroartemisinin and piper-
aquine [55]. In Africa, artemether-lumefantrine (AL) and artesunate-amodiaquine are mostly used in
endemic areas because they show the highest efficacy whereas dihydroartemisinin-piperaquine (DP)
is used mostly in Asia. Artesunate-mefloquine is shown to be effective and safe for treating malaria
among children below 5 years of age in Africa [75].
Artemisinin reacts with heam to form heam-artemisinin adducts in the parasite’s food vacuole. These
adducts interact with proteins in the parasite responsible for heam detoxification and inhibit haemo-
zoin polymerization. This interaction leads to accumulation of toxic heam which results in parasite’s
damage [9]. Artemisinin kills the young intraerythrocytic malaria parasites by inhibiting the parasite’s
enzyme (PfATP6) encoded by the pfatp6, a calcium transporting ATPase gene [55].
The use of combination therapies is to increase drug efficacy and to delay parasite resistance [17].
However, there is a high risk of tolerance or resistance to ACT by Plasmodium falciparum especially
in endemic areas. This phenomenon is characterized by reduced ring stage susceptibility, prolonged
parasite clearance and parasite recrudescence as a result of selection due to artemisinin partner drugs
which circulate longer at decreased levels [76]. Artemisinin resistance therefore contributes signifi-
cantly to parasite selection to partner drugs [22]. However, in Africa, amodiaquine and lumefantrine
are of much a concern since resistance to them is prevalent. This phenomenon, therefore increases
the chance for resistance emergence to artemisinin derivatives. Nevertheless, there are reports of re-
sistance to artemisinin, an integral component of ACTs, apart from its first report in Cambodia [24].
P. falciparum resistance to artemisinin is rapidly evolving in the Greater Mekong Subregion through
selective sweeps [22]. This resistance leads to a significant decrease in the parasite biomass clear-
ance rate, thus, resulting in increased load of residual parasites unable to be cleared by partner drugs.
Subsequently, this phenomenon brings about increase in recrudescent and spread of resistance.
Genome analysis has revealed that variation in the propeller domain of the gene encoding Kelch
protein 13, such as C580Y, Y493H, R539T and I543T are associated with higher artemisinin resis-
tance [17]. These variations have been studied to have emerged independently from multiple occa-
sions [77] and confer resistance. Recent studies have shown that low levels of immunity to Plas-
modium falciparum in the Mekong population in South-east Asia is associated with high prevalence
of variations in the propeller domain of Kelch protein 13 encoding gene (kelch13) [9]. The vari-
ant PfKelch13 C580Y in parasite lineage observed in Cambodia, northeastern Thailand and southern
Laos is reported to be the most dominant and to be more transmissible such that it has now spread
to 3 countries in the Mekong region thus causing high ACT failure rate [22]. Pfplasmepsin2 gene
amplification has emerged on the back of PfKelch13 C580Y variant and contribute to the widespread
of multidrug-resistant parasite lineage [22]. Studies have shown that the Pfplasmesin2 gene, involved
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in hemoglobin digestion pathway, is targeted by artemisinin. It is suggested that Pfplasmesin2 am-
plified parasites evolved after selection of the pfkelch13 C580Y lineage, which has intensified ACT
treatment failure. In a study to assess prevalence of kelch13 polymorphisms within Sub-Saharan
Africa, 22 unique variants comprising of 7 nonsynonymous SNPs were identified. A578S and V566I
variants with frequency > 1% were found to be present in 5 African countries. They are closer to the
C580Y variant but confer no resistance to artemisinin [78]. There is, therefore, a higher possibility
that the K13 variant that confer resistance work together with other factors depending on the parasite
population. Interestingly, the K13-propeller M476I together with the PF3D7−0110400D56V variant
have been reported to confer resistance to artemisinin in the artemisinin-resistant parasite line from
Africa [79].
Alterations in the parasitic membrane proteins Pgh-1, PfCRT and PfMRP1 are major contributors
to artemisinin resistance through decreasing intracellular drug accumulation by their active drug
transport mechanism between the food vacuole lumen and the cytoplasm [1, 17]. A disruption
of the pfmrp1 gene within a parasite provides a higher sensitivity to artemisinin, chloroquine and
lumefantrine, thus, confirming the gene’s ability to influence the parasite’s drug response [20]. A
genome-wide association study using field isolates from China-Myanmar boarder, further implicated
the autophagy-related protein 18 (PfATG18) to be associated with decreased sensitivity to artemether,
dihydroartemisinin and piperaquine [16].
Research findings by Veiga et al. [1] on association between copy number variation of pfmdr1 and
drug sensitivity together with other studies highlighted observations that increase in copy number
decreased sensitivity of Plasmodium falciparum to artemisinin, lumefantrine and mefloquine [55].
The Pfmdr1 variants N86Y, Y184F, D1246Y and N1042D and the pfcrt 76T variant are shown to confer
resistance to amodiaquine and lumefantrine [17, 80]. A recent study in eastern Africa reported no
significant selection for pfmdr1 polymorphisms upon treatment and re-treatment of children between
12 and 59 months with artemether-lumefantrine and artesunate-amodiaquine thus supporting the use
of same or alternative ACTs for malaria treatment [80]. In vitro analysis revealed diminished response
to artemisinin and lumefantrine with the pfmdr1 wild-type alleles N86 and D1246 [81]. However, a
study conducted in Uganda revealed that the pfmdr1 86Y and 1246Y variants mediated diminished
response to amodiaquine [76].
A recent study conducted in Senegal, Mali and The Gambia to determine the frequency of pfcrt
and pfmdr1 variant associated with artemether lumefantrine resistance reported a decrease in the
frequency of the pfcrt K746T and the pfmdr1 variants at codon 86 during the study period [19]. The
study reported a decrease in parasite sensitivity to artesunate and lumefantrine in Senegal.
With the spread of multidrug-resistant parasites from Cambodia, southern Laos and northeastern Thai-
land, its emergence in Africa would be a major public health concern.
1.5 Influence of human genetic variations on antimalarial drug resis-
tance
Resistance to antimalarials is complex and involves host genetics, environmental factors and parasite
compensatory variants. Having established that malaria has the strongest evolutionary selection on
the human genome, there is a higher probability of parasite genetic diversity influencing the host
genome leading to significant changes in immunity, parasitemia and malaria risk [82]. There is no
direct relationship between evolution of the human genome towards drug resistance as compared to
the parasite’s genome, however, the host genetic factors contribute significantly to drug metabolism
and effectiveness. Variations in host genes involved in drug metabolism such as the cytochrome P450
genes may down-regulate processes including but not limited to oxidative processes, hydrolysis and
hydrophilic functionalities leading to poor catalytic activities and renal excretion.
It is important to note that, acquired host immunity a dependent variable of population endemicity,
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drug exposure and transmission intensity influences drug clearance rate [82]. High immunity would
mean low disease infection rate, low drug pressure resulting in delayed drug resistance development
and vice-versa. Recent genome-wide studies have reported significantly diminished protective and
non-replication of some host protective variants in some population although the general frequency
of resistant alleles is high [83]. For instance traditional HLA alleles such as HLA-B*53 associated
with malaria resistance showed no evidence of association in Gambia population [83]. Also, there
are reported complication of the nature of protection of malaria protective variants such as G6PD
predominant in Africa. Moreover, new protective variants have been reported [83]. Because Africa
is characterized with high levels of immunity and faster parasite clearance, early signs of low-grade




Genetic variations are believed to be the cause of Plasmodium falciparum drug resistance [2]. Genetic
polymorphisms of candidate genes from the disease causing pathogen generally provide effects that
counteract the drugs controlling the disease. In view of that observation, spontaneous alterations
in the form of single nucleotide variation in different genes of the Plasmodium falciparum genome,
enhances the pathogen’s ability to develop strategic mechanisms to tolerate or resist the drug action
over time, thus, yielding the unexpected result [8]. Drug resistance poses a major challenge to the
quest to controlling, eliminating and eradicating malaria. It is a principal reason for the expansion of
this life-threatening disease.
The use of antimalarial drugs has been the optimal avenue for malaria control and artemisinin-based
combination therapies (ACTs), which are presently the first line of treatment are used globally [1].
ACTs were adopted in Africa after the decline in efficacy of previous widely used antimalarial drugs,
including chloroquine and sulfadoxine–pyrimethamine. This was to ensure that, each component of
the combinatorial drug acts through different mechanism within the parasite, with the aim to reduce
the likelihood of emergence of multi-drug resistant parasites significantly.
Unfortunately, the Plasmodium falciparum parasite has shown a tremendous ability to develop re-
sistance and tolerance to these artemisinin derivatives and to the long half-life ACT partner drugs
in some countries of the Greater Mekong Sub-region [84]. Accordingly, there is a higher likelihood
of the emergence and spread of artemisinin–resistant parasites in Africa just as it was the case for
chloroquine and sulfadoxine–pyrimethamine resistant parasites. Several reports support the signif-
icant decrease in the therapeutic response of artemisinin derivatives against P. falciparum [9, 85].
There is evidence of the appearance of ACT resistant strains of P. falciparum in Africa where the
disease–associated morbidity and mortality rate are highly significant [9, 57]. This raises questions
about the mechanism of resistance and the efficacy of the drug in Africa and the hypothesis that the
resistance and susceptibility dilemma could result from a selection by the parasite.
1.7 Need statement
The emergence of artemisinin resistance has led to the identification of novel therapeutic targets,
candidates and small-molecule inhibitors. Due to the selection resulting in resistance development by
Plasmodium falciparum, this research study proposes the need to clearly understand the mechanism of
action of Artemisinin Combination Therapies (ACTs) antimalarial drug and assess the prevalence of
drug resistance. Using bioinformatics analysis, this study is proposing to identify specific molecular
markers under selection that are involved with drug resistance. Through gene mapping and protein-
protein interaction networks between the parasite and human, this study will help elucidate the target
mechanisms. This is subjected to the use of systematic approach through a large-scale data-driven
integrative framework to identify targets and more effective drugs.
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1.8 Aims and objectives
The overall aim of this study is to identify potential protein targets to understand the mechanism of
drug resistance and identify those molecular targets that can help design drugs that are more effec-
tive and more specific to the African populations through a comparative analysis of both host and
Plasmodium falciparum genome.
Specific Aim 1:
Leveraging malaria-specific genome-wide association studies(GWAS) summary statistics from
African populations, Plasmodium falciparum selective pressure variants and functional dataset
(host-pathogen intra-organism and host-pathogen inter-organism PPIs) will be used to construct
overlapping networks for both host and pathogen.
a Identifying selective pressure variants from literature and databases to construct malaria
specific subnetwork of the pathogen.
b Retrieving and integrating inter and intra functional protein-protein interaction data be-
tween host and pathogen into a unified framework.
c Constructing overlapping network between the host and the pathogen.
Specific Aim 2: Leveraging disease–target–drug relationships to identify protein targets from
the overlapping functional network of host and pathogen.
a Integrating all generated subnetwork to identify densely connected subnetworks and hubs.
b Elucidating clusters or densely connected subnetworks containing important functional
proteins by computing functional similarity score.
c Performing disease-associated process and pathway enrichment analysis to identify the
involvement of proteins in essential processes.
d Drawing conclusion on the drug failure mechanisms and proposing drug target variants.
Specific Aim 3: Predict potential drug candidates for identified targets using semantic similarity
approach.
a Investigating disease similarity by exploiting relationships between gene ontological terms
and disease pathology.
b Identifying repurposable approved drug candidates by leveraging drug-target-disease as-
sociations and pharmaceutical datasets.
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1.9 Methodology
The general schematic representation of the methodology for this study is shown in Figure 3.
Figure 3. Diagrammatic representation of general methodology implemented in this study.
Specific Aim 1: Identifying susceptible and resistant human genes associated with malaria from
previous Genome-wide association studies in African populations.
a. Host-malaria associated genes:
This study proposes to use genome-wide association studies (GWAS) summary statistics
shown in Table 3 and bioinformatics approaches to identify and investigate genetic poly-
morphisms in selected African populations that are subjected to a high burden of malaria
susceptibility and resistance. Disease-associated genes identified from analysis of GWAS
summary statistics data will be used to construct malaria–specific subnetwork using bioin-
formatics tools.
This approach will facilitate assessing malaria-associated genes in specific African popu-
lation thus enhancing novel target identification for drug discovery.
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Table 3. MalariaGen Human GWAS Data set on which the analysis will be conducted
retrieved from www.malariagen.net/data/human-gwas/access-apply.
Datasets Sample size EGA Dataset
ID
Ref.
Genome-wide study of resis-




ents & 33 other
EGAD00010000904 [86]
Genome-wide study of resis-
tance to severe Malaria in
eleven populations (Gambia)
2807 cases, 2786




Kenya, Gambia, Malawi), “A
novel locus of resistance to







analysis of severe Malaria
(Gambia) & 1247 cases
1533 controls EGAD00010000572 [89]
Imputation-based meta-
analysis of severe Malaria
(Kenya)
1711 cases & 1544
controls
EGAD00010000570 [89]
Gambia Case Control Study 1059 cases and
1496 controls
EGAD00000000087 [86]
Gambia Trios 658 trios EGAD00000000019 [90]
Ghana Trios 608 trios EGAD00000000020 [90]




b. Identifying selective pressure variants from literature and databases to construct malaria
specific subnetwork of the pathogen:
Selective pressure variants in Plasmodium falciparum will be retrieved from literature and
essential genome databases provided in Table 4 genome database category. The single
nucleotide polymorphisms (SNPs) detected to show causality from the GWAS data will
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be annotated, interpreted and assessed using bioinformatics tools and other tests described
by Chimusa et al. [92] to construct gene network.
c. Retrieving and integrating inter and intra functional protein-protein interaction data be-
tween host and pathogen into a unified framework:
Reviewed protein sequences of human and the parasite will be retrieved from Uniprot
database [93]. La Count et al. [94] experimental Plasmodium falciparum protein-protein
interaction (PPI) data, Bossi and Lenner human experimentally derived PPI data [95] to-
gether with other inter-specie and intra-specie PPIs from REACTOME database [96] and
other essential functional databases shown in Table 4 protein-protein interaction database
category will be used. These functional datasets will be integrated using a large-scale
data-driven computational framework described by Mazandu et al [97].
Table 4. Useful resources and their descriptions required for this research.






UniProt Centralized resource for protein se-
quences and functional information
[93]









A classification system for annota-
tion of genes and gene products with
molecular function, biological pro-
cess and cellular component
[99]
KEGG Database An integrated database of genes and
metabolic pathway information
[100]
MetaCyc A universal database consisting of
enzymes and experimentally anno-
tated metabolic pathways
[101]
BioCyc A database which contains predicted
metabolic network of an organism of
interest, including metabolic path-







STRING Retrieval of functional associations
inferred from sequence and high-
throughput data
[102]
Continued on next page
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falciparum PPIs derived using pro-
tein domains
[103]
Wuchty et al in
silico PPI
Computationally derived Plasmod-
ium falciparum PPIs derived using
protein domains, interologs and ex-
perimental PPIs
[104]





























Experimentally derived sexual stage
microarray data
[108]
REACTOME Database of manually curated, peer-
reviewed pathway database of hu-
man pathways and processes
[96]
IntAct Protein interaction database system
and analysis tools for molecular in-
teraction data
[109]
MINT Molecular interaction database of
experimentally verified PPIs mined
from scientific literatures
[110]
BioGRID Curated biological database of PPIs,
genetic interactions, chemical inter-
actions and post-translational mod-
ifications
[111]
Continued on next page
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Database of diverse datasets to facil-
itate the identification and prioriti-
zation of drugs and drug targets
[112]
Drug Bank Resource combining detailed drug
data with comprehensive drug tar-
get information
[111]
d Constructing overlapping network between the host and pathogen:
An overlapping network will be constructed using python scripts and the large-scale data-
driven computational framework.
Specific Aim 2: Identify protein targets from the overlapping functional network of host and
pathogen (leveraging disease-target-drug relationships)
a Integrating all generated subnetwork to identify densely connected subnetworks:
All interaction networks generated in previous steps will be unified using custom python
scripts and the computational framework characterized by its ability to integrate heteroge-
neous data.
b Elucidating clusters or densely connected subnetworks containing important functional
proteins by computing functional similarity scores:
The unified network will be partitioned into different functional networks using Blonde et
al [113] clustering method to detect connected subnetworks. This step will help identify
complex properties including robustness, adaptability and regulation most often observed
in living systems.
c Disease-associated gene annotation and pathway enrichment analysis:
Essential biological processes involving the extracted proteins will be predicted using gene
functional genomics database shown in Table 4 under functional genomics database cat-
egory. Pathways enrichment analysis will be performed on the extracted essential func-
tional proteins to identify statistically relevant pathways which are most likely participate
in malaria pathogenesis.
Specific Aim 3: Predict potential drug candidates for identified targets
a Predicting repurposable approved drug candidates by leveraging drug-target-disease asso-
ciations and pharmaceutical datasets:
The computational framework would be used to map approved drugs to the set of Plas-
modium falciparum proteins identified implementing semantic similarity method.
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1.10 Summary
In this chapter, we described the background of malaria, the origin and spread of resistant variants into
Africa, malaria drug resistance and some malaria-specific variants associated with drug resistance and
susceptibility. We also described the rationale for this study, the project pipeline and the various tools
and source of datasets implemented.
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CHAPTER 2
2 Reviewing computational/ in silico methods of drug dis-
covery
2.1 Introduction
Drug research and development pipeline entails the following steps: (a) target identification and val-
idation, (b) hit to lead molecule generation, (c) lead molecule optimization and characterization, (d)
drug formulation and delivery, (e) pharmacokinetics and drug disposition, (f) preclinical drug candi-
date identification, and (g) bioanalytical testing and clinical trials [114]. Computational drug discov-
ery has over the past few decades become very relevant mainly due to the reduced risks, time, and
resources as compared to the traditional experimental approaches [115]. This has been made possible
due to the improved computational power and in silico methods.
These steps will complement experimental approaches by streamlining the research scope and guiding
in vivo validation [116].
Discovery of sildenafil and thalidome are some of the successes in the application of computational
approaches to drug design [117]. Traditional novel drug development from scratch to its availability in
the market costs about $2.558 billion over a period of 10 to 15 years [114]. With this large investment,
the success rate of a drug progressing to the market is about 13% [114].
Rejection of potential drugs particularly during safety and efficacy assessment in phase II and
phase III clinical trial development is associated with unexpected clinical side effects and cross-
reactivity. This result is significantly increased attrition rate [118]. These unexpected effects cen-
tralize on the drug target which may be disease candidate proteins or genes, biological pathways,
disease-associated microRNAs, biomarkers, crucial nodes of biological network or molecular func-
tions [119]. This could be linked to inadequate knowledge on the drug targets, undesirable phar-
macokinetic expressions upon target interaction or off target effects. This challenge relies on the
methods and population data used to identify targets especially for polygenic diseases and this there-
fore serves as a major bottleneck in drug development. It is also due to the first fundamental stage of
drug development which is identifying and validating drug targets of interest for downstream analy-
sis. This highlights the need for modulating drug targets to improve the disease state observed and
achieve the desired biological response by elucidating off-targets as observed in promiscuous kinase
inhibitors [120].
Experimental drug target identification approaches rely on the characterization of proteins of interest
followed by the experimental validation using techniques, such as gene knock-outs, animal studies
and site-directed mutagenesis [121]. However, identifying drug targets through these methods are
difficult [97].
In the post-genomic era where there is an exponential increase in open access of biological data
generated by bioinformatics pipelines, the drug discovery field has been revolutionized with diverse
biological datasets which enables scientists to understand comprehensively the biological system rel-
evant to the disease in focus. Thus, the need arose to implement in silico methods that would facilitate
designing, redesigning and repositioning of drug-like molecules exhibiting desired bioactivity profiles
as well as predicting and validating drug targets [122]. This is particularly critical given the increased
incidence of widespread drug resistant strains threatening the efficacy of common drugs. Compu-
tational methods have transformed rational and systematic approaches for exploring efficiently the
space of drug combinations in combinatorial drug discovery.
In silico methods have led to the repositioning of old drugs [123, 124] as well as the prediction of
side effects [125] and anatomical therapeutic indicators of approved drugs [126]. This implies that the
inception of computational approaches have contributed immensely to a systematic rational guidance
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of the processes and to reduction of the period required for drug’s availability in the market [124,
127]. This is possible based on the hypothesis that drug side effects would be minimized if the drug
candidate is potent and highly selective [127].
The baseline criteria for selecting drug targets requires the potential target(s) to be essential and
indispensable to disease outcome. For instance, in genetic diseases, gene therapy involves identifying
genetic variants associated with diseases. However, infectious diseases, require an understanding of
the complex interplay between the host and the disease causing organism or pathogen [128]. Host
target(s) therefore must be unique and homologous to the microbe. Pathogens protein targets that are
homologous to the host are eliminated in the computational drug discovery process to primarily avoid
any adverse drug reaction. Additionally, the effectiveness of a drug is highly dependent on the target
protein(s) in the microbe or essential biological pathway(s) or process that is key to the survival and
propagation of the pathogen in the host system.
Leveraging analytical platforms and omics databases containing biological information, compu-
tational approaches have become core components in drug discovery pipeline [121]. For instance,
analytical platforms help to elucidate essential chemogenomic relationships between available tar-
gets data and potential drug candidates or molecules, thereby facilitating the prospects of identifying
novel druggable targets, possible off-targets, drug leads and potential repurposable drug candidates.
So, it is expected that powerful computational models including but not limited to network-based and
machine-learning methods, would lead to better prediction and understanding of drug-target interac-
tions and underlying disease molecular mechanisms.
Computational approaches to drug discovery have helped to translate biological data into func-
tional knowledge treatment interventions against diseases at a faster rate. This approach is charac-
terized by providing a system view of the disease in relation to the biological system of interest.
This helps to elucidate important processes, molecular and cellular networks usually difficult to ex-
plore experimentally. The ability to reveal such patterns helps to design predictive models to identify
disease biomarkers and potential drug targets [129]. Considering complex diseases which are dis-
tinguished by their ability to dysregulate biological functions and pathways, computational methods
provide the means to understand the regulatory mechanisms through gene regulatory network analy-
sis [129]. Also, the development of computational integrative framework using biological processes,
functional data sets (protein-protein interactions between disease causing pathogens and host) to-
gether with pharmaceutical data sets facilitates the extraction of drug targets and the identification of
drugs possible for repositioning or repurposing against an infection [97, 121].
In the field of pharmacogenomics and pharmacomicrobiomics, computational techniques have
facilitated the prediction of drug metabolism by elucidating inhibitors and substrates of specific en-
zymes involved in metabolism. This has led to an in-depth understanding of in silico evaluation of
absorption, distribution, metabolism, excretion and toxicity (ADMET) properties though interactive
optimization of leads, therefore mitigating the tendency of drug failure [130].
36
2.2 Current computational approaches for drug target and potential
drug candidate identification
2.2.1 Network based analysis approach
The study of disease mechanisms to develop drugs or vaccines have evolved from single gene or
protein analysis to an entire multi-scale analysis of genomics, pharmacogenomics, metabolomics and
proteomics relevant to the disease of interest. This approach consists of integrating these different
large-scale datasets from heterogeneous sources to generate disease-specific networks, fostering a
whole genome-based integrative approach to achieve global view. This disease-specific network,
which is a biological entity composed of sub-units connected as a whole, is used to elucidate essential
nodes which could serve as targets due to their influence within the network [131].
A typical example is observed in the case of drugs, such as artemisinin combination therapies (ACTs)
and clozapine for treating malaria and schizophrenia, respectively, which interact with multiple targets
to deliver the required therapeutic response [132, 133]. This integrative approach presents a multi-
view perspective of elucidating causal genes, relevant pathways and novel drug targets to overcome
drug resistance. Also, it increases the reliability in predicting novel drugs and/or putative drugs as
well as engineering drug targets to overcome drug resistance [134, 135].
Integrating different biological datasets requires developing algorithms and systems biology tools to-
gether with the use of network analysis and functional genomic databases, as shown in functional
genomics database and tools category of Table 4, to unify the dataset [135]. These tools (Table 4) are
used to interpret the interactions within the network by identifying sub-networks and regions of simi-
larity and dissimilarity that best explains the disease of interest, to narrow down the research scope for
further enrichment and validation analysis to improve disease classification, disease-associated gene
prioritization and drug discovery [135].
Network based approach is recommended when identifying targets and drug candidates for most
complex diseases [135]. It allows to uncover biological mechanisms involved in development and dif-
ferentiation of complex diseases [129] The technique is implemented in analyzing nodes and edges in
various types of networks including chemical structure and reaction networks, protein structure net-
works, protein-protein interaction networks, signal transduction networks, genetics interaction net-
works and metabolic networks.
Moreover, network based approaches sometimes involves computational analysis of metabolisms dur-
ing the life cycle of the pathogen. Network construction categorizes various metabolic processes into
pathways and their reactions and enzymes [136]. This break–down enables analysis of the entire
network more conveniently. Flux balance analysis together with in silico knock-out studies are im-
plemented in studies during network analysis to identify vital reactions or biological processes essen-
tial for the pathogen’s survival, thus narrowing down the drug target search space [137]. There are
evidences on the use of cellular networks to elucidate complex genotype-to-phenotype relationships
among diseases and their associated genetics variants [138]. This technique has become an effective
tool for predicting drug-target associations.
Network-based approaches have been widely used to predict candidate targets and drug target
interactions. Luo et al. [134] developed an integrative pipeline capable of integrating various data
types as well as coping with the noise, incomplete and high-dimensional nature of data sets by learn-
ing low-dimensional vector representations of essential features. They identified novel interactions
between three drugs and cyclooxygenase of which was experimentally verified and further showed
to be potential for preventing inflammatory diseases. Also, various biological network pipelines and
algorithms have been developed to predict essential molecular processes and pathways to enhance
drug research, thus controlling pathways cross-talk and possible drug resistance [129, 136].
Overall, network based approaches requires a comprehensive understanding of the interaction
network particularly regions where potential drug target are located. This, therefore, requires path-
way and enrichment analysis to accurately classify the potential drug target. Figure 4 describes the
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summarized workflow of network-based approach.
Figure 4. Generalized workflow of network-based approach in predicting potential drug
targets and drug candidates.
2.2.2 Data mining (DM)/Machine learning (ML)
With the exponential increase in biological data from high throughput and combinatorial synthesis, the
technological and paradigm shift to data mining and machine learning-based methods have enhanced
the extraction and processing of these datasets by combining both biological knowledge, computa-
tional tools and algorithms. These indispensable techniques are gaining most attention and credibility
because of the reliability and accuracy in predicting key property values of compounds and its signif-
icant success rate [139]. This is attributed to their abilities to identify and map relationships between
large number of compounds which is difficult to obtain using substructural similarities only [139].
Also, machine learning techniques are implemented in both system and molecular methods to predict
drug targets through proteomic, microarray and chemogenomic data mining and analysis[119]. In
addition, ML approaches have played significant role in the pharmaceutical industry due to essential
predictive models, optimization tools and compounds libraries developed to facilitate drug research.
Data mining approaches are primarily characterized by an automatic subsetting of essential in-
formation from a pool of datasets. Data mining models ranging from simple parametric equations
derived from linear methods to complex models derived from non-linear methods [140] play a criti-
cal role in uncovering significant patterns in chemical and pharmacological property space essential
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for drug discovery. In addition to that, advanced machine learning models and algorithms such as
support vector machines on databases [141], neural networks [139], logistic regression [142], naive
Bayesian classification [139, 143], binary kernel discrimination[142], partial least squares [144] and
random forest [139] as described in Table 5 have been significantly instrumental in drug research.
For instance, they have contributed to determining pattern recognition underlying the relationship be-
tween compounds and calculated molecular descriptors or experimental measurements within large
chemogenomic space [122, 140]. ML and DM attempts to find correlations between specific activi-
ties or classifications for a set of compounds and their features thus, enabling clustering similarities
among drug-like compounds in multidimensional space [122, 140].
For example, Fatumo et al. [145] in their research to identify Plasmodium falciparum drug targets
developed a machine learning-based metabolic network analysis approach that identified essential re-
actions/enzymes as drug targets from the metabolic network of the pathogen. The authors identified
46 essential reactions of which 19 had been reported in literature. A study conducted by Sturm el
al. [146] applied neural networks machine learning approach to develop an algorithm for microRNA
target prediction. The algorithm developed has the ability to predict potential targets sites with or
without the presence of a seed match. The model was based on machine learning and automatic fea-
ture selection using a wide spectrum of compositional, structural, and base pairing features covering
current biological knowledge.
In relation to both structure-based and ligand-based virtual screening, combination of DM ap-
proaches and a collection of selective pharmacological agents enables mapping of such chemoge-
nomic libraries into biological activity space to predict potential targets [147]. Particularly, when
training sets are available, ML methods are more effective in predicting the physical, chemical and
biological properties of small molecules as compared to ab initio methods [148]. DM and ML meth-
ods are used to develop Quantitative Structure–Activity Relationship (QSAR) or quantitative models
for drug-like property predictions and chemical risk assessment [149]. Also, in silico in vitro absorp-
tion, distribution, metabolism, excretion and toxicity (ADMET) models and in vivo pharmacokinetic
models for optimizing molecular properties and predicting pharmacokinetic parameters have been
developed using ML and DM techniques [150]. These models facilitate the selection of leads with
improved strong binding affinity to targets.
Application of DM in target similarity search enables the identification of putative protein tar-
gets. This approach involves data mining of pathogen’s sequence and querying against drug target
databases to identify putative drug targets with suitable druggability index [131]. In a study con-
ducted by Mogire et al. [124] to identify putative drug targets against Plasmodium falciparum, target
similarity search of the parasites proteome against drug target databases was performed.
ML models are implemented in predicting sensitivity of drug candidates based on cell lines re-
sponse or the chemical properties of the drugs or a combination of both approaches. This improves
the power of designing and systematically analyzing experimental screenings against panels of cell
lines in order to identify potential drugs or repurposable drugs [151]. This approach is critical in
the area of personalized medicine in terms of leveraging genomic traits to drug sensitivity. Menden
and colleagues developed machine learning models that integrates chemical properties of drugs and
genomic alterations such as copy number variant and sequence variant from cancer cell lines [151].
Their model predicts sensitivity of genomically characterized cancer cell lines to the drugs in order
to ascertain the drug’s efficacy [151]. This model have the ability to optimize experimental design of
drug-cell screenings by estimating missing half maximal inhibitory concentration (IC50) values [151]
In addition, their model predicts essential target-specific association information between compounds
and target.
Nidhi and colleagues developed a multiple-category Laplacian-modified Bayesian model that
works on the basis of chemical structures to predict targets for all MDDR (MDL Drug Database
Report) database compounds [147]. The model generated was trained on extended-connectivity fin-
gerprints of compounds from 964 target families characterized by various levels of annotation in the
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WOMBAT (World Of Molecular BioAcTivity) chemogenomics database. It was then used to predict
top three most likely targets for all MDDT database compounds. Nigsh et al. [152] compared the
predictive power of multiple-category Laplacian-modified Bayesian model and Winnow algorithm,
a linear threshold learning algorithm. The Winnow algorithm implements additive machine learning
rule in order to minimize ligand-target prediction related errors [152]. It was observed that, both
algorithms predict slightly different targets due to compounds that are exclusively retrieved by each
algorithm.
Recently, Polypharmacology Browser (PPB2), a new target predicting tool has been reported [153].
This tool implements neural networks and Naive Bayesian classification models to classify ligands
based on their molecular fingerprints or descriptors [153]. Figure 5 describes a summary of applica-
tion of data mining and machine learning approaches in drug discovery.




A model-based learning method capable of deriv-
ing meaning from complicated data based on lay-
ers of connected neurons to extract patterns and
detect trends that are complex to easily observe.
[139]
Logistic regression A statistical method with a binomial response vari-





A probabilistic classifier that makes classification
using Bayesian theorem with strong independent




Used to generate models that can be used to pre-





A statistical procedure that implements an orthog-
onal transformation to transform a set of possi-





A classification technique that group data points
into clusters either by the agglomerative hierarchi-
cal clustering technique or the divisive hierarchical
clustering technique
[139]
Partial least squares A statistical method for constructing predictive
models
[144]
Random forest Learning method for classification and regression
based on decision trees
[139]
k-nearest neighbor A non parametric technique for classification and
regression where an object is classified by rules
among it nearest neighbors(k)
[139]
Continued on next page
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A supervised machine learning algorithm which
can be used for both classification or regression by






A classification method that group similar data
points according to a fixed number of clusters (k)
[139]
Figure 5. Generalized workflow of data mining and machine learning methods to biological
data in predicting potential drug targets and drug candidates.
2.2.3 Reverse / Inverse docking
This computational approach is used for identifying putative binding proteins from protein or ge-
nomic databases for particular small molecules with known biological activity [155]. Reverse or
inverse virtual screening or inverse docking is a technique that facilitates developing hypothetical re-
lationships among protein targets by chemical probing [156]. It is the structural-based approach of
virtual screening unlike the ligand-based methods which require pharmacophores, two dimensional
(2D) fingerprints and three dimensional (3D) similarity search [117]. It aims to identify drug targets
by screening drug-like molecules against rightful protein databases [157]. Molecular docking simula-
tion involves an optimization process of finding the most favorable 3D binding conformations of the
ligand to the target [150]. The targets are assessed and scored using scoring functions algorithms and
ranked according to best binding modes and interaction [158]. Interestingly, reverse docking outputs
could be used as a profile to characterize the druggability index or enzyme promiscuity of the protein
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structures [159]. Reverse docking approach remains a valuable computational technique for exploring
alternative uses for existing drugs in terms of drug repurposing and drug rescue [117]. It therefore
plays a vital role in the discovery of novel drugs, drug leads, natural products, and other ligands for
treating neglected diseases which most pharmaceutical industries are hesitant to invest in due to the
fear of inadequate return–on–investment [117].
Unlike the conventional forward docking approaches wherein variety of ligands are docked to
a target, reverse docking process involves screening to a set of different protein targets a ligand or
compound to identify potential partners through statistical analysis of binding modes within the tar-
gets [155]. The framework of this technique is dependent on the knowledge of the distribution of
non-homogeneous proteins, their complexities due to the combination of domains and their confor-
mational flexibility due to multiple folds [160]. Due to that, a ligand fits or docks into the functional
binding pocket of a specific protein fold based on its three-dimensional conformation and thus, in-
teracts with specific protein residues [156]. This technique enhances elucidation of mechanisms of
action and control possible off-target effects. Various tools described in Table 6 including TarFis-
Dock [157], IdTarget [161], INVDock [162] and AutoDock [163] have been proven to be very useful
in drug leads and target prediction [164, 165]. These tools implement different scoring functions to
approximate the standard chemical potentials of the system [163].
For instance, idTarget implements the AutoDock4 robust scoring functions [161, 166]. These func-
tions have been shown to have better statistical performance in terms of binding mode prediction [166]
and binding site searching efficiency even at the dimensionality of 30 [167].
TarFisDOCK, a valuable tool for target prediction was developed from DOCK version 4. The tool
however is still under improvement due to associated false positives as a result of inaccuracies in the
scoring function for reverse docking [157]. These errors could be associated with less coverage due
to limited target datasets and inability to incorporate protein flexibility during docking.
INVDOCK implements a scoring scheme capable of performing binding competitive analysis as well
as evaluate the interaction energy between docked structures [162]. It is based on the concept of
binding competitiveness such that, a drug that binds to its target non-competitively is likely to be less
effective.
AutoDOCK implements a machine learning based scoring function that explores the iterated lo-
cal search global optimizer approach [163]. The scoring scheme is based on the advantages of
knowledge-based potentials as well as extracting empirical information from conformations of receptor-
ligand complexes and the experimental affinity measurements [163].
Inverse docking has the ability to predict off-targets for ligands aside facilitating predicting activity
and selectivity of unknown ligands against known targets [168]. It has been applied in evaluating the
binding energies (usually expressed in kcal/mol) and modes of libraries of compounds against panel
of proteins. This evaluation results in a defined group of protein-ligand complexes thus, enhancing
the identification of lead compounds for subsequent biological test. This application reduces cost
involved in compound development and biological screening as well as reduces synthetic efforts and
time required for de novo drug discovery [156]. Lauro et al. [168, 169] applied this method to natural
bioactive molecules to investigate their efficacy against a panel of cancer associated proteins. The
idea of polypharmacology led to the development of selective optimization of side activities (SOSA)
approach which enhances the generation of new biological activities [170]. The challenging part of
this approach is the construction of panel of target proteins taken in to account careful selection of
proteins not belonging to the same folds. Also the accuracy and reliability of this approach is limited
when 3D structures of the protein targets are not available.
Regardless of the advantages of reverse docking methods in in silico drug research, they are
complex as compared to forward docking techniques such that larger target structure datasets are
required to increase the coverage and predictive power [155, 159]. Also, aside its associated biases in
inter-protein scoring yielding false positives [171], it requires high computational cost [159, 172].
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Table 6. Description of various tools applied in reverse/inverse docking.
Tool Description Reference
TarFisDock A web-based tool that offers potential drug target
databases together with a reverse ligand-protein
docking approach which are used in searching for
small molecule-target interactions. The tool ac-
cept small molecule as input and predicts possible
binding drug targets.
[157]
IdTarget A web-based tool for predicting potential bind-
ing proteins for chemical compounds through a
divide-and-conquer docking approach and robust
scoring function based on regression analysis and
quantum charge models. It has the ability of
screening against majority protein structures in
Protein Data Bank
[161]
INVDock This software enables automatic identification of
potential protein, RNA and DNA targets of small
molecules by searching in both protein and nu-
cleic acid 3-D databases. It implements a flexible
docking algorithm
[162].
AutoDock A suite of automated docking tools to predict
binding interactions between small molecules and
targets of known 3D structure
[163]
2.2.4 Biological activity spectra (Biospectra) analysis
There are several reported evidences to the fact that most drugs establish therapeutic response through
multiple target modulation [173, 174]. The ability to predict such functional consequences of bi-
ological perturbations between the genome or proteome of an organism and biologically profiled
compounds is indispensable in drug research. In relations to that, analysis of the modularity effect
drug-like molecules impact on target’s function is a must to understanding the expressed pheno-
type or therapeutic response capacity of the molecule [175, 176]. Biospectra simply refers to the
activities of compounds across potential targets which could enable investigating structure-property
relationships [177]. Biospectra analysis is a probabilistic structure–activity relationship approach that
complements experimental affinity-based studies [176]. The technique herein is used for measuring
quantitatively the patterns and dynamics of the functional activity of a molecule across multiple po-
tential targets [176, 177]. It is therefore a determinant of the inhibitory or stimulatory effect profiles
of drug–like molecules on targets within a system. Studies have shown that the association between
proteins, drug-like molecules and biospectra serves as the building blocks for developing probabilistic
approaches to drug discovery [178].
This method provides a firm foundation in determining quantitatively the correlation between
molecular structures and biological effect profiles by providing estimates of the therapeutic effect of a
molecule. Estimation is done by constructing a nonlinear multivariant model which provides an unbi-
ased tool for investigating associations between structure and function similarities of molecules [176].
Such analysis is relevant for predicting drug targets for orphan compounds based on the concept of
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chemical structure similarity [177].
It provides the means to classify molecules on the basis of biospectra similarity as well as predict in-
teracting capabilities of molecules with multiple targets. This classification mechanism allows for
identification of molecules with similar function with no prior information concerning the target
which is difficult using experimental techniques. Biological activity spectra is an essential indica-
tor of molecular property descriptor [179]. This method was implemented by Fliri and colleagues
to identify agonist and antagonist effect profiles of medicinal agents on brain dopamine receptors
belonging to the GPCR superfamily [176]. This technique facilitates the ability to conduct spectra
similarity and hierarchical clustering methods through profile similarity measurements thus, estab-
lishing quantitative relationships between chemical structures and biological activity spectra [179].
Biospectra analysis have been shown to be critical in mining pharmacology datasets as well as pre-
dicting possible adverse drug effects based on profile similarity with drug-like molecules known for
adverse reactions [177]. Similarity between molecules are measured using Tanimoto similarity coef-
ficient [180], cosine correlation [181], Euclidean distance [182] or city block distance [183].
Paolini and colleagues presented a comprehensive mapping of pharmacological space by applying
probabilistic model on integrated structure-activity relationships data [178]. They found 836 human
genes discovered verified targets for small molecules. This integration enables the identification of
unique molecular targets through construction of a ligand-target matrix.
Since similar drug-like molecules express similar biospectra, this approach is useful for drug repur-
posing because it facilitates the translation of biological response data into chemical structure de-
sign [176]. This implies that, the ability to correlate off-target effects with biological spectra would
help map unto new targets where the response might be beneficial to address a different diseases.
For example, sildenafil initially developed to treat angina expressed a side effect of prolonged penile
erection and this resulted in a change of the treatment focus of the drug [184].
However, biospectra analysis is highly dependent of experimental data obtained from various
ligand-binding assays or a martix of targets which could be difficult.
2.2.5 Ligand-based in silico target prediction
Ligand–based computational approach is the framework for ligand-based drug discovery. It is based
on the concept of chemical structure similarity, which states that similar ligands or compounds would
bind to similar targets with almost the same binding affinity and express similar biological responses
[160]. This concept of similarity has been extensively utilized in lead discovery and optimization
primarily because it takes into account the polypharmacological nature of drugs [185]. Also, it is
essential for quick investigation on primary and secondary targets as well as selectivity among target
families [177]. The approach herein involves the interplay between characterized protein targets
and characterized ligands with similar chemical structure, properties and pharmacophoric features to
enable predict biological targets. This is achieved by mapping the structures of compounds known to
modulate cellular phenotypes (mostly natural products or orphan compounds) unto chemogenomics
databases containing biologically profiled compounds with known targets [177].
In that regard, cheminformatics and bioinformatics have developed mapping models including but
not limited to topological-based models, Bayesian classification models and atom pair-based models
from available bioactivity data using machine-learning and statistical methods [173]. These models
are implemented in mapping compounds into chemogenomical space or bioactivity database taking
into account either 2D or 3D molecular descriptors [160, 186] and chemical fingerprints [187] for
measuring similarity among structures to predict targets. An advantage of using chemical fingerprints
in designing models is that it enables back-projections of correlation between characterized proteins
and compounds unto orphan compounds with the knowledge that similar compound structures would
exhibit similar affinity chemical fingerprints [177].
Molecular descriptors are numerical features extracted from the compounds based on their molecular
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properties [160, 188] whereas chemical fingerprints are high dimensional vectors that encodes the
presence of substructural fragments [187, 189].
Ligand-based approaches to target prediction provides the platform to understand the relationships
between structurally dissimilar but functionally related proteins based on their ligand similarity, thus,
helping to form hypothesis which can be verified using statistical methods. Similar to biospectra,
ligand-based approach is more informative for pharmacology, medicinal chemistry and biochemistry
[173].
Similarity among 3D structures are measured using Minkowski distance metrics and Tanimoto
similarity coefficient and its complement, the Soergel distance [160]. Tanimoto similarity coefficient
can be applied to 3D structures [139] however, this metric is susceptible to molecular size because
it fails to account irrelevant features of a large molecule, thus, resulting into odd size dependencies
[160].
These measurable features of compounds have been implemented in developing tools such as Sim-
ilarity Ensemble Approach (SEA) [173], Swiss Target Prediction (STP) [190], SpiDER [191], Su-
perPred [192], Polypharmacology Browser [193], HitPick [194], Prediction of Activity Spectra for
Biologically Active Substance (PASS) [195], MOst-Similar ligand-based Target inference approach
(MOST) [196], Candidate Ligand Identification Program (CLIP) [197] and Chemical Similarity Net-
work Analysis Pulldown (CSNAP) [198]. These tools described in Table 7 implements fingerprints
and/or structural similarity to predict ranked targets from ligand-target datasets in order of decreasing
similarity score.
Ligand-based target prediction approach is not feasible in the cases of predicting targets with no
or only a small number of bioactive ligands and ligands that exhibit activity cliffs characterized by
high structural similarity but different activity. [122, 199].




This method is based on different types of molec-




A web-based server for predicting targets for bioac-
tive small molecules. This tool is based on a com-
bination of 2D and 3D similarity measures or fea-







This computational tool is used for predicting
macromolecular targets for both de novo designed
molecules and known drugs. It merges concepts of
self-organizing maps, consensus scoring and statis-
tical analysis.
[191]
Continued on next page
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Table 7 – continued from previous page
Tool Description Reference
SuperPred This tool is based on the hypothesis that simi-
lar structures have similar activity profiles. It is
a web-based tool that translates molecules into
molecular descriptor or fingerprints and then maps
unto drugs with established molecular targets
links. Similarities between compounds and exist-
ing drugs are expressed using Tanimoto coefficient




A versatile web-based tool that predicts potential
drug targets for small molecules by searching near-
est neighbors using 10 different fingerprints which
integrates the composition, substructures, molec-
ular shapes as well as pharmacophore features.
[193]
HitPick A web-based tool that implements the B-score
method and other statistical methods for identify-







A web-based tool for predicting the biological ac-
tivity spectra of compounds on the basis of struc-
tural formula. These predictions are efficient in







A computational tool that uses fingeprint similar-
ity and bioactivity of most-similar ligands to pre-





A target prediction tool that implements the sim-
ilarity search approach using the Bron-Kerbosch
clique detection algorithms to find structures com-
mon to that of a known bioactive target 3D struc-
tures. This is achieved by characterizing pharma-






A drug target prediction method that is based on
chemical similarity networks for large-scale consen-
sus chemical pattern recognition through cluster-
ing used for drug target profiling.
[198]
2.2.6 Target-based in silico prediction
In contrast to ligand-based in silico prediction, target-based approach involves predicting ligand or
compound partners from the targets perspective noting their complexities resulting from combina-
tion of multiple domains, promiscuity of fold families and conformational flexibilities [160]. This is
because, protein conformational changes coupled to ligand binding constitutes the structural stabiliza-
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tion and energetics basis underlying protein regulation [200]. In this approach, targets are predicted by
investigating protein functionalization when ligands or substrates bind to a well characterized binding
pocket. Due to that, several algorithms such as Bron–Kerbosch clique detection algorithms [197] are
used to build binding site similarity methods which are implemented to identify significant targets.
These methods including CavBase [201], SuMo [202], IsoMIF [203], PocketMatch [204], Pocket
Alignment in Relation to Identification of Substrates (PARIS) [205] captures local physico-chemical
correspondence and functional relationships among proteins structures or substructures (especially
regions in binding sites) as well as local spatial similarities.
Other techniques implement functional pharmacophore screening approach. This approach entails
using pharmacophores of small-molecule drugs to investigate their binding interactions within binding
pockets of targets and identify such compounds whose features aligns with the description [160, 206].
PharmMapper [207] tool has been developed to implement such an approach. This approach has been
extensively used to search for targets for components of Chinese medicines.
Predictive models have been modified to incorporate functional effect prediction (activation or inhi-
bition) of compounds on the target since this may positively or negatively modulate a pathway which
may result in a desired or undesired functional activity [208, 209]. A recent study by Mervin et
al. [210] used models ranging from simplistic random forest to cascaded models which implements
separate binding and functional effect classification steps to predict functional effects. Table 8 pro-
vides a description of the various tools used for target-based approach.
Table 8. Description of various tools applied in target-based approach.
Tool Description Reference
CavBase A database that stores set of cavities retrieved from Pro-
tein Data Bank for detecting functional relationships
among proteins. It is based on the hypothesis that pro-
tein functions are associated to their ability to recognize
small molecules as well as the interactions established in
a defined binding pocket. The method queries a protein
cavity to extract similar ones using clique detection al-
gorithm.
[201]
SuMo A web-based tool used for finding arbitrary 3D struc-
tures or substructures of proteins. It is based on how
macromolecules are uniquely represented using selected
triplets of chemical groups.
[202]
IsoMIF A web-based tool for identifying molecular interaction
field similarities. The tool is useful in predicting func-
tions of targets, identifying polypharmacological targets
or cross reactivity as well as identifying potential repur-
posable small molecules.
[203, 211]
PocketMatch An algorithm that has the ability to infer functional sim-
ilarities between protein structures in a high-throughput
manner by accurately and efficiently performing large-
scale comparison of their binding sites
[204]
Continued on next page
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A tool capable of quantifying the relationships between
binding pockets to investigate there essentiality for lig-
and prediction. In this tool, each pocket is represented
as cloud of atoms. Similarities are measured by by align-
ing these atoms in 3D space and analysed using convo-
lution kernel
[205]
PharmMapper A computational pharmacophore web-based tool for
drug target identification. It is based on a reverse phar-
macophore principle where by the query compound is
mapped against an annotated pharmacophore model
database thus, enabling polypharmacology prediction
techniques critical for drug repositioning and potential
offtarget risk prediction
[207]
2.2.7 Genomic analysis approach
In this post genomic era, high-throughput hybridization-based technologies and deep sequencing
methods have led to the generation of large genomic datasets. Systematic analysis of gene expression
and transcriptome of an organism is key to identifying relevant pathways in disease pathology and
characteristic expression patterns of specific disease–associated genes. This supports developing di-
agnostic and prognostic biomarkers critical for disease treatment specifically in areas of personalized
or precision medication [212]. Also, analysis of these datasets enhances the identification of func-
tional genetic variants (derived and risk alleles) and prediction of traits. For instance, an extensive
study on the morphology of cancer has led to the understanding that, it is as a result of multiple ge-
netic anomalies and as such, individuals with the same cancer type have different genetic anomalies
in their tumour [213].
Genomic analysis is a data-quality dependent technique that involves both knowledge-based for
the case of genes known to be associated to the disease of interest and data-driven unbiased ap-
proaches for cases of no prior knowledge of contribution of a gene to the disease of interest. It
requires no assumptions of a genes role. Comparative genomics analysis between cases and controls
together with advanced computational models and various genome reference panels, provides the
platform to interpret and analyze disease-associated gene variants identified through genome wide as-
sociation studies (GWAS) or next generation sequencing (NGS) or whole exome sequencing (WES)
or transcriptomic studies (RNAseq). This helps to translate these functional knowledge into treatment
interventions particularly leveraging disease-target associated data sets [128, 212]. Genes identified
could be prioritized to identify putative drug targets and vaccine candidate targets [214]. However
because GWAS is not able to explicitly identify causal relationships, the combination of different
methods would increase the predictive power of identifying highly potential targets. A study con-
ducted by Fan-Minogue and colleagues evaluated the effectiveness of differential gene expressions
(DGE) data, disease associated single nucleotide polymorphisms (SNPs) as well as the combination
of the DGE and SNPs to predict drug targets for 56 human diseases [215]. Their studies showed
that the combination provided higher predictive statistical power for prioritizing candidate targets as
compared to individual DGE and SNPs datasets.
Studies have shown that genes with disease associated alleles are highly potential drug targets [216,
217]. Careful analysis of gene expressions data, somatic mutations data as well as genetic associa-
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tion data has been widely explored to study genetic causes of disease and also identify drug tar-
gets [218, 219]. In view of that, genomic approaches to drug discovery is a delicate field to address
genetic diseases particularly, those with few effective therapies such as neurodegenerative diseases.
Genome analysis provides the platform to identify genes that encodes novel proteins or regulatory
elements encoding potential drug targets.
Comparative genomics method, a well studied analytical approach enables integration of omics
data and the use of several bioinformatics tools such as Identity Plot Maker and Visualization Tool
for Alignment (VISTA) [220]. This method enables comparison of two or more genomic sequence
of an organism to discover the similarities and differences among the genome thus, exploring and
understanding the significance of biologically conserved active regions [220]. In addition, it helps
examine the broad spectrum and selectivity of potential genes or proteins as targets across various
species of an organism. Comparative genomics therefore provides a means for studying evolutionary
changes among organisms by investigating derived and risk alleles which helps to identify genes that
are conserved or common among species, and also genes that contribute to the uniqueness of an or-
ganism.
Subtractive genomics on the other hand is a widely used approach in drug discovery to identify
novel drug targets [137]. This in silico approach is based on the identification of essential and non-
homologous proteins within the pathogen of interest [221]. Various tools required for genomic anal-
ysis are described in Table 3 and Table 4.
2.3 Comparing different approaches in computational drug discovery
As described previously, several computational drug discovery approaches have been suggested,
including genomic, biospectra, network-based, machine learning / data mining and virtual screen-
ing/molecular docking simulation approaches. Although these methods individually have their spe-
cific areas in drug discovery that best describes their usefulness, they have the ability to be integrated
to understand complex biological system in order to address challenges in computational drug dis-
covery. This is because, technological advancement has led to the generation of various datasets
types describing biological systems from different dimensions some of which are sequencing, gene
expression activity and proteomics [222].
In the area of predicting and assessing pharmacological effects of a drug, the combination of these
techniques has been instrumental in determining drug target interactions (DTIs) with high efficiency
and low cost. In comparison to experimental techniques (in vitro and in vivo methods), computational
methods have provided the technicalities to systematically determine all possible interactions in or-
der to clearly elucidate the pharmacological patterns [223]. Higher dimensional levels of prediction
revolve around systematic analysis of biological complex networks and large integrated biomedical
datasets, and as such, using a combinatorial approach is highly essential. Some approaches share
similar concepts but applied in different forms in addressing similar issues, thus, combination helps
to compensate for individual limitations. This in turn increases the accuracy of predicting and mini-
mizing possible adverse effects [224]. For instance, molecular docking principles in elucidating DTIs
require 3D structures. Due to that, there are associated biases and false positives when high quality 3D
structures are not available [223]. Unlike molecular docking approaches, ML drug target interaction
predictive models have the extended capacity of taking into consideration not only the 3D struc-
tures of targets but also molecular and protein sequence descriptors [223]. However, network-based
methods in predicting DTIs to investigate pharmacological effects apply recommendation algorithms
implemented in recommender system [225] and link to prediction algorithms [226] rather than 3D
structures and molecular systems. Also, network-based methods are relatively faster compared to
the other methods. This is because, the DTI network of interest can be represented as a matrix on
which calculations can be computed easily [223]. Additionally, they have the extended capacity of
predicting drug effects through simple dynamic processes such as random walk, resource diffusion
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and collaborative filtering on biological networks [223].
For example, Paolini and colleagues studied polypharmacology interaction network for human pro-
teins by constructing ligand-target matrix using a Laplacian-modified Bayesian probabilistic models
to explore the relationships between chemical structure and targets by integrating diverse structure-
activity relationships data [178]. They observed 35% of 276,122 active compounds within their
database to hit more than one target whiles 65% hit a target, thus indicating extensive promiscuity
of drugs and leads across targets.
Data mining is highly essential in chemogenomics to mine chemogenomic datasets. This is crit-
ical in establishing the relationship between set of potential drug targets and ligands. However, the
interplay among a holistic picture of the biological system (network), molecular docking approaches
and ML methods in chemogenomics presents a broader scope to investigate the effects of compounds
on gene/protein expression. To efficiently identify and assess the effects of specific protein targets
on specific drugs, robust molecular docking systems that implements ML and DM models have been
developed to optimize the performance of predicting drug’s effect across molecular networks [227].
These models provide the platform to avoid unnecessary assumptions by specifically accounting for
binding effects most often challenging to model without ML and DM techniques. Utilization of
this approach in designing scoring functions have significantly enhanced the accuracy of establish-
ing binding affinities of various protein-ligand complexes [228]. Ballester and colleagues developed
a competitive high performance scoring function that implements random forest to capture binding
effects [228]. The flexibility of their scoring function compared to other rigid functions ensured that
it has high predictive power when tested on trained datasets. Another application of this approach is
developing machine learning-based scoring and binding affinity functions integrated with molecular
docking tools to address difficulties involved in molecular docking. Hsin et al. [224] developed a
computational screening approach using machine learning and docking packages to investigate the
polypharmacological nature of compounds against potential targets within a biological network. The
model developed, has the ability to assess binding modes and predict the best binding mode to tar-
gets. This approach increases the reliability and confidence in assessing the binding conformations of
compounds and predicting best modes [227]. It also helps to rate the performance of various docking
packages as well as compensate for scoring functions–associated errors [229, 230]. Advanced ML
methods provide the technique to investigate drug effect in preclinical research and clinical trials.
Also, they provide an efficient way to systematically and analytically extract meaningful biological
information from clinical trial datasets. This facilitates the ability to design the chemical structure of
drugs to modulate drug-target interactions. However, it is of importance to that, the ability to interpret
such datasets is challenging and as such requires experience and high technical skills.
Deep learning, a class of machine learning, has strong generalization ability and feature extrac-
tion capability. It has emerged as a powerful tool capable of identifying highly complex patterns
in both homogeneous and heterogeneous datasets. In computational drug discovery, deep learning
method has enhanced prediction of bioactivity, de novo molecular design, virtual screening, activity
scoring and synthesis prediction [141, 231]. This is mainly because it has less generalization errors,
thus, yielding impressive results as compared to traditional machine learning. It has been extensively
applied in functional genomics in discovering DNA-binding motifs, and determining sequence speci-
ficity of DNA and RNA binding proteins [232].
Data mining and machine learning models are implemented in computational drug discovery for
unbiased mining and analysis of genetic datasets mostly in the focus of personalized medicine [233].
The aim of personalized medicine is to discover novel drugs and biomarkers for specific patient
groups, most suffering from complex disorders. Developments in this field are applied most often
in gene and immuno-oncology therapies for highly personalized and specific group treatments re-
spectively [234]. In view of that, genomic approach together with ML methods provides the platform
for identifying disease associated genes (particularly rare disease variants) and their corresponding
mutations from methods like DNA sequencing and GWAS [234]. This helps to translate functional
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results into treatment and strategic measures. Analyzing genetic functional networks with ML and
DM methods enhances the chances of identifying novel biomarkers and drug targets. For example,
combination of network-based approach and ML methods plays an increasingly significant role to pre-
dict novel mechanisms underlying disease-specific targetable genes or pathways associations. This in
turn offers the opportunity for finding new applications for drugs as well as predicting potential ad-
verse effects. Bari and colleagues developed a machine learning-assisted network inference algorithm
capable of identifying Class II cancer-associated genes in a cancer network generated from support
vector machine models [235]. Also, this combination have been implemented in target fishing using
chemical fingerprints [236].
Integration of ML and DM approaches together with network-based techniques is of noteworthy im-
portance in analyzing biological networks to identify potential set of genes or pathways that could
serve as targets in combinatorial therapy. The rationale behind this combination strategy is not only
to overcome resistance and limitations of monotherapy regimens but also, to overcome the complex-
ities of diseases such as malaria, tuberculosis, cancer and HIV [237]. In that regards, predictive
models based on ML, DM, network-based and sometimes molecular docking approaches have been
developed to investigate the synergistic effects of drug-like molecules on specified targets [238, 239].
These models incorporate heterogeneous datasets such as cell signaling pathway, transcriptomic and
pharmacological datasets [239]. The models have the extended ability of providing insights into bio-
logical mechanisms underlying the synergistic combination.
Combination of genomics approach with molecular docking simulations are mostly applied in dis-
covering novel ligands or drug-like molecules to treat infectious diseases.
2.4 Source of Drug Failure: Challenges and Opportunities
2.4.1 Incomplete knowledge on the biological mechanisms underlying certain dis-
eases:
A critical draw–back in the success story of drug discovery is associated with poor understanding
of the underlying mechanisms behind some diseases such as nervous system disorders, chronic kid-
ney disease, idiopathic pulmonary fibrosis and other complex disorders [240]. Inability to elucidate
genetic variants, biomarkers, pathways or proteins involved in the aetiology of such diseases con-
tinues to be a challenge to drug research. Due to that, specific targeted drugs or vaccines have not
yet been developed. Researchers have shown that indepth knowledge of disease mechanisms and
the elucidation of critical biomarkers would contribute significantly to drug development [240]. This
could be associated with inadequate specific datasets available to help unravel the mystery behind a
disorder. Due to that, there is an intensified scientific research into bridging the gap between dis-
ease mechanisms and drug development. Combination of genomics, chemistry and clinical datasets
together with advance ML techniques has been promising in exploring potential targets. A typical
example is Alzheimer’s disease, in which various mechanisms are been identified through extensive
research [241].
2.4.2 Drug resistance development:
Drug resistance has been a major burden in drug use. More often, drugs, particularly, those target-
ing disease causing pathogens in infectious diseases lose potency with time primarily as a result of
selective pressures resulting in drug resistant strains development. This challenge contributes to dis-
ease resurgence and increased morbidity and mortality rates. In complex diseases, drugs targeting
human cells develop resistance through factors like epigenetics, DNA damage repair and epithelial-
mesenchymal transition [242]. In general, drug efflux and drug inactivation are common factors
linked to drug resistance. This phenomenon continuously necessitates further research and alterna-
51
tive treatment development. In addition, researchers are investigating the core biological associated
activities resulting into resistance to identify novel approaches to counter such effects.
2.4.3 Inability to reproduce generated disease-related datasets:
Data reproducibility crisis remains a critical challenge in this post-genomic era. Data validation is
a measure of the confidence and integrity of the datasets. It is noteworthy that, inconsistencies in
results obtained from replicating experiments in different laboratories breeds unsuccessful translation
of discovery research as a result of the level of mistrust in the data [240]. This situation significantly
slows the rate of translating biological data into functional knowledge and treatment interventions.
However, it is argued out that such differences in results could be attributed to confidence interval
defined for the independent study as well as inadequate knowledge in essential statistical methods and
tools used. Researchers have proposed that external validation and explicit reporting of experimental
datasets could possibly increase reproducibility [240]. Also, this challenge presents the opportunity
for researchers to develop standardized procedures tailored to each working environment to ensure
reproducibility of results and continuity of scientific knowledge.
2.4.4 Complex unpredicted metabolism networks
Unpredicted interactions and mechanisms within a network due to associated kinetic interactions
results in an incomplete picture of the cellular behaviour [243]. However, over assumptions in mod-
elling hinders the ability to develop accurate models to answer the biological hypothesis. As a result,
algorithms developed for such models produces results that deviates from the true expectations. This
therefore presents a challenge in modelling the system to overcome unknown associated metabolic
fluxes. As such, there is a higher likelihood of missing essential informations such as pathway and
biological activities essential for drug research. There are off-target metabolic interactions that occur
as result of metabolic pathways that lead to modelling challenges. Off-target metabolic interactions
can be responsible for expected and unexpected responses which most of the time are side effects. In
overcoming these challenges and to minimize drug failures and associated adverse effects, predictive
models for individuals target networks that simultaneously detect metabolic similarity of associated
metabolic pathways using joint learning algorithms.
2.5 Summary
In this chapter, we presented various computational approaches and tools essential for in silico ex-
traction of drug targets, predicting potential drug-like candidates, analyzing bioactivity profile and
elucidating possible off-target effects in drug discovery. These approaches complement experimental
techniques in drug development.
Furthermore, we highlighted on the application of machine learning, data mining, genomics and net-
work analysis techniques in investigating the dynamic patterns within integrated datasets from multi-
ple sources to predict critical nodes, pathways and biological processes. These techniques are relevant
in achieving a global perspective of the biological systems to investigate the interplay between mul-
tiple independent genes or proteins on disease aetiology. This therefore provides the platform to
elucidate set of functional biological entities for drug and vaccine development.
We discussed various molecular docking simulation techniques. We showed the specificity of each
approach in terms of predicting potential drug-like molecules and protein targets in drug develop-
ment. We emphasized on the application of these methods in drug repurposing and reuse particularly
in addressing drug resistance and drug development for orphan diseases thus, contributing to limiting
the risk of drug failure during trials. Also, we highlighted the combination of machine learning and
molecular docking techniques in designing various predictive models to investigate the structural and
chemical properties of ligands or drug molecules and validate their efficacy in drug development.
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We have shown that these approaches can be combined to compensate for limitations of individual
methods thereby increasing the predictive power.
Finally, we presented sources of drug failure looking at the challenges and opportunities involved.
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CHAPTER 3
3 Plasmodium falciparum Proteome Functional Networks
3.1 Introduction
Understanding of disease causing organisms to elucidate the mechanisms behind the evolution and
emergence of resistant strains in order to develop better candidate drugs involves an extensive knowl-
edge of its biological processes at the cellular and molecular level [14]. This activity requires an in-
depth understanding of the organism’s proteome which is regarded to execute the genetic programme.
However, proteins rarely act alone but in extended networks. They establish complex physicochemi-
cal dynamic connections in order to facilitate structural and functional organization of the organism.
These connections makes up the protein–protein interaction network (PPIN). The interactome net-
work provides a general review of possible interactions than can occur between proteins [95]. Pro-
teins interact both directly and indirectly within a system to maintain the stability and robustness of
the system and as such, they are fundamental and critical to every process in the cell. For our study,
we will focus on functional protein-protein networks to ensure potential functional interconnectivity
of host and pathogen.
In this chapter, a computational integration technique is applied to construct Plasmodium falci-
parum functional protein network in order to build human-Plasmodium falciparum protein network.
Primary data sets, such as protein sequences, functional data sets from high–throughput experiments,
protein signatures from databases such as InterPro [98] and in silico generated functional datasets
were implemented to construct a unified functional association protein-protein interaction network.
3.2 Assembling Functional Interaction Datasets for Constructing P.
falciparum Functional Network
Various heterogeneous parasite datasets from different sources such as literature, databases and high-
throughput experiments described in Table 4 were implemented in this step. The datasets are cat-
egorized into functional interaction and genomic datasets as shown in Table 4. Parasite functional
datasets for this research are those retrieved from PPI databases, functional genomics databases and
high-throughput experiments (see Table 4). On the other hand, genomic datasets comprises of protein
sequence and protein family and domain data retrieved from sequence databases such as Uniprot and
Interpro as shown in Table 4. We integrated various datasets in this study with the overall aim to
increase the coverage, sensitivity and accuracy of the generated network.
163 reviewed Plasmodium falciparum isolate 3D7 protein sequences retrieved from Uniprot database
were used to generate pairwise sequence similarity associations using Basic Local Alignment Search
Tool (BLAST) specifically blastp, the protein-protein BLAST algorithm [244]. Only reviewed protein
sequences were considered in this study because they have been manually annotated using literature
records and curator-evaluated computational analysis [93]. The pair-wise relationship was based on
the hypothesis that, proteins sharing conserved domains or families have higher probability of estab-
lishing potential functional associations [245].
Parasite interaction dataset consisting of only reviewed proteins were also retrieved from STRING
database version 11.0 [102], for this study upon querying the sequence data. STRING database makes
predictions based on known interactions from curated databases, experimental findings, gene neigh-
bourhood, gene fusion and gene co-occurrence. It also makes predictions through text mining, co-
expression as well as protein homology. STRING predicted interaction comprised of 386 interactions
among 114 proteins. The score for these functional interactions ranged between 0.4 and 0.99.
In addition, the Plasmodium falciparum interaction dataset from IntAct database [109] was retrieved
for this study. IntAct provides interaction data that are derived from literature curation or direct user
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submission. The database is linked to other functional databases such as BioGrid, MINT and Uniprot
described in Table 4. The retrieved interaction dataset comprised of 2,916 interactions between 1,343
proteins.
Also in our analysis, we included experimentally determined Plasmodium falciparum protein-protein
interaction dataset described by La Count et al. [94]. This dataset was identified through literature
review. This dataset covers about 25% of the parasites proteins. This functional dataset is made up of
2,846 interactions from 32,000 yeast two-hybrid screens with Plasmodium falciparum protein frag-
ments. These proteins are known to be involved in the parasite’s intraerythrocytic cycle [94].
In addition, a comprehensive Plasmodium falciparum protein interaction map predicted by Wuchty et
al. [105] was used in our study. The map augments protein interaction information that has been re-
tained by the evolutionary divergent model organisms such as Saccharomyces cerevisiae, Drosophila
melanogaster, Caenorhabditis elegans, Escherichia coli together with experimental P. falciparum PPI
data. The network consists of 4,918 interactions among 1,872 proteins.
Also, our research study incorporated P. falciparum protein interaction datasets generated using
weighted protein domains of the Protein Family database (PFAM) [103]. The network is made up
of 1,428 protein interactions among 361 proteins. In addition to that, we used another interaction
data generated by Wuchty et al. [104]. This data comprising of 19,979 interactions among 2,321 was
derived by inferring interologs, protein domain and experimental interactions.
P. falciparum experimental interaction dataset used by Wuchty et al. [106] in a study to identify
conserved PPIs in S. cerevisiae, C. elegans and D. melanogaster that have orthologs in P. falciparum
through comparative topological analysis was also used for our study.
Parasite interaction dataset was also retrieved from InterPro version 73.0 database [98]. InterPro is
a protein signature database comprising of protein families, domains and functional sites from other
databases including but not limited to PANTHER and PROSITE described in Table 4. The generated
functional dataset comprised of 1,013 interaction between 256 proteins. The prediction is based on
the idea that each interacting protein pair in the dataset share common domains.
Overall, we were able to ensemble a map of Plasmodium falciparum interaction datasets from nine
independent studies.
3.3 Scoring Functional Interaction Datasets
Protein-protein interaction (PPI) maps are experimentally determined on a large or small scale us-
ing either the binary approach or the co-complex approach [246], the two main technologies for PPI
determination. Several experimental methods such as yeast two-hybrid screen approach, RNA ex-
pression profiles, genetic interaction and mass spectrometric identification methods implement such
approaches to investigate functional PPIs [14, 246]. Yeast two-hybrid and mass spectrometric tech-
niques seek to detect physical binding among proteins whereas RNA expression profiles and genetic
interaction techniques aim to detect functional associations between proteins which most of the time
take the form of physical binding [247]. Aside these methods being labour and resource intensive,
they are limited by their interaction classification biases, noise, sensitivity, coverage, complementari-
ties and accuracy of the data generated [14, 248, 249]. These limitations are attributed mostly to the
coverage of the methods used in generating the datasets. For instance, interactions based on mass
spectrometry predict few proteins involved in transport and sensing whereas yeast two-hybrid gener-
ated data fail to cover some categories for example, proteins involved in translation [246]. Tradition-
ally, experimental datasets are cross validated or quality-checked by benchmarking with a reference
set of trusted interactions [247]. However, the advent of in silico techniques and scoring schemes has
helped to quality-check these datasets prior to functional and structural analysis of the interactome.
The importance of weighing functional associations is to control the biases, uncertainty of data
and noise associated with experimental methods. The effectiveness of a scoring function used in
predicting the reliability and/or confidence in functional associations is critical in managing the
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experimental-associated limitations. This is because, the degree of confidence-level of a functional
dataset is in direct relation to the reliability of the data. Inability to carefully weigh the functional
associations, results in propagation of annotation errors which in turn lead to a compromise of the
integrity and stability of the generated network [245].
In this chapter, we leverage a novel effective information-theoretic based functional scoring scheme
presented by Mazandu and Mulder [245] to score the functional associations obtained from sequence
BLAST, conserved domains interaction datasets from InterPro as well as other functional interaction
datasets. The scheme used in our study have been tested to produce a reliable functional network with
higher coverage [245]. In relation to scoring functional pair-wise relationship, this method provides
the ability to modify parameters based on the users confidence in the data source. On the other hand,
this method considers not only the number of common signatures shared by two proteins in a pro-
tein domain and family data, but also considers the nature as well as databases and experiments from
which the information was retrieved.
3.3.1 Scoring InterPro Datasets
Similarity score (Xij) between a protein pair (pi) and (pj) with common signatures (Sk) is measured
by the minimum number of the occurrence of these signatures [245]. This is defined mathematically
in Equation 1 below,




where nki and nkj represent the number of occurrences of signatures and k is the number of proteins
starting from 1 to the last(M ).
Due to the associated level of uncertainty in experimental datasets, they naturally follow a normal
distribution when compared to other distributions. This implies that, the datasets can be summarized
by its mean (µ) and standard deviation (σ). Also, the optimal distribution maximizes information
entropy in the dataset. Information entropy is a measure of uncertainty within a dataset. It is defined
as the average rate at which information is produced by a stochastic source of data.
Therefore, as established by Mazandu and Mulder [245], the confidence level (δ) of the similarity
score (X) implemented in the customary python algorithm for scoring protein family and domain is
defined as shown in Equation 2






where φ is the cumulative probability function of a normal distribution, α is the calibration control
parameter which strengthens the impact of the confidence level.
The scoring scheme rectifies the dataset to remove all outliers, thus maintaining data points that lie
within a normal distance. After rectifying, the information entropy related to the dataset is computed
using the binary entropy function shown in Equation 3
H2(δ) = −δ log2(δ)− (1− δ) log2(1− δ) (3)
The scheme computes the functional relationship score between protein pairs sharing common signa-
tures. The functional relationship score is defined as shown in Equation 4
Γ(δ) = 1−H2(δ) (4)
The reliability or confidence score of the functional relationship between two proteins is defined as








Upon running the customary python scripts on the InterPro datasets, the pair-wise interaction
derived comprised of 1,013 interactions among 256 unique proteins. The functional interaction score
ranged from 0.4 to 1.0.
3.3.2 Scoring Protein Sequence Similarity
The scoring scheme presented uses the bit score between pair-wise homologous sequence alignments
(s1, s2). The bit score, denoted as (S(s1, s2)), provides a mean for defining homology between pair-
wise sequences by measuring the average information or features available per amino acid position in
the aligned pair-wise sequence [245]. Homology is simply defined as common evolutionary ancestry
between genomic sequences [250].
The bit score is obtained through pair-wise homologous sequence BLAST [244]. BLAST sequence
similarity estimates the bit score by identifying common features and estimating statistically signif-
icant similarity that reflects shared common ancestor [250]. Also, the scheme presented uses the
mutual information I(s1, s2) between pair-wise homologous sequence alignments (s1, s2). Mutual
information is the underlying common substantial biological features contained in pair-wise homol-
ogous sequences [250]. This information is based on the fundamental postulate about homologous
sequences which is paraphrased as "the closer the similarity between a protein sequence pair, the
closer in evolution" [251]. This therefore implies that, the bit score is in direct relation with the mu-
tual information between a protein sequence pair. Therefore, Mazandu et al. [245] established the
relationship shown in Equation 6 below.
S(s1, s2) = λI(s1, s2) (6)
where λ is a constant defining the relationship.
The concept of homology is fundamental to in silico analysis of both DNA and protein sequences.
However, the ability to establish homology when two sequences have more mutual information other
than would be expected by chance is critical for the analysis [250]. This is because homologous
sequences do not always share significant sequence similarity [250]. For example, some homologous
protein alignments are not significant but these proteins are characterized as homologous based on
statistical significant strong sequence similarity to intermediate sequence [250]. For this reason, the
scheme used measures the mutual biological evolution information [251] available per amino acid
position to distinguish an alignment from chance using the relative entropy of target residue and













where qij is the target residue substitution frequency which is defined as the probability of finding a
residue i aligned with residue j after a certain amount of evolution given that they both evolved from
common ancestor who had residue k at that position. qi is defined as the probability of occurrence of
a residue i in a set of sequences. sij is the similarity score between residue i and j.
The reliability score for the pair-wise sequence similarity implemented in the algorithm used is de-





where H(s) is the relative entropy obtained after aligning protein sequence s by it self.
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We used our generated Plasmodium falciparum sequence BLAST data as input data for a cus-
tom python script incorporating the computations described above. The generated output functional
interaction data comprised of 231 interactions between 130 proteins.
3.3.3 Scoring High-throughput Experimental Datasets and Interologs
In the analysis for this section, the following criteria was set in order to score pair-wise functional
associations of experimental and interolog datasets retrieved from databases and literature. Interac-
tions in interolog datasets are based on the concept that orthologs of pair-wise proteins should also
have functional interactions [252]. The criteria listed below were fundamentally based on support-
ing evidence, herein referring to experiments, databases and/or reported literatures confirming such
functional interactions.
1. The number of experimental methods that have confirmed such functional interaction.
2. The number of databases that have reported such functional interaction.
3. The number of times the functional interaction have been reported in literature.
Experimental functional interaction datasets generated by Wuchty et al. [106], LaCount et al. [94] and
IntAct database [109] as described in Table 4 were scored based on these criteria. Pair-wise functional
interactions within each dataset supported by one evidence was assigned a reliability score of 0.4. On
the other hand, we assigned a reliability score of 0.7 if the functional interaction is supported by two
or more evidence be it from literature, databases or experimental methods. Overall, we were able to
define reliability score for these dataset in order to perform filtering and further integrative analysis.
On the contrary, datasets including Wuchty et al. [103, 104, 105] which had reliability scores were
maintained for filtering and integrative analysis.
3.4 Overall Filtering of Datasets
Most of the datasets used in this chapter (summarized in Table 9), had different gene identifiers or
protein identities (IDs) including but not limited to Ensembl and IntAct IDs depending on the source.
To ascertain a uniform ID for convenient data manipulation and downstream analysis, we mapped all
IDs unto Uniprot database to retrieve their corresponding Uniprot IDs. Genes or proteins which had
no corresponding Uniprot ID as at the time of this analysis were discarded. However, upon careful
analysis, such proteins were uncharacterized.
Unlike other studies which use both reviewed and unreviewed or uncharacterized interactions, our
study sought to extract from each dataset, pair-wise functional interactions between Plasmodium
falciparum isolate 3D7 manually annotated proteins.
Table 9 describes individual datasets and the number of pair-wise interactions between manually
annotated proteins whereas Figure 6 shows the graphical representation. The obtained annotated
interactions were used to generate the unified pathogen network.
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LaCount et al. 2,864 1,310 62 17 [94]
Wuchty et al. 1 19,979 2,321 85 74 [104]
Wuchty et al. 2 993 323 12 11 [103]
Wuchty et al. 3 5,459 1,988 91 32 [106]
Wuchty et al. 4 4,918 1,872 81 15 [105]
IntAct 2,916 1,343 67 26 [109]
InterPro 1,013 256 98 241 [98]
Scored BLAST se-
quence similarity
1,090 (BLAST) 163 130 231 [245]
STRING 617 163 114 386 [102]
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Figure 6. Graphical representation of the extracted functional interactions between reviewed
parasite proteins from various datasets as described in Table 9.
3.5 Constructing P. falciparum Functional Network
At this section we integrated all the extracted parasite datasets (Table 9) into a unified functional
PPIN. The datasets were integrated using customary python scripts that operated mainly on the net-
workX package [253]. The generated functional network comprised of 799 interactions between
155 reviewed Plasmodium falciparum isolate 3D7 proteins with an average degree of 10.3097. The
functional network includes chloroquine resistance transporter (Q8IBZ9), ornithine aminotransferase
(Q6LFH8), cofilin/actin-depolymerizing factor homolog 1 (Q8I467), T-complex protein 1 subunit eta
(O77323), anamorsin homolog (C0H4X5), phosphoglycerate kinase (P27362), adenylosuccinate syn-
thetase (Q8IDF8), 40S ribosomal protein S3a (O97313), 60S acidic ribosomal protein P2 (O00806),
v-type proton ATPase catalytic subunit A (Q76NM6), and proliferating cell nuclear antigen (P61074)
proteins targeted by artemisinin [254]. These proteins are involved in the parasite’s protein biosynthe-
sis, glycolisis, antioxidant defense system, hemoglobin digestion and immune response pathways [254].
However, pfcrt has been shown to contribute to artemisinin resistance.
662 functional interactions with confidence score > 0.3 between 140 nodes were selected for further
downstream analysis such as structural and functional analysis. The network consist of eight clusters
which are shown as different colours in Figure 7.
60
Figure 7. A graph network of Plasmodium falciparum protein-protein interactions between reviewed proteins. The nodes are coloured
according to clusters or subnetworks whereas the edges are shown as lines. The subnetwork with black nodes is the most key hub in the
generated functional network.
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3.6 Structural Analysis of P. falciparum Proteome Functional Net-
work
PPIs are studied experimentally using biochemical, biophysical and genetic techniques [246]. How-
ever, in this post-genomic era, computational approaches to analyzing protein interaction have come
to complement high-throughput interaction-detection methods.
PPINs are characterized by topological and dynamic properties essential for biological activities
at the molecular and systems level. The term topology herein simply refers to arrangement of nodes
and edges within the network. These complex interactomes are distinguished by overlapping dense
clusters or subnetworks. The overlapping interconnected nodes suggest the presence of a well defined
functional and topological core of the network [14, 104].
PPINs are represented graphically as nodes and edges. The nodes represent proteins whereas
edges or links represent the information connecting the nodes. Careful study of protein-protein in-
teractions (PPIs) is very critical for understanding cell physiology in normal and disease state thus,
serving as a crucial tool for leveraging disease mechanisms and identifying essential proteins that can
serve as drug targets. However, the ability to extract meaningful information from these networks
requires a systematic computational analysis of the complex topological features of the network to
investigate the impact of each node interaction in relation to the integrity and stability of the sys-
tem. This would contribute to identifying dynamic patterns of essential information flow within the
network for predicting drug targets.
In the following section, we described the application of centrality metrics to analyze the network and
predict key nodes (proteins).
3.6.1 Computing Topological Centrality Metrics
Centrality metric provides a quantitative measure of the functional significance of a node within a
network. It is a measure of the influence a node(gene,protein,etc) plays within a network or the
ability of a particular node to be influenced by other nodes within the same network. The weight of
this metric is determined by the node’s connection topology.
We computed degree, betweenness and closeness centrality metric using NetworkX package in python.
These metrics were measured to evaluate the topology of nodes and edges within the network. This
would facilitate elucidating essential nodes characterized by many connections or hubs thus, con-
tributing to identifying essential processes within the system.
Degree metric is a topological property of a network that measures the ability of a node to interact
or communicate directly with neighbouring nodes [252]. The degree distribution within a network
is a measure of the scale–free property of the functional network. Nodes with higher degree (above
average) are central to the connecting nodes within the network to enable connection at short steps.
Higher degree nodes form the degree-based subnetwork or hub. These type of subnetworks are spe-






where p and q are proteins
δ(p, q) =
{
1 if protein q is functionally linked to protein p
0 otherwise.
Closeness measure determines nodes that are relatively closer to all nodes in the network [97, 248,





(nC − 1) ∗ Sr(p)
(10)
where
nc is the number of nodes in the path of a node of interest.
|Lc| is the number of functional interactions connecting the nodes.
Betweenness centrality is a measure of the influence that a node has over the flow of information
within pair of nodes in the network [97, 248, 252]. It is based on the idea that flow of information
is between shortest paths connecting node pairs. This implies that nodes with high betweenness are
very essential and regulates the functioning of the system. In view of that, knocking out such nodes
with higher betweenness would significantly interfere with the activities of the pathogen linked to its
survival. Nodes with higher betweenness form the structural subnetwork or hubs ensuring the flow
of information within the network thus maintaining the integrity of the network. Unlike the degree-
based hub, structural hub might have connections within several degree-based hubs [252]. Therefore,
removal of a structural hub significantly disintegrates the network.







where σab is the shortest paths between protein a and b passing through protein c.
Shortest path between node pairs in a biological network is that path with the minimum number of
edges.
For each predicted pair-wise interaction, its degree, betweenness and closeness is computed to identify
highly connected nodes.
3.6.1.1 Assessing High-Degree Proteins of the Obtained Parasite Network
Computing centrality metric as described above using a developed python-based algorithm revealed
that the degree of nodes within the parasite’s functional network ranged from 1 to 33 with an average
score of 9.243. The degree score describes the number of direct functional interaction with each
node having at least 9 direct functional interaction as shown by the average degree score. Adss gene
with uniprot ID Q8IDF6 (Adenylosuccinate synthetase) had the highest degree of 33. This protein is
involved in salvage pathway for the synthesis of purine nucleotide [93]. Also, 16 nodes had degree
of 1. Figure 8 shows the node degree distribution which presents an overview of each node and the
number of associated direct functional interaction with other nodes within the network. Figure 9
shows the path length distribution of the nodes within the Plasmodium falciparum network. The path
length describes the shortest paths between all node pairs within the network, which indicated the
level of information spread across the network [252]. Table 10 provides a summary of the network
parameters of the parasite’s functional network.
63
Figure 8. A graph showing the degree distribution of the various nodes in the functional
network, indicating the scale–free property of a network whereby few nodes are characterized
by high degree.
Figure 9. A bar graph showing the path length distribution between pair-wise proteins
(nodes) in the parasite’s network with the minimum, maximum and average length been 1, 7,
2.89577 respectively. The average length is the mean of all the shortest paths between paired
proteins and it is a measure of information relay within the network.
3.6.1.2 Betweenness
The betweenness score ranged from 0 to approximately 923, with an average score of 122.507 in-
dicating the small world property of a network, a measure of non-neighbouring nodes within the
network to influence each other through indirect functional interaction. From our results (Table 10)
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PCNA gene with uniprot ID P61074 (Proliferating cell nuclear antigen) had the highest score. The
protein is involved in the control of eukaryotic DNA replication by increasing the polymerase’s pro-
cessibility during elongation of the leading strand [93]. 29 proteins had the lowest betweenness score
of 0. Figure 10 describes the relationship between the degree and betweenness score of nodes in the
parasite network. It describes nodes that have the ability to directly and indirectly establish functional
interaction within the network.
Figure 10. Relationship between the degree and betweenness centrality measure of the
nodes (dots) in the parasite network. It is observed that majority of nodes have betweenness
score between 0 and 250 with maximum degree of about 20, suggesting the small world
property of the network whereby nodes that are not neighbours within the network can
interact through other nodes.
3.6.1.3 Closeness
The closeness score ranged from 0 to 0.45808 with an average score of 0.331. PCNA gene had the
highest closeness score. Figure 11 and Figure 12 describes the relationship between closeness–
betweenness and closeness–degree metric respectively. It is observed that some nodes have both high
closeness and betweenness score. This suggest that for some non–neighbouring nodes that indirectly
interact, the more closer the nodes are to each other the higher the probability of influencing and
relaying signals or information. However, the converse is true for nodes characterized by both low
closeness and betweenness score. In addition to that, some non-neighbouring nodes are characterized
by high closeness score but low betweenness score. This may also suggest that, although the pair
of non–neighbouring nodes are closer but do not influence each other. This might be that, the nodes
contribute together in few processes as compared to high closeness–high betweenness nodes. Table
10 describes the summary of the parasite’s unified network properties.
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Figure 11. Relationship between the closeness and betweenness centrality measure of the
nodes (dots) in the parasite network, suggesting that some nodes are characterized by either
high closeness and betweenness score, high closeness low betweenness score or low closeness
low betweenness score.
Figure 12. Relationship between the degree and closeness score of nodes in the parasite
network.
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Table 10. General Plasmodium falciparum functional network parameters
Parameters Value
Number of nodes (proteins) 140










3.6.2 Plasmodium falciparum Selective Variant Network
Malaria selective variants are those genes known to be involved in selective events that hinders the
progress in malaria control such as reduced parasite clearance rate and malaria–drug resistance [255].
Usually, the contribution of these variants to a selective event is population–specific based on the
pathogen’s genetics, suggesting that variants common is different populations may not be under se-
lection in each population, but may contribute to a selective event [255]. This implies that, a functional
network comprising of selective variants would enable us investigate the functional interactions be-
tween these variants thus, helping to investigate the combinatorial effect of these genes within a
system towards a specific selective events.
In this section, Plasmodium falciparum known selective variants and other reported variants ex-
pressing strong signature of selection were retrieved from databases and literature. We queried these
variants as input data in STRING database to retrieve a malaria selective variant–specific functional
network. The malaria–specific interactome consisting of 206 interactions between 84 genes was gen-
erated as the output from STRING. The generated network was filtered to include only genes or
proteins specific to Plasmodium falciparum isolate 3D7.
From the generated filtered network, we focused on interactions between some artemisinin targets [254]
as shown in Figure 13. The purpose of this analysis was to investigate the functional interactions to
help determine the level of association between the selective variants and drug targets in order to
explore potential patterns that could underly drug resistance.
Among these variants are dhps (Q8IAU3), pfmdr1 (PFE1150w), plasmepsin2 (PF14−0077), dhfr
(Q8I1R6) and pfcrt (Q8IBZ9) known genes with associated mutations executing specific biological
functions conferring resistance to antimalarial drugs. These variants served as the main nodes con-
necting the clusters.
Our results revealed a higher level of functional interactions between selective variants associated
with drug resistance. Analysis on the shortest paths between the drug targets and the selective variants
to explore routes for possible resistance development suggested that, resistance to artemisinin drug
targets is likely to involve contributions from these resistant genes and might not follow the mode of
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resistance to chloroquine and sulfadoxine-pyrimethamine characterized by pfcrt, dhps and dhfr. Due
to the difference is functional interactions (direct or indirect) between the targets and the selective
variants, there is a higher likelihood that, the targets will experience varying degrees of resistance.
Figure 13. Functional interactions between malaria-resistance conferring genes and some
artemisinin drug targets.
3.6.3 Network Protein Clustering
Network clustering involves the decomposition of networks into sub-networks or communities of
highly interconnecting nodes. PPI networks are undirected networks that are characterized by their
modularity, and as such, they have the likelihood of node clustering [252]. The partitioning of a
network is measured by the transitivity or clustering coefficient. The transitivity of a network is a
measure of the degree to which the relationship between two connecting nodes within a network is
transitive.
In that regards, the purpose of clustering the generated unified network is to identify hubs or densely
connected nodes forming subnetworks to facilitate extraction of critical functional nodes. This pro-
cess helps to identify essential biological mechanisms underlying the system. Various algorithms
including but not limited to network division algorithms which have the capacity of detecting inter-
community links within a network [256, 257, 258] and agglomerative algorithms which merges sim-
ilar nodes within a community [259] have been developed for network clustering. Also, optimization
methods have been developed for such network clustering [257, 260].
However, we implemented a simple but powerful algorithm described by Blonde et al. [113] for net-
work clustering. This is because, it has been investigated to show that it out-performs other methods
such as divisive algorithms especially in terms of computational time and output quality [113]. The
algorithm herein finds high modularity partitions of large networks within shorter time and presents
a complete hierarchical hubs or subnetworks [113]. The ability to elucidate clusters, key proteins and
characterize associated genes was enhanced by the centrality scores of the nodes as well as mapping
disease-associated genes unto the unified parasite network.
Nodes with average betweenness and closeness score with their corresponding degree score were
considered as key targets because of their significant influence within the network. Further structural
and functional analysis on the 43 key genes or nodes helped to filter out key candidate targets or
proteins highly essential to disease pathogenesis and network integrity. These key candidate targets
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are more central and influential in the network.
The generated network (Figure 7) consisted of 8 clusters of which 5 contained the 43 key pro-
teins. 2 of the 5 subnetworks contained candidate key proteins as described in Table 11. The key
candidate proteins were identified in cluster 2 and 4. Cluster 2 contained 1 key candidate gene en-
coding key protein, Putative E3 ubiquitin-protein ligase protein PFF1365c (C6KTB7). There is
accumulation of evidence that C6KTB7 is potential candidate for malaria vaccine and drug develop-
ment [93, 261, 262]. C6KTB7 is involved in the protein ubiquitination pathway of the pathogen [93].
Studies have shown that many biological processes and substrates are targeted by the ubiquitin path-
way such that instability or modification in ubiquitination and deubiquitination reactions influences
the pathogenesis of many eukaryotic system related diseases [261]. For instance, dysregulation of
ubiquitin ligase is associated to neurodegenerative disorders such as Parkinson’s disease and infec-
tious diseases including tuberculosis [262]. This is usually associated with interference with immune
response.
This protein significantly influences the parasite’s development and malaria pathogenesis [263]. This
is because, it regulates various cellular process and pathways critical for the pathogen’s survival in
the human host. For example, it is responsible for positive regulation of DNA-templated transcrip-
tion and epigenetic factors such as histone H3-K4 methylation, essential for transcription regula-
tion [261]. Interestingly, several studies have shown that, inhibition of the activities of C6KTB7
and ubiquitin proteasome system is essential for many disease treatment including Plasmodium falci-
parum malaria [261, 263]. The functional interactions of C6KTB7 in the unified parasite network is
shown in Figure 14.
Cluster 4 contained 2 key proteins of which one was a candidate key protein expressed in the
parasite’s erythrocytic developmental stage. The 2 candidate genes are PF07−0086 (Q8IBP1) and
PFF1440w or SET1 (C6KTD2). These genes have also been reported to be potential candidate
genes for an effective malaria vaccine [264]. However, in our study, putative histone-lysine N-
methyltransferase 1 (C6KTD2) emerged as one of the 2 candidate key proteins critical for disease
pathogenesis after further structural and functional analysis. This gene is expressed in the merozoite
stage of the parasite development. C6KTD2 is known to play an essential role in chromatin structure
and gene expression in the parasite [265]. Also, it is mainly involved in histone lysine methylation
process which usually involves the synergistic effect of histone-lysine methyltransferases and histone
lysine demethylases [265].
The cluster formed by C6KTD2 in the parasite network is shown in Figure 15. Table 12 describes the
degree, betweenness and closeness centrality score for C6KTB7 and C6KTD2 within the pathogen’s
functional network.











0 24 6 0 0
1 27 17 0 0
2 23 3 1 1
3 40 16 1 0
4 16 16 2 1
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Table 12. Degree, betweenness and closeness centrality score of C6KTD2 and C6KTB7





Description Betweenness Degree Closeness
C6KTD2 SET1 Putative histone-lysine N-
methyltransferase 1
510.18 13 0.40623




Also, we observed intersecting nodes within the subnetwork formed by C6KTB7 and C6KTD2. The
nodes P62344 and Q81E47 (yellow nodes in Figure 16) connected the clusters formed by the parasite

















Figure 14. Functional interactions between C6KTB7 (central green node) and directly


















Figure 15. Functional interactions between C6KTD2 (central green node) and directly






























Figure 16. Functional interactions between C6KTD2 and C6KTB7 clusters in the unified
pathogen functional network predicted to be involved in development and disease
pathogenesis.
3.7 Functional Analysis of Parasite Disease–Associated–Candidate
Genes Encoding Key Proteins
In this section, we performed gene annotation and enrichment analysis on disease associated genes
(C6KTB7 and C6KTD2) identified during network clustering. We investigated statistically signifi-
cant gene ontology process or enriched processes which the genes are involved. C6KTB7 is mainly
involved in ubiquitin–protein transferase activity through the protein ubiquitination and modification
pathway (UPA00143, GO:0016567) [93]. The ubiquitylation process, consisting of a complex net-
work of enzymes (E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme and an E3
ubiquitin ligase) within the parasite is known to be highly critical for numerous cellular processes
contributing to the parasite’s survival and propagation [262]. This usually happens as a result of post-
translational modifications within the biological system through processes such as transcriptional
regulation and cell cycle progression [262].
C6KTD2 is involved in histone H3-K4 methylation post–translational modification process
(GO:0051568), transcriptional regulation, activation and silencing [93, 266]. The methylation process
regulates various biological processes particularly, it is highly influential in the parasite’s ability to
invade the red blood cells as well as regulates virulence genes in the parasite [266].
3.8 Summary
In this chapter, we constructed a unified parasite functional network from Plasmodium falciparum
3D7 isolate reviewed proteins and various functional interaction datasets retrieved from literature
and databases. We computed the network centrality scores for the nodes to investigate subnetworks
and key nodes critical for Plasmodium falciparum malaria pathogenesis. We investigated on nodes
with degree above the average degree score of approximately 9 (degree-based subnetwork or hub)
and nodes critical in disconnecting functional interactions within the network (structural subnetwork
or hub) to identify key candidate targets at parasite side. Importantly, we identified C6KTD2 and
C6KTB7 as key candidate target proteins within the parasite functional network for new drug de-
velopment from structural and functional analysis of the network. Our results consolidates several
studies which have predicted these targets for novel drug development using our algorithms, models
and network analysis techniques. The functional interaction between these targets may suggest them
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as co-targets in combinatorial drug design. We performed functional analysis on the candidate key
genes to elucidate enriched processes and pathways in which they are involved. Interestingly, these
targets share a common activity of post-translational modifications in the parasite’s life cycle. Also,
we investigated the relationship between parasite selective variants and their functional interactions
with artemisinin drug targets within the unified parasite functional network. We observed that pos-
sible down regulation to these drug targets which could lead to resistance may be influenced by the




4 Host Malaria–Specific Proteome Functional Network
The fundamental criteria for selecting disease–associated proteins or genes as drug targets requires the
potential target(s) to be essential and indispensable to disease aetiology. For instance, in genetic dis-
eases gene therapy involves identifying genetic variants associated with the disorder. However, with
infectious diseases like malaria, the criteria requires understanding the complex interplay between the
human host and the pathogen to identify essential proteins or pathways [128, 267].
Human functional network serves as a rich and critical resource for understanding protein organization
and functions within a cell.
In this chapter, a computational integration technique is applied to build a comprehensive human
protein network based on previously identified malaria risk/resistance genes from GWAS in order to
finally construct a unified human-Plasmodium falciparum protein network. Primary datasets, such as
protein sequences, functional data sets from high–throughput experiments, protein signatures from
databases such as InterPro and in silico generated functional datasets were used to construct a unified
host malaria–specific protein–protein interaction network.
4.1 Functional Interaction Datasets for Constructing Human Func-
tional Network
Similar to datasets implemented in generating a unified interaction dataset for the pathogen (Chapter
3 section 3.2), this section uses functional interaction and genomic datasets summarized in Table 13.
Human protein interaction network proposed by Bossi and Lehner described in Table 4 was used as
one of the datasets to build the functional network. The dataset was generated by integrating tissue-
specific interactome and gene expression data from 21 different sources. The network comprises of
80,922 physical interactions among 10,229 human proteins.
In addition, human PPIs derived from reactome database [96] was implemented. Reactome is an
open-source, open access, manually curated and peer-reviewed pathway database. The interactome
consisted of 79,620 interactions between 8,059 proteins.
20,395 reviewed human protein sequences were retrieved from Uniprot database as at the time of this
study to generate pairwise sequence similarity associations using Basic Local Alignment Search Tool
(BLAST) specifically blastp, the protein-protein BLAST algorithm.
Also, human protein interaction data including interologs were retrieved from STRING database [102]
for this study. The dataset comprised of 11,759,454 interactions between 19,354 proteins. Finally,
interaction data was obtained from InterPro database [171]. The dataset obtained comprised of all
UniProtKB proteins and the InterPro entries and individual matching signatures. Overall, we were
able to assemble a map of 18,830,696 host protein–protein interaction dataset from six independent
sources (Table 13).
4.2 Scoring Interaction Datasets
Similar to scoring Plasmodium falciparum interaction datasets (Chapter 3 section 3.3), the same
scoring scheme and criteria described above was implemented in scoring human interaction datasets
(Table 13). The scored interpro interaction data generated from the scheme comprised of 2,646,550
interactions between 17,797 proteins. Also, the scored protein sequence similarity comprised of
3,807,888 functional interactions between 20,395 proteins.
73
4.3 Filtering Datasets
All protein or gene IDs were mapped unto uniprot to retrieve their corresponding UniProtKB IDs.
Similar to the filtering process implemented on the pathogen’s interaction datasets (Chapter 3 section
3.4), at this section pair-wise interactions between reviewed human proteins was extracted from each
dataset. Table 13 describes individual datasets and the observed pairwise interactions between human
reviewed proteins.


























20,395 143,533 9,611 [244]
InterPro 2,646,550 35,928 231,799 17,797 [98]
Bossi and
Lerner
80,922 10,229 54,238 8,416 [95]
STRING 11,759,454 19,354 5,244,655 18,836 [102]
IntAct 456,263 35,770 169,627 16,061 [109]
4.4 Construction of a Human Functional Network
In generating the host malaria–specific functional network, only pair-wise interactions with high con-
fidence score ie. score > 0.3 were considered. NetworkX package in python was the primary pack-
age implemented to construct the network. The final human unified network comprised of 4,133,136
functional interactions between 20,329 unique nodes.
4.5 Structural Analysis of Human Proteome Functional Network
Exploring the constructed human protein-protein interactome particularly at the system’s level could
contribute significantly to elucidate critical biological processes and pathways that influence malaria
susceptibility within human. Critical topological analysis helps to unravel nodes that influence the
compactness and the information relay capacity within the network. At this section, we performed
structural analysis on the network by investigating the topology through degree, betweenness and
closeness centrality metric analysis.
4.5.1 Computing Topological Centrality Metrics
The same computations for calculating the centrality metric of the pathogen’s functional network was
repeated at this section to evaluate the human functional network. Table 14 describes the summary
of the network centrality parameters whereas Figure 17 shows the path length between the nodes, a
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measure of information relay within the network. Comparing Figure 17 to Figure 9, it is observed
that the average path length in the host network is shorter due to the difference in network density.
Table 14. Summary of human functional network parameters.
Parameters Value
Number of nodes 20,329










Figure 17. A bar graph showing the path length distribution between the nodes in the
parasite’s network with the minimum, maximum and mean length been 1, 6, 2.31420
respectively.
75
4.5.1.1 Assessing High-Degree Proteins
From the centrality metrics computed, it was observed that the degree of nodes within the human
functional network ranged from 1 to 3424 with an average degree of 406.467. LRRK2 gene with
uniprot ID Q5S007 (Leucine-rich repeat serine/threonine-protein kinase 2) had the highest degree.
The protein is primarily involved in the regulation of autophagy [93]. However, 232 nodes had a
degree of 1. Proteins with higher degree contribute significantly to the stability of the network in
such a way that they form communities or hubs or subnetworks within the network. Removal of high
degree nodes results in disintegration of the connectivity with the network. Figure 18 describes the
degree of distribution of the nodes with respect to the connection frequencies.
Figure 18. Power law property (P (k) = k−λ, where λ is the degree exponent) of human
functional network generated from integrated heterogeneous datasets. This distribution shows
the scale-free property of the functional network whereby large number of nodes are
characterized by lower degree score compared to few nodes connected with many neighbours.
4.5.1.2 Closeness and Confidence Measure of a Protein
The closeness score ranged from 5e-05 to 0.53623 with an average score of 0.43554. It was observed
that the node with the highest degree had the highest closeness score of 0.53623. However, 8 proteins
or nodes had the lowest closeness score. Figure 19 shows the relationship between the degree and
betweenness score of nodes in the human network. It is observed that the closeness of nodes within a
network as direct and indirect relationship with the degree such that some nodes characterized by high
closeness value could either have a higher or lower degree. Nonetheless, most nodes characterized by
high closeness value (≥ 0.2) have degree between 0 and 1000.
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Figure 19. Relationship between the degree and betweenness score of nodes in the human
network.
4.5.1.3 Betweenness
The betweenness score ranged from 0 to 894567.24 with an average score of 13318.12. GAPDH
gene with uniprot ID P04406 (Glyceraldehyde-3-phosphate dehydrogenase) had the highest score of
894567.24. There were 660 proteins with a zero betweenness score. Figure 20 shows the relation-
ship between the degree and betweenness whereas Figure 21 describes the relationship between the
closeness and the betweenness centrality measure of the nodes in the human network. It is observed
that, nodes with higher betweenness score have higher closeness and degree score. This implies that
few nodes are associated to relaying wider information thus contributing significantly to the structural
integrity of the network.
Figure 20. Relationship between the degree and betweenness centrality measure of the
nodes (dots) in the human network. It is observed that few nodes with higher betweenness
score are characterized by higher degree score.
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Figure 21. Relationship between the closeness and betweenness centrality measure of the
nodes (dots) in the human network.
4.6 Retrieving Disease–Associated Genes from GWAS Summary Statis-
tics Data
Genome–wide association study (GWAS) is a critical single-marker testing technique for identifying
and examining disease-specific genetic variants in different populations [92]. In this study, human
Malaria susceptibility-associated SNPs for Kenya, Gambia and Malawi populations were retrieved
from GWAS summary statistics datasets. Table 3 describes the number of cases and controls involved
in each study.
The homogeneous summary statistics dataset comprised of 20,273,529 SNPs from chromosome one
(1) to twenty two (22). A total of 688,577 significant SNPs with p-value 6 0.05 were retrieved
from the datasets. The SNPs were mapped to genes using the dbSNP database [268]. The dbSNP is a
general public archive of all short sequences variant. It contains human single nucleotide variants, mi-
crosatellites, and small-scale insertions and deletions along with publication, population frequency,
molecular consequence, genomic and RefSeq mapping information for both common variants and
clinical mutations. A total of 79 malaria-associated genes (Table 15) were retrieved and mapped
to uniprot database to retrieve their corresponding IDs. We queried the 79 genes into genemania
database [269] to generate a host malaria–specific network shown in Figure 22. Functional interac-
tion prediction by genemania is based on co–expression, co–localization, physical interaction, shared
protein domains, genetic interactions and literature prediction. Table A1 in the appendix section
describes the genes involved in the functional interaction predicted from genemania database.
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Table 15. Malaria-associated genes retrieved by mapping significant SNPs to gene level. The






Description Betweenness Degree Closeness




associated protein 1) (Plasma
membrane calcium ATPase
isoform 4) (Plasma membrane
calcium pump isoform 4)
13,348.53 295 0.46096
















P17927 CR1 Complement receptor type 1
(C3b/C4b receptor) (CD anti-
gen CD35)
750 61 0.36270
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Description Betweenness Degree Closeness
P12318 FCGR2A Low affinity immunoglobu-
lin gamma Fc region recep-
tor II-a (IgG Fc receptor II-




P08637 FCGR3A Low affinity immunoglobu-
lin gamma Fc region recep-
tor III-A (CD16a antigen)
(Fc-gamma RIII-alpha) (Fc-
gamma RIII) (Fc-gamma RI-
IIa) (FcRIII) (FcRIIIa) (FcR-
10) (IgG Fc receptor III-2)
(CD antigen CD16a)
833.02 1,085 0.46941
O75015 FCGR3B Low affinity immunoglobulin
gamma Fc region receptor III-
B (Fc-gamma RIII-beta) (Fc-
gamma RIII) (Fc-gamma RI-
IIb) (FcRIII) (FcRIIIb) (FcR-
10) (IgG Fc receptor III-1)
(CD antigen CD16b)
382.27 1,066 0.46501
P0C091 FREM3 FRAS1-related extracellular
matrix protein 3
2,648.44 83 0.41347




P02724 GYPA Glycophorin-A (MN sialogly-
coprotein) (PAS-2) (Sialogly-
coprotein alpha) (CD antigen
CD235a)
198.02 24 0.36143





P68871 HBB Hemoglobin subunit beta
(Beta-globin) (Hemoglobin
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P01889 HLA-B HLA class I histocompatibil-
ity antigen, B-7 alpha chain
(MHC class I antigen B*7)
4,058.91 1,079 0.46633
P03989 HLA-B HLA class I histocompatibil-
ity antigen, B-27 alpha chain
(MHC class I antigen B*27)
851.17 1,073 0.46468
P10319 HLA-B HLA class I histocompatibil-
ity antigen, B-58 alpha chain
(Bw-58) (MHC class I antigen
B*58)
451.76 1,072 0.46419
P18463 HLA-B HLA class I histocompatibil-
ity antigen, B-37 alpha chain
(MHC class I antigen B*37)
332.13 1,071 0.46416
P18464 HLA-B HLA class I histocompatibil-
ity antigen, B-51 alpha chain
(MHC class I antigen B*51)
332.13 1,071 0.46416
P18465 HLA-B HLA class I histocompatibil-
ity antigen, B-57 alpha chain
(Bw-57) (MHC class I antigen
B*57)
43,292.30 1,075 0.46424
P30460 HLA-B HLA class I histocompatibil-
ity antigen, B-8 alpha chain
(MHC class I antigen B*8)
27,355.05 1,073 0.46418
P30461 HLA-B HLA class I histocompatibil-
ity antigen, B-13 alpha chain
(MHC class I antigen B*13)
332.13 1,071 0.46416
P30462 HLA-B HLA class I histocompatibil-
ity antigen, B-14 alpha chain
(MHC class I antigen B*14)
332.13 1,071 0.46416
P30464 HLA-B HLA class I histocompatibil-
ity antigen, B-15 alpha chain
(MHC class I antigen B*15)
451.76 1,072 0.46419
P30466 HLA-B HLA class I histocompatibil-
ity antigen, B-18 alpha chain
(MHC class I antigen B*18)
332.13 1,071 0.46416
Continued on next page
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Description Betweenness Degree Closeness
P30475 HLA-B HLA class I histocompatibil-
ity antigen, B-39 alpha chain
(MHC class I antigen B*39)
332.13 1,071 0.46416
P30479 HLA-B HLA class I histocompatibil-
ity antigen, B-41 alpha chain
(Bw-41) (MHC class I antigen
B*41)
332.13 1,071 0.46416
P30480 HLA-B HLA class I histocompatibil-
ity antigen, B-42 alpha chain
(MHC class I antigen B*42)
76,201.46 1,330 0.49009
P30481 HLA-B HLA class I histocompatibil-
ity antigen, B-44 alpha chain
(Bw-44) (MHC class I antigen
B*44)
352.06 1,072 0.46425
P30483 HLA-B HLA class I histocompatibil-
ity antigen, B-45 alpha chain
(Bw-45) (MHC class I antigen
B*45)
352.06 1,072 0.46425
P30484 HLA-B HLA class I histocompatibil-
ity antigen, B-46 alpha chain
(Bw-46) (MHC class I antigen
B*46)
451.76 1,072 0.46419
P30485 HLA-B HLA class I histocompatibil-
ity antigen, B-47 alpha chain
(Bw-47) (MHC class I antigen
B*47)
332.13 1,071 0.46416
P30486 HLA-B HLA class I histocompatibil-
ity antigen, B-48 alpha chain
(Bw-48) (MHC class I antigen
B*48)
332.13 1,071 0.46416
P30487 HLA-B HLA class I histocompatibil-
ity antigen, B-49 alpha chain
(HLA class I histocompatibil-
ity antigen, B-21 alpha chain)
(MHC class I antigen B*49)
332.13 1,071 0.46416
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Description Betweenness Degree Closeness
P30488 HLA-B HLA class I histocompatibil-
ity antigen, B-50 alpha chain
(Bw-50) (HLA class I his-
tocompatibility antigen, B-21
alpha chain) (MHC class I
antigen B*50)
332.13 1,071 0.46416
P30490 HLA-B HLA class I histocompatibil-
ity antigen, B-52 alpha chain
(Bw-52) (HLA class I histo-
compatibility antigen, B-5 al-
pha chain) (MHC class I anti-
gen B*52)
332.13 1,071 0.46416
P30491 HLA-B HLA class I histocompatibil-
ity antigen, B-53 alpha chain
(Bw-53) (MHC class I antigen
B*53)
451.76 1,072 0.46419
P30492 HLA-B HLA class I histocompatibil-
ity antigen, B-54 alpha chain
(Bw-22) (Bw-54) (MHC class
I antigen B*54)
451.76 1,072 0.46419
P30493 HLA-B HLA class I histocompatibil-
ity antigen, B-55 alpha chain
(Bw-55) (HLA class I his-
tocompatibility antigen, B-12
alpha chain) (MHC class I
antigen B*55)
451.76 1,072 0.46419
P30495 HLA-B HLA class I histocompatibil-
ity antigen, B-56 alpha chain
(Bw-22) (Bw-56) (MHC class
I antigen B*56)
451.76 1,072 0.46419
P30498 HLA-B HLA class I histocompatibil-
ity antigen, B-78 alpha chain
(MHC class I antigen B*78)
332.13 1,071 0.46416
P30685 HLA-B HLA class I histocompatibil-
ity antigen, B-35 alpha chain
(MHC class I antigen B*35)
451.76 1,072 0.46419
Q04826 HLA-B HLA class I histocompatibil-
ity antigen, B-40 alpha chain
(Bw-60) (MHC class I antigen
B*40)
332.13 1,071 0.46416
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Description Betweenness Degree Closeness
Q29718 HLA-B HLA class I histocompatibil-
ity antigen, B-82 alpha chain
(MHC class I antigen B*82)
332.13 1,071 0.46416
Q29836 HLA-B HLA class I histocompatibil-
ity antigen, B-67 alpha chain
(MHC class I antigen B*67)
332.13 1,071 0.46416
Q29940 HLA-B HLA class I histocompatibil-
ity antigen, B-59 alpha chain
(MHC class I antigen B*59)
451.76 1,072 0.46419
Q31610 HLA-B HLA class I histocompatibil-
ity antigen, B-81 alpha chain
(B’DT) (MHC class I antigen
B*81)
332.13 1,071 0.46416
Q31612 HLA-B HLA class I histocompatibil-
ity antigen, B-73 alpha chain
(MHC class I antigen B*73)
32,036.80 1,283 0.49117
Q95365 HLA-B HLA class I histocompatibil-
ity antigen, B-38 alpha chain





HLA class II histocompati-
bility antigen, DR beta 5
chain (DR beta-5) (DR2-beta-
2) (Dw2) (MHC class II anti-
gen DRB5)
26,778.34 1,290 0.48645
P09601 HMOX1 Heme oxygenase 1 (HO-1)
(EC 1.14.14.18)
27,916.14 515 0.47913
P00738 HP Haptoglobin (Zonulin)
[Cleaved into: Haptoglobin
alpha chain; Haptoglobin beta
chain]
44,329.89 554 0.47580
P05362 ICAM1 Intercellular adhesion








Continued on next page
84





Description Betweenness Degree Closeness




P35225 IL13 Interleukin-13 (IL-13) 16,060.33 589 0.46863
P01584 IL1B Interleukin-1 beta (IL-1 beta)
(Catabolin)
43,577.22 866 0.48631
P18510 IL1RN Interleukin-1 receptor antago-
nist protein (IL-1RN) (IL-1ra)
(IRAP) (ICIL-1RA) (IL1 in-
hibitor) (Anakinra)
4,992.78 340 0.45408
P05112 IL4 Interleukin-4 (IL-4) (B-cell
stimulatory factor 1) (BSF-
1) (Binetrakin) (Lymphocyte
stimulatory factor 1) (Pitrak-
inra)
50,896.72 899 0.48677
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Description Betweenness Degree Closeness
P14174 MIF Macrophage migration in-








P11055 MYH3 Myosin-3 (Muscle embryonic
myosin heavy chain) (Myosin
heavy chain 3) (Myosin heavy
chain, fast skeletal muscle,
embryonic) (SMHCE)
26,135.36 1,122 0.49250
P60321 NOS2 Nanos homolog 2 (NOS-2) 3,112.42 123 0.42336
P35228 NOS2,
NOS2A
Nitric oxide synthase, in-
ducible (EC 1.14.13.39) (Hep-
atocyte NOS) (HEP-NOS)
(Inducible NO synthase) (In-
ducible NOS) (iNOS) (NOS
type II) (Peptidyl-cysteine S-
nitrosylase NOS2)
14,718.65 425 0.47056






P16284 PECAM1 Platelet endothelial cell
adhesion molecule (PECAM-
1) (EndoCAM) (GPIIA’)
(PECA1) (CD antigen CD31)
63,425.28 1,634 0.49978
P28065 PSMB9 Proteasome subunit beta
type-9 (EC 3.4.25.1) (Low
molecular mass protein 2)
(Macropain chain 7) (Mul-
ticatalytic endopeptidase
complex chain 7) (Proteasome
chain 7) (Proteasome subunit
beta-1i) (Really interesting
new gene 12 protein)
13,964.38 417 0.46688
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Description Betweenness Degree Closeness
O75880 SCO1 Protein SCO1 homolog, mito-
chondrial
20,845.03 391 0.44647
O00206 TLR4 Toll-like receptor 4 (hToll)
(CD antigen CD284)
111,490.44 1,360 0.50077
Q9NR96 TLR9 Toll-like receptor 9 (CD anti-
gen CD289)
25,906.76 869 0.48774
P01375 TNF Tumor necrosis factor
(Cachectin) (TNF-alpha)
(Tumor necrosis factor ligand
superfamily member 2) (TNF-
a) [Cleaved into: Tumor
necrosis factor, membrane
form (N-terminal fragment)
(NTF); Intracellular domain 1
(ICD1); Intracellular domain
2 (ICD2); C-domain 1;
315,200.15 1,805 0.50908
Q13829 TNFAIP1 BTB/POZ domain-containing
adapter for CUL3-mediated








P0DSE2 TRB M1-specific T cell receptor
beta chain (TR beta chain
TRBV19*01J2S7*01C*02)
Q8NB14 USP38 Ubiquitin carboxyl-terminal








Figure 22. Functional interaction network between malaria–specific genes of the host and other host genes generated from genemania
database. Genes are represented as nodes and interactions as edges.
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4.7 Network Clustering
The ultimate aim of the GWAS behind identifying disease–associated genes is to map them onto
the unified human functional network to identify hubs or clusters containing key genes or proteins
regulating the structural integrity of the functional network. The centrality score for each node within
the network was used to investigate key nodes or proteins in the functional network.
Based on the degree, betweenness and closeness metric, hubs formed within the network were catego-
rized as either degree-based or structural hub. Degree-based hubs are formed by nodes with a degree
score above the average degree score of approximately 406.
Similar to the criteria implemented in identifying key proteins with the parasite network, we filtered
out nodes with betweenness and closeness score above the average for further structural and functional
network analysis to elucidate key candidate proteins. These nodes are characterized with high degree
score.
Also, we implemented the Blonde et al [113] clustering algorithm to cluster the human functional
network. The disease-associated genes were mapped onto the network to identify subnetworks or
communities containing candidate disease-associated gens and those encoding key proteins. These
key proteins are considered to be more influential and significant in the network. The human func-
tional network contained 760 key proteins within the 32 clusters. Out of the 32 clusters, 7 contained
78 malaria candidate genes whiles 2 of these 7 clusters contained 6 malaria-associated genes encoding
key proteins. These key host malaria-associated genes (Table 17) could serve as essential targets of
protective immunity against malaria particularly in relation to antibody–based therapies [270]. Table
16 describes the distribution of proteins in the 7 clusters.












0 7,620 136 4 0
1 7,12 24 1 0
2 3,964 186 28 5
3 2,107 46 5 0
4 930 120 1 0
5 1,302 113 38 1
6 1,218 49 0 0
Total 17,853 674 78 6
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Table 17. Key malaria-associated genes found in the human functional network with
their betweenness, degree, and closeness network centrality measures.
UniProt-ID Gene name Betweenness Degree Closeness
P22301 IL10 60,689.17 1,027 0.49031
P05362 ICAM1 68,177.95 1,690 0.50307
P01375 TNF 315,200.15 1,805 0.50908
P30480 HLA-B 76,201.46 1,330 0.49009
P16284 PECAM1 63,425.28 1,634 0.49978
O00206 TLR4 111,490.44 1,360 0.50077
4.8 Functional Analysis of Human Disease-Associated Candidate Genes
Encoding Key Proteins
In this section, we investigate the molecular and biological functions of the candidate genes encod-
ing candidate key proteins in the functional network using functional genomics databases (Table 4)
and statistical methods such as the Bonferroni multiple test correction to estimate adjusted p-values.
The p-values were estimated primarily by using the frequency of occurrence of each process in re-
lation to the candidate genes. These candidate genes are involved in essential biological processes
(Table 18) and pathways (Table 19) that are linked to the proper functioning of the biological sys-
tem. Having established that nodes within a cluster might be involved in the same biological process,
it is therefore possible that these key proteins within the clusters contribute significantly to similar
processes [97]. We used the six key candidate proteins (Table 17) as target sets in order to per-
form disease-associated gene annotation to investigate statistically significant biological processes
that influences malaria pathogenesis in human. 23 significantly enriched malaria-related biological
processes described in Table 18 were identified. These gene ontology groups comprised of those in-
volved in cell immune and inflammatory response, regulation and production of transcription factors,
biosynthetic processes, cell-cell adhesion, cell signaling and cell apoptotic processes.
GO:0042346 process responsible for regulation of NF-kappaB importation have been studied to
be involved in immune and inflammatory responses particularly in eukaryotic cells. Down or negative
regulation of NF-kappaB has been reported to be associated with Plasmodium falciparum-modulated
endothelium transcriptome contributing to cerebral malaria [271]. GO:0045348 process responsible
for positive regulation of major histocompatibility complex (MHC) class II biosynthetic process reg-
ulates immune response to malaria [272]. Pre-erythrocytic immunity to malaria (cerebral malaria) in
Africa is linked to MHC antigens such that variations in class I and class II in these antigens con-
tribute significantly to malaria susceptibility thus, reduced or increased host immune response [272].
Also, other processes such as GO:0032689, GO:0032715, GO:0002740 and GO:0032729 serves as
immunological mediating processes that influence malaria susceptibility by either conferring protec-
tion or influencing disease pathogenesis.
Activation and regulation of NLRP3 inflammasomes, immune system receptors, controls the activa-
tion of caspase-1 and induce inflammation in response to infectious pathogens [273]. Due to their
influence on a wide range of diseases, their dysfunctioning results in the initiation or progression of
diseases.
Endothelial cell apoptosis has been studied to contribute to malaria severity. For instance, heme-
induced microvasculature endothelial cell apoptosis mediated by proinflammatory and proapoptotic
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pathways contributes significantly to severe malaria.
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Table 18. Statistically significant biological processes of key human malaria-associated genes.
The GO term level is a numerical representation of the biological process from the root (level






GO Term Level p-value Adjusted
p-value
GO:0042346 positive regulation of NF-
kappaB import into nucleus
12 2.00161e-05 0.00432
GO:0045348 positive regulation of MHC
class II biosynthetic process
7 2.40637e-06 0.00052




GO:0007157 heterophilic cell-cell adhe-
sion via plasma membrane
cell adhesion molecules
5 0.00012 0.02714
GO:2000352 negative regulation of en-
dothelial cell apoptotic pro-
cess
9 2.70760e-05 0.00585
GO:0032715 negative regulation of
interleukin-6 production
6 8.99764e-08 1.9434e-05








GO:0070374 positive regulation of ERK1
and ERK2 cascade
11 2.8883e-05 0.00623
GO:0050830 defense response to Gram-
positive bacterium
7 2.65221e-05 0.00572
GO:0034116 positive regulation of het-
erotypic cell-cell adhesion
6 1.68841e-05 0.00364
GO:0044130 negative regulation of
growth of symbiont in host
7 6.07930e-06 0.00131
GO:0030198 extracellular matrix organi-
zation
4 5.39819e-05 0.01166
Continued on next page
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GO Term Level p-value Adjusted
p-value




GO:0032755 positive regulation of
interleukin-6 production
6 0.00016 0.03562
GO:0002740 negative regulation of cy-
tokine secretion involved in
immune response
10 1.00303e-06 0.00021
GO:0045429 positive regulation of nitric
oxide biosynthetic process
8 1.23374e-07 2.665e-05
GO:0043032 positive regulation of
macrophage activation
7 1.02165e-05 0.00220
GO:1904999 positive regulation of leuko-






GO:1904707 positive regulation of vascu-
lar smooth muscle cell pro-
liferation
7 0.00016 0.03663
GO:0032800 receptor biosynthetic pro-
cess
6 6.68766e-07 0.00014





In this section, we performed pathway enrichment analysis to investigate statistically significant path-
ways inferred from KEGG database and UniProtKB-GOA data set that potentially play essential roles
in malaria pathogenesis. Similar to investigating the biological processes, we implemented a Bonfer-
roni multiple test correction adjusted hypergeometric test to identify enriched pathways linked to the
candidate genes. Also, we estimated the p-values for these pathways using their frequency of occur-
rence in relation to the key proteins and the human proteome in general. Table 19 describes pathways
which potentially contribute to malaria pathogenesis. These pathways are involved in immune re-
sponse, cell-cell signaling and production of key transcription factors specific to disease pathogenesis.
Interestingly, artemisinin derivatives, particularly artesunate mostly used in SSA are involved in most
of the processes and pathways identified in our study. For instance, it blocks the production of IL-
1β, IL-6 and IL-8 [274]. It also inhibits phosphoinositide 3-kinase (PI3K)/Akt signaling pathway and
lipopolysaccharide-induced production of TNF-α, IL-6 and nitric oxide (NO) [274]. Also, artemisinin
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derivatives are involved in NF-kappaB transcription activities and anti-inflammatory processes.
Among the pathways are the Malaria pathway (hsa05144), Natural killer cell mediated cytotoxicity
pathway and other disease-enriched pathways including but not limited to Tuberculosis, Autoimmune
thyroid disease, Hematopoietic cell lineage and Type I diabetes mellitus.
Table 19. Statistically Significant Pathways of Human Key Malaria-Associated Genes.
textbfKEGG-
Pathway ID
KEGG-Pathway-Name p-value Adjusted p-
value
path:hsa05133 Pertussis 8.77858e-06 0.00107
path:hsa04940 Type I diabetes mellitus 9.00124e-05 0.01098
path:hsa05144 Malaria 0.0 0.0
path:hsa05310 Asthma 6.52960e-07 7.966e-05
path:hsa04145 Phagosome 1.46003e-06 0.00017
path:hsa05146 Amoebiasis 0.00014 0.01745
path:hsa04640 Hematopoietic cell lineage 1.70661e-06 0.00020
path:hsa05330 Allograft rejection 3.03329e-06 0.00037
path:hsa05162 Measles 8.93218e-05 0.0108
path:hsa04650 Natural killer cell mediated cytotoxicity 0.00014 0.01724
path:hsa04657 IL - 17 signaling pathway 0.00037 0.04624
path:hsa05152 Tuberculosis 1.92895e-10 2.35332e-08
path:hsa05150 Staphylococcus aureus infection 4.40440e-08 5.37336e-06
path:hsa05142 Chagas disease (American trypanosomi-
asis)
7.77032e-05 0.00947
path:hsa05143 African trypanosomiasis 7.32790e-10 8.9400e-08
path:hsa05140 Leishmaniasis 1.16192e-11 1.41754e-09
path:hsa05321 Inflammatory bowel disease (IBD) 9.68744e-08 1.18186e-05
path:hsa05322 Systemic lupus erythematosus 3.51918e-05 0.00429
path:hsa05323 Rheumatoid arthritis 0.00027 0.03331
path:hsa05320 Autoimmune thyroid disease 9.62632e-06 0.00117
path:hsa05332 Graft - versus - host disease 0.00010 0.01229
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4.10 Summary
In this chapter, we constructed human functional network from human proteome and protein-protein
functional interaction data retrieved from literature and databases. We also identified human malaria
associated genes by mapping significant SNPs from GWAS summary statistics data among Gambia,
Malawi and Kenya population to gene level. We extracted host malaria–specific network from the
generated human network. These 79 identified genes were mapped onto the functional network to
identify clusters and disease-associated candidate genes encoding key proteins in the network. We
identified 32 clusters of which 7 contained candidate proteins. Out of the 7 clusters were 2 clusters
containing 6 candidate key proteins (P22301 (IL10), P05362 (ICAM1), P01375 (TNF), P30480 (HLA-
B), P16284 (PECAM1) and O00206 (TLR4)) highly relevant to malaria pathogenesis. We performed
disease-associated gene annotation enrichment analysis on the candidate key proteins to elucidate
statistically significant processes and pathways related to the disease.
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CHAPTER 5
5 Combined Human–P. falciparum Proteome Functional
Networks
The manifestation of malaria depends on the action of host system on the pathogen and the reaction
from the pathogen to the human host. From the parasite’s perspective, these actions mainly includes
the pathogen’s ability to invade the host system as well as evading host immune response by affecting
essential pathways and other processes in the host [275]. These interactions are key to the survival
of the pathogen within the host. In contrast to the parasite optimal survival mechanisms, the host re-
sponse to the invader through initiation of signaling cascade to increase defense mechanism. The pur-
pose of constructing host-pathogen network is to understand the interplay between the inter-species
PPIs to elucidate critical overlapping nodes underlying functional interactions and mechanisms essen-
tial for disease aetiology. Also, host–pathogen network analysis would contribute to understanding
possible interactions and mechanisms underlying the development of resistance to current drugs. In
this chapter, we focused mainly on interactions between our identified putative drug targets (Table
20) and the host. Also, we investigate functional interactions between malaria drug resistant genes
(Table 2) and their interactions with the identified host malaria–susceptible genes (Table 15) and its
contribution to adaptation to host immunity and development of resistance.
5.1 Functional Interaction Datasets for Constructing Host–Pathogen
Functional Network
To construct the host-pathogen network, the generated host and pathogen network together with other
host-pathogen interaction dataset retrieved from literature and databases such as InterPro, BioGrid,
DIP, HPIDB and MINT described in Table 4 were used together. Also, sequence BLAST between
the host and pathogen were used in this section to develop the unified host-pathogen network. We
applied scoring algorithms implemented in Chapters 3 and 4 to score the functional datasets prior to
generating the network. The interaction score between each pair-wise proteins ranged from 0.3 to 1.
5.2 Construction of Human–P. falciparum Functional Network
The defined scheme implemented in generating separate organism network was applied in this section.
The unified network comprised of 31,512 host-pathogen functional interactions between 8,023 nodes.
However, as most of the drug resistance genes were not yet reviewed during the time of this study, we
extracted interactions between the drug resistant genes and the host genes from interpro and sequence
blast. In total, 68,285 interactions and 8,690 nodes were used for further downstream analysis. The






where sdpq is defined as the confidence score between p and q proteins using data type d.
Figure 23 shows the distribution of the node degrees following the power law distribution. The
graphs shows that many nodes within the network are characterized by less degrees score whereas the
converse is true for few nodes.
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Figure 23. Power law degree distribution of nodes in the unified human-falciparum
functional network. The distribution shows that the network is made up of fewer nodes with
higher degree.
5.3 Investigating Potential Host–Pathogen Interactions Influencing
Resistance to Artemisinin
To explore potential mechanisms that could likely account for reduced artemisinin sensitivity pheno-
type, susceptibility and resistance development within the African populations with a view of control-
ling resistance, we investigated interactions between artemisinin–resistant genes and the host malaria
susceptible genes identified from the GWAS data. We started by filtering the host–pathogen network
(Chapter 5 section 5.2) for pairwise interactions that contained either pfk13, pfmdr1, pfcrt, pfdhps,
dhfr or any of the host malaria susceptible proteins(Table 15). We identified 410 functional interac-
tions between 431 nodes. We assessed the network formed from the extracted interactions to identify
subnetworks.
We observed disjoint subnetworks (Figure 24) between host susceptible genes and the parasite
resistant genes formed within the network. We observed that pfk13 protein (PF3D7−1343700) has
direct functional interactions (Figure 25) with other host kelch–like proteins highly expressed in
the host. Among the Kelch–like proteins are Kelch-like protein 2 (KLHL2), Kelch-like protein 18
(O94889), Kelch repeat and BTB domain-containing protein 8 (KBTBD8), Kelch domain-containing
protein 8A (KLHDC8A), Kelch repeat and BTB domain-containing protein 12 (KBTBD12), Kelch-
like protein 30 (KLHL30) and Kelch-like protein 13 (KLHL13) involved mainly in protein ubiquitina-
tion, translation regulation, post–translational protein modification and regulation of cytokinesis [93].
These interactions suggests that, regulations of protein–associated processes and pathways play a crit-
ical role in the biological activities of artemisinin particularly protein ubiquitination, knowing that the
drug targets various proteins in the parasite [276].
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Interestingly, the pfk13 protein interacts with other host regulatory genes involved in essential
processes such as transcription regulation, cell–surface, cell–cell signaling and regulation of phos-
phorylation [93]. Among the regulatory genes include the Transcriptional regulator Kaiso (ZBTB33),
Zinc finger and BTB domain-containing protein 17 (ZBTB17), BTB/POZ domain-containing protein
10 (Q9H3F6), Zinc finger and BTB domain-containing protein 10 (ZBTB10), Myoneurin (MYNN),
Nucleoprotein TPR (TPR) and Gigaxonin (GAN).
In our analysis, we did not observe a direct functional interaction between pfk13 and the host
malaria–associated genes. However, we observed a subnetwork (blue nodes) centralized by Coagu-
lation factor XIII A chain(F13A1) as shown in Figure 24. From our data, these interactions could
imply that, the contribution of pfk13 to artemisinin resistance development is likely to be modulated
by other latent genes that can provide more insight.
Figure 24. Subnetworks formed between malaria selective genes and host malaria
susceptible genes.
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Figure 25. Subnetwork comprising of 295 interactions formed between pfk13 (central node)
within the host–pathogen network.
5.4 Investigating Potential Host–Pathogen Interactions Influencing
Drug Resistance and Host Immune Tolerance through C6KTD2
and C6KTB7
Within the host–pathogen functional network, 6,139 human proteins functionally interacts with 108
candidate pathogen proteins. We investigated the functional interactions between our key candidate
proteins (Table 20) and host proteins within the constructed host–pathogen network. The purpose
was to investigate whether these key candidate proteins influence the structural integrity and the flow
of information within the host-pathogen generated functional network.
First, we analyzed the nodes that are common to subnetworks formed by C6KTD2 (Figure 26) and
C6KTB7 (Figure 27) to elucidate the connectivity between these clusters within the human–pathogen
functional network. Host proteins with uniprot ID’s Q99728, Q86YT6, Q96KQ7, Q9H9B1, Q7L622,
Q96AX9, Q9P2G1 and Q9P2R3 were found to functionally connect these clusters as shown in Figure
28. These intersecting proteins (yellow nodes in Figure 28) are involved in protein ubiquitination,
positive regulation of cell apoptotic process, signal transduction, regulatory processes and histone
methylation [93].
Knowing that genes and their products such as proteins interact with the cellular environment in
multiple levels to ensure proper functioning of the cell and biological pathways [252], our second
analysis in this section focused on elucidating genes or proteins and their related pathways that could
possibly interfere with host immune response and contribute to resistance under drug pressure. This
analysis is highly essential in drug research and proper understanding of the pathogen’s behaviour.
Such analysis would help to understand the modes and dynamic patterns underlying such processes.
Drug resistance machinery remains to be the natural driving force influencing the parasites survival
when exposed to antimalarials. Usually, the resistant mechanism and pathogen adaptiveness to host
response involves different pathways compared to the paths resulting to target inhibition by a drug
and effective immune-related pathways [277].
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In this section, we analyzed the host-pathogen functional network to investigate shortest paths
between the key candidate proteins identified in the host and pathogen functional network to gain in-
sight on the possible routes for innate immune response interference and drug resistance development.
Studies have shown that, shortest path analysis of a functional network yields high coverage compared
to direct neighbours within the network [277]. Shortest paths between host-pathogen disease asso-
ciated candidate key genes herein refers to the minimum number of edges required to connect these
genes.
Longer paths consist of more nodes involved in a cascade of signaling process to trigger innate im-
mune response by inducing the production of chemokines and cytokines upon parasite infection. It
is therefore a measure of information relay between the candidate key genes, thus, the shorter the
path the quicker the transmission. It is of noteworthy that, shortest path lengths between the pathogen
disease-associated genes and human disease-associated genes conferring immunity in the functional
network are the most feasible routes of drug resistance development [277]. Due to the dynamic pattern
of the network, shortest distance highly increases the susceptibility of human to malaria infection.
The shortest paths identified and their associated pathways as shown in Figures 29 and 30 suggests
that inhibition or alteration to the proper function of each path might help the parasites to survive
immune responses, thus, aggregation of small effects. The development of adaptive immunity and
drug resistance is expected to happen when the parasite undergoes diversity throughout time such
that they evade the host system when they become tolerant and establish different mechanisms to
interfere the host’s response. Parasite diversity could be in the form of the modulation of surface
proteins that results in the development of antiparasitic immunity leading to severe malaria. These
interferences can also be in the form of production of effector mechanisms that can down-regulate
innate immunity. We observed that, the dynamic pattern to resistance and immune adaptiveness is
mediated by other human-specific genes or proteins conferring immunity herein referred to as co-
targets. The co-targets are very critical in the resistant network such that they strongly influence the
resistance machinery [277].
In our study, we identified human immune-related genes and pathways that could be inhibited by
the pathogen, knowing that the pathology of malaria is immune mediated.
We observed potential resistance pathways between host malaria-associated protein O00206 (Toll-
like receptor 4, TLR4) and pathogen proteins C6KTB7 (Putative E3 ubiquitin-protein ligase protein
PFF1365c) and C6KTD2 (Putative histone-lysine N-methyltransferase 1, SET1).
Severe malaria is associated with an increased level of pro-inflammatory cytokines such as interleukin
(IL)-12, IL-8, and interferon (IFN)-γ in the affected person which helps to modulate defense against
the infection [278]. This is because, the severity of malaria is proportional to the flawlessness in
inflammatory response by the host.
TLR4, a pathogen–recognition receptor, detects pathogen-associated molecular mechanisms in the
body and initiates immune response through activation of signaling cascades such as nuclear factor-
kB, mitogen-activated protein kinase (MAPK) and Plasmodium antigens [278]. Toll-like receptor
4, TLR4 (O00206), and its immune-related signaling pathways have been reported to contribute sig-
nificantly to Plasmodium falciparum growth and malaria pathogenesis, such that dysregulation and
dysfunction of the gene increases malaria severity, symptomatic malaria, severe malarial anemia and
resistance in Africa [279]. This implies that inhibition of such related pathways by C6KTB7 and
C6KTD2 will contribute significantly to resistance.
In our analysis, we identified some mediators (nodes) connecting the targets (Figures 28 ). These
mediators are host proteins involved in various immune signaling pathways. These proteins are in-
volved in processes such as the toll–like receptor signaling pathway, tumor necrosis factor–mediated
signaling pathway, NF-kappaB signaling pathway, inflammatory signaling pathway, adherence–mediated
pathways, cell apoptosis pathway and the regulation of T-cell cytokine.
Furthermore, we investigated possible functional interactions or shortest paths between key proteins
in human and the pathogen that could lead to resistance. We identified O00206 (Toll-like receptor
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4, TLR4) human candidate key protein to interact with C6KTB7 (Putative E3 ubiquitin-protein ligase
protein PFF1365c) 15 possible paths through mediating nodes which are specific to human. From
our analysis, we propose the essential pathways of the mediating nodes to contribute to host immune
adaptiveness and drug resistance development. Table 21 shows the functional interactions between
O00206 and C6KTB7.
Table 20. Degree, betweenness and closeness centrality score of C6KTD2 and C6KTB7





Description Betweenness Degree Closeness
C6KTD2 SET1 Putative histone-lysine N-
methyltransferase 1
1634413.73 525 0.30214
























































































































































































































































































Figure 26. Functional interactions between C6KTB7 (green node) and other nodes in the
unified human-pathogen functional network. C6KTB7 functionally interacts with 284 human













































































































































































































































































































































































































































































































































Figure 27. Functional interactions between C6KTD2 (green node) and human proteins in
the unified human-pathogen functional network. C6KTD2 interacts with 525 human proteins
(skyblue nodes).
Figure 28. Investigating the shared proteins (yellow nodes) that connects clusters formed by
C6KTD2(left green node) and C6KTB7(right green node) in the unified human-pathogen
functional network.
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From the shortest paths networks described in Figures 29 and 30, C6KTD2 has relatively higher short
paths as compared to C6KTB7.
Table 21. Shortest paths linking O00206 and C6KTB7 nodes within the






O00206 Q9BYH8 C6KTB7 T cell receptor signaling pathway
O00206 Q05823 C6KTB7 Interferon alpha/beta signaling
O00206 Q5S007 C6KTB7 canonical Wnt signaling pathway
O00206 Q38SD2 C6KTB7 canonical Wnt signaling pathway
O00206 O75762 C6KTB7 cell surface receptor signaling pathway
O00206 Q96HA7 C6KTB7 cytoplasmic sequestering of transcription factor
O00206 Q00653 C6KTB7 NIK/NF-kappaB signaling
O00206 P25963 C6KTB7 I-kappaB kinase/NF-kappaB signaling
O00206 P46531 C6KTB7 immune response
O00206 P20749 C6KTB7 antimicrobial humoral response
O00206 P42771 C6KTB7 regulation of NF-kappaB transcription factor
activity
O00206 Q8NI38 C6KTB7 inflammatory response
O00206 P19838 C6KTB7 apoptotic process
O00206 Q8NDB2 C6KTB7 B cell activation









Figure 29. Predicted functional network that could influence resistance and host
adaptiveness between C6KTB7 (green node) and O00206 (bottom skyblue node) via
co–targets (central skyblue nodes) in the host-pathogen network.







O00206 Q13114 C6KTD2 apoptotic process
O00206 Q86WT6 C6KTD2 protein ubiquitination pathway
O00206 Q12933 C6KTD2 protein ubiquitination pathway
O00206 Q9UPN9 C6KTD2 protein ubiquitination pathway
O00206 P55895 C6KTD2 MAPK6/MAPK4 signaling
O00206 O75626 C6KTD2 adaptive immune response
O00206 Q96CA5 C6KTD2 protein ubiquitination
O00206 Q8NHM5 C6KTD2 positive regulation of cell growth
O00206 Q9BUZ4 C6KTD2 activation of NF-kappaB-inducing kinase activity
O00206 Q96P53 C6KTD2 positive regulation of protein phosphorylation
O00206 P15918 C6KTD2 adaptive immune response
O00206 P19474 C6KTD2 innate immune response
O00206 Q9Y4K3 C6KTD2 activation of MAPK activity
O00206 Q6PCT2 C6KTD2 post-translational protein modification
O00206 Q14258 C6KTD2 innate immune response
Continued on next page
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O00206 Q9UNE7 C6KTD2 protein ubiquitination pathway
O00206 Q15075 C6KTD2 endocytosis
O00206 Q8IWB7 C6KTD2 positive regulation of toll-like receptor 3 and 4 sig-
naling pathway
O00206 Q09472 C6KTD2 apoptotic process
O00206 Q8IYM9 C6KTD2 interferon-gamma-mediated signaling pathway
O00206 Q9Y2K7 C6KTD2 ubiquitin conjugation pathway
O00206 Q9NQV6 C6KTD2 regulation of gene expression
O00206 Q92793 C6KTD2 positive regulation of type I interferon production
O00206 Q6UWE0 C6KTD2 protein ubiquitination pathway
O00206 Q8WVD3 C6KTD2 protein ubiquitination pathway
O00206 Q8TCQ1 C6KTD2 protein ubiquitination pathway
O00206 Q6Q0C0 C6KTD2 protein ubiquitination pathway
O00206 O00463 C6KTD2 apoptotic process
O00206 Q13233 C6KTD2 protein phosphorylation
O00206 P98170 C6KTD2 regulation of innate immune response
O00206 Q6ZMZ0 C6KTD2 protein ubiquitination pathway
O00206 O14964 C6KTD2 protein ubiquitination pathway





































Figure 30. Shortest possible resistance pathways between C6KTD2 (green node) and
O00206 (skyblue node) via co–targets (central skyblue nodes) in the host-pathogen network.
5.5 Summary
In this chapter, we focused on two main analysis to assemble a unified human-Plasmodium falci-
parum functional network from host and pathogen proteome and other host-pathogen interacting data
retrieved from databases and literature. In the first analysis, we focused on investigating functional
interactions between parasite resistant genes and their interactions with host malaria susceptible genes
to explore potential mechanisms that could account for drug resistance during drug pressure and par-
asite diversity. Our results showed that, pfk13 forms a subnetwork (Figure 25) with other essential
regulatory host proteins but not with the host malaria susceptible genes. We propose that as the para-
site undergoes diversity, the surface protein will evolve and adapt to essential processes contributing
to the production of cytokines regulating immunity and proper functioning of the system. During
the process of evolving under the influence of drug pressure, there is a likelihood of blockage in the
inhibition and stimulatory effect of artemisinin on the host such that the host defense system such
as antibody production and T cell response becomes overwhelmed and suppressed by the pathogen’s
activities thus resulting in increased parasite clearance time and drug resistance.
In the second analysis, we investigated the network focusing on the functional interactions be-
tween our identified key candidate proteins. We predicted possible resistant pathways and adaptive
immune pathways by evaluating shortest paths between the host and pathogen key candidate pro-




6 Predicting Repurposable Drugs for Malaria Treatment
Based on Implicit Semantic Similarity
The development of human disease ontology terms [280] have provided an enriched platform of hu-
man disease data to evaluate similarities between various diseases of different disorder class based
on gene–related molecular functions. To predict repurposable drugs for malaria treatment, the list of
identified human disease candidate genes and their enriched biological processes generated from the
analysis of human functional network were exploited in this chapter to investigate their contributions
to other human–related diseases. This is to help predict repurposable treatment options that can be
appropriated for malaria. Our analysis in this chapter was based on the hypothesis that varying com-
binations of disease–associated genes can influence the pathogenicity of similar diseases [281]. This
hypothesis has been implemented in the analysis of gene expression datasets to identify breast can-
cer prognosis signatures and also to investigate disease similarities [281]. This is because, similarity
between set of human diseases does not depend entirely on the shared disease-associated genes but
rather, the biological processes influencing disease etiology. Having established earlier that proteins
or genes within a biological network function through the modularity effect, it implies that they could
contribute to specific processes within the system. Diseases are said to be similar if there are common
biological processes that contribute to disease manifestation.
In this section, we implemented an implicit semantic similarity approach to investigate different
diseases of the same disorder class as malaria. The purpose of this investigation is to measure the
similarity between enriched gene ontology annotations of our identified host candidate genes (Table
17) and the annotations related to other diseases in order to predict treatment options or repurposable
drugs that can be explored for malaria control. Similarity between two diseases is estimated by
computationally quantifying the co-occurrence of associated ontological terms among the diseases
other than exact gene matches [281].
The approach used in this chapter has been shown to perform better because it considers not only the
exact biological processes that are common but rather a systematic approach to investigating semantic
similarities between the gene ontology processes [97, 281].
6.1 Identifying Human Diseases in the Same Disorder Class with
Malaria
Identifying similarities between diseases is dependent on the ability to explore genes or variants or
biological processes shared among such diseases. In this section, we leveraged drug-target disease-
associations to compute disease similarity.
Gene ontology annotations were retrieved from gene ontology database. We retrieved gene–disease
associations from DisGeNET version 6.0 platform [282]. The platform contains about 628,685 gene-
disease associations between 17,549 genes among approximately 24,166 diseases as at the time of
our research.
Human disease ontology datasets were downloaded from disease ontology database [280]. The
disease ontology terms are linked to terminologies that contain disease and disease-related concepts
such as disease pathology (UMLS), MeSH, ICD-9 and ICD-10. The disease ontology dataset is to
facilitate the cross-walk among disease-associated genes and the disease-related concepts. Pathway
enrichment analysis of the human disease candidate genes (Table 19) elucidated diseases that the
genes are involved. However, we investigated similarities between our human-malaria candidate
genes and all human-disease genes in DisGeNet by filtering out all genes with no annotation and
maintaining appropriate genes and their associated diseases.
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To ascertain whether a disease is similar to malaria, we considered the semantic similarity score
between the pair of diseases. The score is a quantitative measure of the underlying shared biological
processes among the disease targets. A higher score between disease enriched processes suggests that
the disease–pair and their associated candidate proteins are functionally similar thus, the likelihood
for similar treatment options irrespective of the observed symptoms. The developed python–based
model implemented for disease similarity uses our identified host targets (Table 17), disease–target
datasets, gene ontology datasets as input data to predict similarity based on functional similarities
inferred from associated gene ontology terms. With a defined threshold based on the upper quartile
and interquartile range of the distribution given by tr = Q3+ε*IQR, where ε, tr, Q3 and IQR represent
the tunning parameter (0 ≤ ε ≤ 1.5 ), threshold, upper quartile and interquartile range respectively.
The tuning parameter was set to 1.5 and the defined threshold was 0.47700375 for our analysis.
Figure 31 describes the semantic similarity scores between Plasmodium falciparum malaria and other
diseases using enriched disease-associated processes.
Out of the 24,166 diseases in DisGeNet database, we identified 1,944 diseases to be semantically
similar to malaria after defining a semantic similarity score threshold. We then filtered the disease hits
by maintaining diseases whose targets are involved in the pathways of our host disease candidate key
genes. As at the time of our studies, our host candidate genes were involved in 69 pathways (Table
23). We performed this analysis by estimating the Kappa and Jaccard statistics measure(described






where σpq is defined as the observed frequency of co-occurrence between the profiles of protein p






where Ap and Aq represents the biological pathways associated to protein the profiles p and q.
The final filtered disease hits consisted of 115 as described in Table 24. These filtered disease hits
identified to be similar to malaria are mostly pathogenic diseases including but not limited to para-
sitic, viral and bacterial infections that cause the human immune defense machinery to overproduce
cytokines during host–pathogen interaction confirming the fact that malaria is an inflammatory dis-
ease [284]. These diseases fall in the category of mostly infectious, inflammatory and genetic neu-
rological diseases which are caused by non–infectious agents. Among the top disease hits includes
sickle cell anemia, liver dysfunction, fever, hepatitis and respiratory distress syndrome. The diseases
described (Table 24) have been reported to be governed by same pathologic principles as malaria
infection [284, 285].
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path:hsa05140 Leishmaniasis Infectious disease (parasitic)
path:hsa04064 NF-kappa B signaling pathway Signal transduction
path:hsa01523 Antifolate resistance
path:hsa04931 Insulin resistance Endocrine and metabolic disease
path:hsa05169 Epstein-Barr virus infection Infectious disease(viral)
path:hsa05152 Tuberculosis Infectious disease(bacterial)
path:hsa05310 Asthma Immune disease
path:hsa04933 AGE-RAGE signaling pathway in dia-
betic complications
Endocrine and metabolic disease
path:hsa04920 Adipocytokine signaling pathway Endocrine system
path:hsa04350 TGF-beta signaling pathway Signal transduction
path:hsa05150 Staphylococcus aureus infection Infectious disease(bacterial)
path:hsa04668 TNF signaling pathway Signal transduction
path:hsa05205 Proteoglycans in cancer Cancer
path:hsa04940 Type I diabetes mellitus Endocrine and metabolic disease
path:hsa04620 Toll-like receptor signaling pathway Immune system
path:hsa05321 Inflammatory bowel disease (IBD) Immune disease
path:hsa05130 Pathogenic Escherichia coli infection Infectious disease(bacterial)
path:hsa05322 Systemic lupus erythematosus Immune disease
path:hsa04630 JAK-STAT signaling pathway Signal transduction
path:hsa05330 Allograft rejection Immune disease
path:hsa05168 Herpes simplex virus 1 infection Infectious disease(viral)
path:hsa05134 Legionellosis Infectious disease(bacterial)
path:hsa04217 Necroptosis Cell growth and death
path:hsa04514 Cell adhesion molecules Signaling molecules and interac-
tion
path:hsa05416 Viral myocarditis Cardiovascular disease
path:hsa04621 NOD-like receptor signaling pathway Immune system
path:hsa05133 Pertussis Infectious disease(bacterial)
Continued on next page
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path:hsa05144 Malaria Infectious disease(parasitic)
path:hsa04071 Sphingolipid signaling pathway Signal transduction
path:hsa05162 Measles Infectious disease(viral)
path:hsa04151 PI3K-Akt signaling pathway Signal transduction
path:hsa05146 Amoebiasis Infectious disease(parasitic)
path:hsa04010 MAPK signaling pathway Signal transduction
path:hsa05010 Alzheimer disease Neurodegenerative disease
path:hsa04932 Non-alcoholic fatty liver disease
(NAFLD)
Endocrine and metabolic disease
path:hsa04380 Osteoclast differentiation Development and regeneration
path:hsa04060 Cytokine-cytokine receptor interaction Signaling molecules and interac-
tion
path:hsa05418 Fluid shear stress and atherosclerosis Cardiovascular disease
path:hsa04657 IL-17 signaling pathway Immune system
path:hsa05320 Autoimmune thyroid disease Immune disease
path:hsa04150 mTOR signaling pathway Signal transduction
path:hsa05143 African trypanosomiasis Infectious disease(parasitic)
path:hsa05132 Salmonella infection Infectious disease(bacterial)
path:hsa05165 Human papillomavirus infection Infectious disease(viral)
path:hsa04930 Type II diabetes mellitus Endocrine and metabolic disease
path:hsa04660 T cell receptor signaling pathway Immune system
path:hsa04068 FoxO signaling pathway Signal transduction
path:hsa04640 Hematopoietic cell lineage Immune system
path:hsa04664 Fc epsilon RI signaling pathway Immune system
path:hsa04622 RIG-I-like receptor signaling pathway Immune system
path:hsa05414 Dilated cardiomyopathy (DCM) Cardiovascular disease
path:hsa04670 Leukocyte transendothelial migration Immune system
path:hsa04066 HIF-1 signaling pathway Signal transduction
path:hsa05332 Graft-versus-host disease Immune disease
path:hsa05142 Chagas disease Infectious disease(parasitic)
Continued on next page
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path:hsa05014 Amyotrophic lateral sclerosis (ALS) Neurodegenerative disease
path:hsa05160 Hepatitis C Infectious disease(viral)
path:hsa04612 Antigen processing and presentation Immune system
path:hsa05410 Hypertrophic cardiomyopathy (HCM) Cardiovascular disease
path:hsa04145 Phagosome Transport and catabolism
path:hsa04650 Natural killer cell mediated cytotoxic-
ity
Immune system
path:hsa04672 Intestinal immune network for IgA pro-
duction
Immune system
path:hsa05145 Toxoplasmosis Infectious disease
path:hsa05161 Hepatitis B Infectious disease(viral)
path:hsa04210 Apoptosis Cell growth and death
path:hsa05164 Influenza A Infectious disease(viral)
path:hsa05323 Rheumatoid arthritis Immune disease
path:hsa05166 Human T-cell leukemia virus 1 infec-
tion
Infectious disease(viral)
path:hsa05167 Kaposi sarcoma Cancer
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Figure 31. Different distributions of disease similarity scores obtained in terms of
frequencies (proportions) of disease matches vs similarity scores between disease-associated
processes. The bigger rectangular bar indicates the threshold for similarity between disease
pair of which we used the enriched similarity score (ESS) for further analysis.
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Table 24. Predicted malaria–similar diseases identified using semantic similarity approach. ESS represents the estimated enriched
similarity scores.








C0001175 Acquired Immunodeficiency Syndrome 226 69 0.54266 0.0 0.30531
C0002871 Anemia 277 69 0.51979 0.0 0.24909
C0002873 Anemia of chronic disease 140 66 0.51902 -0.04288 0.47143
C0002874 Aplastic Anemia 223 68 0.51064 -0.00899 0.30493
C0002893 Refractory anemias 248 69 0.49309 0.0 0.27823
C0002895 Anemia, Sickle Cell 255 68 0.55156 -0.00786 0.26667
C0003123 Anorexia 200 68 0.52716 -0.01002 0.34
C0003864 Arthritis 270 69 0.50061 0.0 0.25556
C0006111 Brain Diseases 250 69 0.52636 0.0 0.276
C0006118 Brain Neoplasms 277 69 0.51262 0.0 0.24909
C0006287 Bronchopulmonary Dysplasia 237 69 0.5246 0.0 0.29114
C0007785 Cerebral Infarction 263 69 0.50857 0.0 0.26236
C0007786 Brain Ischemia 237 69 0.52724 0.0 0.29114
C0007789 Cerebral Palsy 201 68 0.51322 -0.00997 0.33831
C0007847 Malignant tumor of cervix 283 69 0.51019 0.0 0.24382
C0011311 Dengue Fever 196 69 0.53769 0.0 0.35204
Continued on next page
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C0011991 Diarrhea 280 69 0.53301 0.0 0.24643
C0015672 Fatigue 261 69 0.52095 0.0 0.26437
C0015674 Chronic Fatigue Syndrome 148 69 0.56246 0.0 0.46622
C0015967 Fever 228 69 0.51222 0.0 0.30263
C0018621 Hay fever 178 69 0.55729 0.0 0.38764
C0019101 Hemorrhagic Fever with Renal Syndrome 109 68 0.54928 -0.01823 0.62385
C0019158 Hepatitis 268 69 0.50801 0.0 0.25746
C0019159 Hepatitis A 253 69 0.52661 0.0 0.27273
C0019187 Hepatitis, Alcoholic 178 68 0.55737 -0.01126 0.38202
C0019189 Hepatitis, Chronic 212 69 0.53011 0.0 0.32547
C0019193 Hepatitis, Toxic 253 69 0.52166 0.0 0.27273
C0019196 Hepatitis C 285 69 0.51194 0.0 0.24211
C0019207 Hepatoma, Morris 200 66 0.53196 -0.03021 0.33
C0019208 Hepatoma, Novikoff 200 66 0.53286 -0.03021 0.33
C0020542 Pulmonary Hypertension 214 69 0.52169 0.0 0.32243
C0021400 Influenza 269 69 0.50113 0.0 0.25651
C0023267 Fibroid Tumor 248 69 0.52817 0.0 0.27823
C0023290 Leishmaniasis, Visceral 182 69 0.54409 0.0 0.37912
Continued on next page
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C0023440 Acute Erythroblastic Leukemia 236 68 0.49545 -0.00849 0.28814
C0027497 Nausea 194 67 0.52302 -0.02071 0.34536
C0027498 Nausea and vomiting 219 67 0.52054 -0.01836 0.30594
C0027540 Necrosis 177 66 0.53155 -0.03411 0.37288
C0034063 Pulmonary Edema 186 67 0.53161 -0.02160 0.36022
C0034067 Pulmonary Emphysema 227 69 0.52845 0.0 0.30396
C0034069 Pulmonary Fibrosis 254 69 0.507 0.0 0.27165
C0035220 Respiratory Distress Syndrome, Newborn 193 67 0.53741 -0.02082 0.34715
C0035222 Respiratory Distress Syndrome, Adult 238 69 0.54066 0.0 0.28992
C0035235 Respiratory Syncytial Virus Infections 183 69 0.54611 0.0 0.37705
C0035242 Respiratory Tract Diseases 171 67 0.54095 -0.02348 0.39181
C0035436 Rheumatic Fever 166 68 0.51759 -0.01207 0.40964
C0036205 Sarcoidosis, Pulmonary 152 69 0.53268 0.0 0.45395
C0036974 Shock 106 66 0.5684 -0.05525 0.62264
C0036983 Septic Shock 113 68 0.5668 -0.01761 0.60177
C0038436 Post-Traumatic Stress Disorder 203 69 0.53531 0.0 0.33990
C0040034 Thrombocytopenia 269 69 0.51614 0.0 0.25651
C0041228 African Trypanosomiasis 134 67 0.57142 -0.02982 0.5
Continued on next page
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C0041296 Tuberculosis 277 69 0.50244 0.0 0.24909
C0041327 Tuberculosis, Pulmonary 207 69 0.54692 0.0 0.33333
C0041466 Typhoid Fever 125 67 0.56711 -0.03188 0.536
C0042721 Viral hepatitis 168 67 0.51131 -0.02389 0.39881
C0085293 Hepatitis E 121 68 0.55996 -0.01648 0.56198
C0085605 Liver Failure 239 69 0.5282 0.0 0.28870
C0085742 Injuries, Acute Brain 157 67 0.54269 -0.02555 0.42675
C0086404 Experimental Hepatoma 199 66 0.53361 -0.03036 0.33166
C0086565 Liver Dysfunction 250 69 0.49199 0.0 0.276
C0151332 Active tuberculosis 114 69 0.56211 0.0 0.60526
C0152171 Idiopathic pulmonary hypertension 202 67 0.48326 -0.01989 0.33168
C0155728 Other specified transient cerebral ischemias 212 68 0.5116 -0.00946 0.32075
C0206624 Hepatoblastoma 253 69 0.52569 0.0 0.27273
C0206754 Neuroendocrine Tumors 235 68 0.51095 -0.00853 0.28936
C0220620 Gastrointestinal Carcinoid Tumor 218 68 0.49072 -0.00919 0.31193
C0220650 Metastatic malignant neoplasm to brain 220 68 0.52063 -0.00911 0.30909
C0221505 Lesion of brain 191 69 0.53327 0.0 0.36126
C0231528 Myalgia 167 68 0.53991 -0.01199 0.40719
Continued on next page
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C0235946 Cerebral atrophy 268 69 0.48964 0.0 0.25746
C0241910 Hepatitis, Autoimmune 204 69 0.52297 0.0 0.33824
C0242584 Autoimmune thrombocytopenia 160 68 0.54667 -0.01252 0.425
C0242966 Systemic Inflammatory Response Syndrome 167 69 0.5554 0.0 0.41317
C0243026 Sepsis 280 69 0.5082 0.0 0.24643
C0270611 Brain Injuries 157 67 0.54269 -0.02555 0.42675
C0271650 Impaired glucose tolerance 273 69 0.52643 0.0 0.25275
C0271907 Acquired aplastic anemia 153 66 0.53914 -0.03935 0.43137
C0272945 Brain Lacerations 157 67 0.54269 -0.02555 0.42675
C0282687 Hemorrhagic Fever, Ebola 112 67 0.56975 -0.03533 0.59821
C0375023 Respiratory syncytial virus (RSV) infection in
conditions classified elsewhere and of unspeci-
fied site
219 69 0.5294 0.0 0.31507
C0452047 Brain Injuries, Focal 157 67 0.54269 -0.02555 0.42675
C0521158 Recurrent tumor 258 67 0.53361 -0.01558 0.25969
C0524909 Hepatitis B, Chronic 230 69 0.51533 0.0 0.3
C0524910 Hepatitis C, Chronic 258 69 0.52971 0.0 0.26744
C0598935 Tumor Initiation 242 68 0.51708 -0.00829 0.28099
Continued on next page
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C0600327 Toxic Shock Syndrome 135 67 0.53981 -0.02961 0.49629
C0740391 Middle Cerebral Artery Occlusion 204 68 0.51866 -0.00983 0.33333
C0740392 Infarction, Middle Cerebral Artery 209 68 0.54169 -0.00959 0.32536
C0751690 Malignant Peripheral Nerve Sheath Tumor 212 67 0.51253 -0.01896 0.31604
C0751955 Brain Infarction 166 67 0.52277 -0.02418 0.40361
C0917798 Cerebral Ischemia 252 69 0.50236 0.0 0.27381
C0917996 Cerebral Aneurysm 149 69 0.57101 0.0 0.46309
C0948008 Ischemic stroke 258 69 0.51378 0.0 0.26744
C1145670 Respiratory Failure 208 67 0.53727 -0.01932 0.32212
C1175175 Severe Acute Respiratory Syndrome 181 68 0.55008 -0.01107 0.37569
C1262760 Hepatitis, Drug-Induced 253 69 0.52172 0.0 0.27273
C1275126 TNF receptor-associated periodic fever syn-
drome (TRAPS)
141 67 0.55724 -0.02839 0.47528
C1282496 Metastasis from malignant tumor of prostate 228 68 0.51473 -0.00879 0.29825
C1290398 Cerebral arterial aneurysm 173 69 0.55418 0.0 0.39884
C1336708 Testicular Germ Cell Tumor 207 68 0.51821 -0.00969 0.32850
C1512409 Hepatocarcinogenesis 272 68 0.52216 -0.00737 0.25
C1519666 Tumor-Associated Vasculature 140 66 0.54477 -0.04288 0.47143
Continued on next page
118











C1519670 Tumor Angiogenesis 265 69 0.51521 0.0 0.26038
C1519680 Tumor Immunity 192 68 0.54724 -0.01044 0.35417
C1658953 tumor vasculature 196 68 0.52328 -0.01023 0.34694
C1719672 Severe Sepsis 194 69 0.53222 0.0 0.35567
C1800706 Idiopathic Pulmonary Fibrosis 245 69 0.54026 0.0 0.28163
C1857276 Trichohepatoenteric Syndrome 244 68 0.48569 -0.00822 0.27869
C3203102 Idiopathic pulmonary arterial hypertension 251 69 0.50683 0.0 0.27490
C3241937 Nonalcoholic Steatohepatitis 256 68 0.52614 -0.00783 0.26563
C3263723 Traumatic injury 104 67 0.54475 -0.03776 0.64423
C3469521 Fanconi anemia, Complementation group A
(disorder)
246 69 0.52568 0.0 0.28049
C0264408 Childhood asthma 208 69 0.54101 0.0 0.33173
C0155877 Allergic asthma 211 69 0.5141 0.0 0.32701
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6.2 Identifying Putative Drug Hits
We retrieved 1,426 approved drugs and their corresponding targets from DrugBank database out of
which 1,282 were related to human. We first filtered these drugs by considering those with target–
processes associated to malaria and predicted similar diseases (Table 24). We implemented the se-
mantic approach described in (Chapter 6 section 6.1) to predict putative repurposable drugs. We
analysed the existing drugs for treating the predicted similar diseases to elucidate those diseases whose
drugs targets our predicted disease candidate genes.
From the identified drugs sharing some similarity in terms of processes, we extracted and ordered
those that are over 1.5 of the interquartile range. This subset of drugs share higher similarity. With a
defined similarity score threshold of 0.31099875 based on similarity in terms of processes the drugs
are involved, we identified 26 drug hits (Table 25). Majority of the drug hits target interleukin,
Interleukin-6, interferon (IFN)-γ and toll–like receptor as antagonist, agonist or inhibitors.
However, we observed that most of the drug hits involved in regulating host immune response to
inflammatory–driven disorders targets the Tumor necrosis factor. Such drug hits are mostly used for
the treatment of rheumatoid arthritis. Among the drug hits are chloroquine and certolizumab pegol.
Figure 32 shows the different distribution of relative frequency of drug matches against candidate
gene–drug functional similarity scores.
Figure 32. Distributions of drug similarity scores obtained in terms of relative frequency of
drug matches against functional similarity scores between candidate gene and drug.
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Table 25. Putative drug hits identified using semantic similarity approach.
Drug-ID Drug-Name ESS NRSS RSS
DB00608 Chloroquine 0.56954 0.7663 0.8063
DB08904 Certolizumab pegol 0.56393 0.7877 0.81003
DB06674 Golimumab 0.56393 0.7877 0.81003
DB00065 Infliximab 0.56393 0.7877 0.81003
DB00051 Adalimumab 0.53534 0.72775 0.75849
DB01296 Glucosamine 0.53079 0.69089 0.74441
DB00005 Etanercept 0.52932 0.72005 0.75654
DB08910 Pomalidomide 0.52833 0.69503 0.73025
DB00668 Epinephrine 0.52095 0.65483 0.69113
DB01041 Thalidomide 0.50493 0.64995 0.68472
DB01611 Hydroxychloroquine 0.40335 0.51466 0.58274
DB01250 Olsalazine 0.39014 0.47881 0.53864
DB05679 Ustekinumab 0.3856 0.4261 0.46755
DB06168 Canakinumab 0.37554 0.49231 0.55968
DB09036 Siltuximab 0.36098 0.48012 0.5382
DB01404 Ginseng 0.36071 0.4769 0.52545
DB01017 Minocycline 0.3551 0.46679 0.54531
DB08895 Tofacitinib 0.324 0.44454 0.50481
DB06273 Tocilizumab 0.31913 0.4223 0.47212
DB00029 Anistreplase 0.31537 0.40083 0.44003
DB00015 Reteplase 0.31537 0.40083 0.44003
DB00009 Alteplase 0.31537 0.40083 0.44003
DB00480 Lenalidomide 0.31461 0.41723 0.48212
DB00108 Natalizumab 0.31162 0.58395 0.62286
DB00031 Tenecteplase 0.31136 0.41706 0.4763
DB08877 Ruxolitinib 0.31119 0.44161 0.50625
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6.3 Summary
The massive disease datasets present to the bioinformatics community have resulted in a continuous
effort to understand diseases in an era whereby drug discovery is challenged by resistance and drug
failure during clinical trials. Due to that, various computational methods and tools are implemented to
harness the datasets to improve health care by translating biological knowledge into identifying drug
targets and developing effective repurposable therapeutics thus, reducing both the drug development
time and the risk of drug failure. In this chapter we implemented semantic similarity approach on
the bases of exploring gene ontology annotations and processes associations between various human
diseases to predict putative diseases in the same disorder class as malaria. The purpose of estimating
disease similarity was to enable us predict diseases whose drugs can be appropriated experimentally
for malaria treatment thus significantly reducing the cost and time involved in developing new drugs.
We primarily used disease ontology, drug-bank datasets and disease–gene association datasets to carry
out the analysis in this chapter. After defining the criteria of shared biological processes, pathways and
literature-based evidence, we identified 115 similar diseases to malaria including but not limited to
sickle cell anaemia, tuberculosis, respiratory distress, liver dysfunctioning and hepatitis as described
in Table 24. We identified putative drug hits (Table 25) including but not limited to chloroquine,
infliximab, Hydroxychloroquine, glucosamine, ginseng, minocycline, ruxolitinib and natalizumab
which can be appropriated for malaria treatment. These drug hits have been reported to control
malaria infection by inhibiting residual malaria infection, knocking parasite gene expression and acti-
vates eryptosis. Also, some of the drugs such as adalimumab, Natalizumab, etanercept, thalidomide,
ustekinumab and canakinumab are anti-TNF monoclonal antibodies and anti-inflammatory agents
that trigger immune response. Knowing that malaria is an inflammatory-response driven disease,




7 General Discussion and Conclusion
Plasmodium falciparum malaria remains to be a major public health concern especially in highly
endemic regions like Africa which contributes significantly to the global malaria morbidity and mor-
tality statistics. The continuous spread of artemisinin resistance in Southeast Asia, a region known
for founder events of chloroquine and sulphadoxine resistance, threatens the agenda of controlling
and eradicating malaria [17]. Researchers have suggested that, the emergence of artemisinin parasite
resistant strains in Africa would result in about 78 million additional cases annually [9]. Due to that,
various research are conducted in the drug discovery field to develop effective new drugs.
In the beginning section of our study, we presented known antimalarial drugs, the origin of re-
sistance and the resistant–associated variants rendering such drugs ineffective. The review of anti-
malarials provided an overview of their nature, mechanism of action and investigate those that are
currently used for malaria treatment. We followed up by reviewing various computational methods
implemented in drug discovery to complement experimental approaches. We emphasized on the role
of machine learning, data mining, genomics and biological network analysis in current drug discov-
ery pipeline. The purpose of the review was to investigate how to leverage computational approaches,
disease data and drug datasets to predict targets, protein interactions within an interactome, enriched
processes underlying disease pathology and repurposable drugs.
In this study, we aimed at elucidating potential possible mechanisms that may influence artemisinin
reduced sensitivity or resistance in Africa. We conducted protein-based analysis to explore functional
interactions between known parasite resistance genes and artemisinin drug targets to elucidate pat-
terns that might contribute to drug resistance development. Interestingly, our results (Figure 13)
showed that possible resistance to artemisinin may involve multiple parasite drug resistant genes such
as pfcrt, dhps, pfmdr1, dhfr and plasmepsin 2 (PF14−0077). This suggests the additive contribution of
drug resistant genes and their functional relationship towards antimalarial resistance. Results provide
gene/protein level functional interaction evidence on reported association of these drug resistant gene
polymorphisms. These findings may support decisions on the nature of artemisinin resistance de-
velopment involving multiple genes and the use of artemisinin combinations therapies particularly in
hyper-endemic and hypo-endemic malaria regions. The results may suggest the likelihood of combin-
ing artemisinin with other agents or the use of other antimalarials. Such initiative may help increase
drug sensitivity, thus, reducing the development and widespread of drug resistance.
Next, we performed further analysis to elucidate pfk13 functional interactions that may contribute to
possible host immune adaptiveness, artemisinin reduced sensitivity or malaria resistance in Africa by
analyzing the assembled host-pathogen functional network. Network analysis (Figure 25) revealed
that pfk13 functionally interacts with other host regulatory proteins and kelch-like genes. This may
suggest that the protein can influence and adapt to host immune response upon infection as well as
drug resistance development under drug pressure.
Furthermore, we identified potential protein targets that can play essential role for developing ef-
fective antimalarial drugs and vaccines.
We conducted protein-based analysis by leveraging the various heterogeneous experimental and in
silico datasets retrieved from databases and literature to assemble Plasmodium falciparum, human
and human-Plasmodium falciparum functional protein-protein interaction network comprising of re-
viewed proteins. Using host–malaria GWAS summary statistics datasets from Kenya, Malawi and
Gambia populations, we identified host-disease associated genes by mapping nominally significant
SNPs to their associated genes. By leveraging Blonde et al. [113] clustering algorithm, we mapped
these identified genes, malaria parasite selective variants and parasite variants under strong signature
of selection unto the host and pathogen functional network respectively to partition the network into
subnetworks (Tables 11 and 16). We observed that the subnetworks describe proteins involved in
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similar processes.
Thereafter, we leveraged the topological features of nodes within the subnetworks of each assem-
bled network to investigate nodes (candidate key proteins) that contribute significantly to the stability
and integrity of the network. We identified hub genes and performed gene annotation and enrichment
analysis to elucidate underlying statistically significant enriched biological processes and pathways of
the genes that are involved. From the parasite assembled functional network, we predicted C6KTD2
(SET1) and C6KTB7 (PFF1365c) as essential target hubs mainly involved in the protein ubiquiti-
nation and histone-lysine methylation within the parasite. SET1 is known to be involved in protein
binding (GO:0005515, GO:0019904). C6KTB7 is mainly involved in ubiquitin-protein transferase
activity (GO:0004842, GO:0019787) through the protein ubiquitination and modification pathway
(UPA00143). Studies have shown that many biological processes and substrates are targeted by the
ubiquitin pathway such that instability or modification in ubiquitination and deubiquitination reactions
influences the pathogenesis of many eukaryotic system related diseases. For instance, the dysregula-
tion of ubiquitin ligase is associated to neurodegenerative disorders such as Parkinson’s disease and
infectious diseases including tuberculosis. These targets have been reported as candidates for drug
and vaccine development. Our results confirm the essentiality of these targets. Also, our analysis
showed that these targets could be critical for combinatorial drug design.
Interactome analysis on the host functional network revealed P22301 (IL10), P05362 (ICAM1),
P01375 (TNF), P30480 (HLA-B), P16284 (PECAM1) and O00206 (TLR4) as key targets. Interest-
ingly, we observed that HLA-B encoded multiple proteins within the host network. This suggests that
HLA-B has multiple protein coding exons. This observation may suggest the viability of the gene in
Africa and its contribution towards malaria susceptibility. However, we acknowledge the role of these
hub genes in other populations, but we have insufficient data to explicitly say that there is a difference.
These host candidate key proteins are involved in immune response and resistance against malaria in-
fection including severe and cerebral malaria, thus, critical targets for adjunctive and antibody-based
therapy for malaria control [286, 287, 288]. Studies have shown that even the most potent artemisinin
derivatives in insufficient to treat severe malaria and cerebral malaria and therefore requires the ad-
ditive contribution of host-directed therapy involved in modulating host response to infection. This
may contribute significantly to improve treatment efficacy, reduce disease-associated complexity, re-
duce malaria-associated mortality and morbidity as well as slow artemisinin resistance development.
Functional analysis revealed 23 significantly enriched malaria-related biological processes described
in (Table 18) were identified. Enrichment analysis showed an overlap enriched pathways to other
infectious diseases, including tuberculosis, measles, leishmaniasis, and hepatitis (Table 23). These
findings support the evidence of similarity between diseases and overlapping gene processes under-
lying such disorders.
Next, we investigated the shortest paths to elucidate pathways that could account for parasite
adaptiveness to host response and drug resistance development (Tables 21 and 22). We investigated
the pathways of immune tolerance and potential resistance development among the host and pathogen
key targets by analyzing shortest distance between these genes with the host–Plasmodium falciparum
functional network. Our analysis showed that these shortest paths between the candidate genes or
proteins are mediated by host genes involved in cell regulatory activities, inflammatory response and
general cell integrity.(Figures 29 and 30).
Additionally, we investigated the functional interactions between reported artemisinin drug targets
and Plasmodium falciparum resistance selective genes to explore functional interactions and mecha-
nisms that can contribute to artemisinin resistance in Africa. We observed that, these selective variants
functionally interact with each other to form hubs whereas artemisinin targets functionally associates
to these hubs either by high degree or betweenness (Figure13). Also, we explored to understand
modes of resistance development and realized that, this could arise within the African populations due
to interference by pathogen candidate targets inhibiting host genes conferring immunity to malaria.
Finally, we implemented semantic similarity approach to identify 115 diseases similar to malaria
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(Table 24) that facilitate the prediction of 26 repurposable drug hits (Table 25) that can be computa-
tionally and experimentally modified for malaria treatment.
Critically, as for any other computational or in silico approaches which always need validation
through further functional study, we believe that the presented in silico (computational approach and
pipeline) can inform functional study for potential experimental and clinical validation.
7.1 Potential Impact
Identifying novel potential drugs and repurposable drugs could contribute to developing informed
hypothesis for malaria drug research. Such hypothesis could provide insights for drug repurposing
and/or discovery of highly efficient therapeutics and vaccines, thus, streamlining experimental ap-
proaches and reducing significantly the cost and drug production time.
In this study, protein-based analysis between pathogen, host and host-pathogen has contributed to
investigating functional interactions underlying disease pathogenesis and host response to infection.
Such analysis is critical to understand the genetic architecture of complex biological phenomena and
the enriched pathways and biological processes relevant for prioritizing experimental findings.
Analysis on potential resistance to current malaria drug, artemisinin, has provided insights that
could contribute to developing informed public health policies that would on the use of artemisinin
combination therapies particularly in endemic settings. This may contribute to the longevity of the
drug.
Malaria is reported to have significant measurable direct and indirect costs, thus, shown to be a
major constraint to economic development by retarding productivity and growth. This is experienced
mainly through diversion of resources to control malaria and loss of human lives which is very essen-
tial to the socio-economic development of a nation. This study has therefore contributed to knowledge
that could help in the translation of research findings in measurable outputs for malaria control.
7.2 Potential Implementation Strategies
Perturbation analysis is critical to investigate targets that exacerbate or hinder a disease. In-vitro
gene knock-out analysis on the identified targets is recommended because this could help determine
their mechanistic function, expression level and how it can be engineered and/or harnessed in drug
research. We further suggest in vivo studies to investigate the targets druggability.
We propose experimental validation of predicted drug resistant mechanisms to fully ascertain the
functional effect of protein-protein interactions and their systemic effect.
7.3 Limitations and Future Work
In this project, we based our functional networks on generated protein–protein interaction datasets
to perform our analysis between human (host) and parasite (Plasmodium falciparum). We have
used the protein–protein interaction datasets to assemble Plasmodium falciparum, Plasmodium falci-
parum malaria–specific, human and human–parasite functional networks in order to achieve results.
Nonetheless, a way to improve upon this studies is to explicitly include micro-array datasets and other
complementary biological datasets such as transcriptomic datasets and time series gene expression
data in order to comprehensively understand gene expression changes, thus improving our knowl-
edge on human-falciparum interactions to fully perform advanced computational analysis. This will
provide an insightful understanding of the conditions at which the observed functional interactions
would occur.
As at the time of our study, we observed that majority of Plasmodium falciparum protein data from
uniprot are uncharacterized. A way to improve on our study could be the application of semantic
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similarity-based approaches to functionally annotate uncharacterized parasite proteins. Such annota-
tion would contribute to increased functional datasets thus increasing power and coverage for analysis.
This approach could improve upon our analysis on exploring interactions between parasite selective
variants and existing drug targets to elucidate their role to resistance development.
Overall, our current study results have provided insights to the dynamic patterns of human-Plasmodium




Table A1. Host Malaria–specific genes and other host genes predicted from functional
interaction generated from genemania database.
Gene Description
OR51V1 olfactory receptor family 51 subfamily V member 1
NANOS2 nanos C2HC-type zinc finger 2
FREM3 FRAS1 related extracellular matrix 3
BGLAP bone gamma-carboxyglutamate protein
MARVELD3 MARVEL domain containing 3
SCO1 SCO1 cytochrome c oxidase assembly protein
GYPB glycophorin B
IL4 interleukin 4
USP38 ubiquitin specific peptidase 38
GYPA glycophorin A (MNS blood group)
ATP2B4 ATPase plasma membrane Ca2+ transporting 4
INPP4B inositol polyphosphate-4-phosphatase type II B
HBE1 hemoglobin subunit epsilon 1
HLA-DRB5 major histocompatibility complex, class II, DR beta 5
G6PD glucose-6-phosphate dehydrogenase
AMH anti-Mullerian hormone
TLR9 toll like receptor 9
IL13 interleukin 13
TLR4 toll like receptor 4
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic
HP haptoglobin
CR1 complement component 3b/4b receptor 1 (Knops blood group)
HLA-B major histocompatibility complex, class I, B
FCGR3B Fc fragment of IgG receptor IIIb
FCGR2A Fc fragment of IgG receptor IIa
IL10 interleukin 10
Continued on next page
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Table A1 – continued from previous page
Gene Description
HBB hemoglobin subunit beta
IL1RN interleukin 1 receptor antagonist
FCGR3A Fc fragment of IgG receptor IIIa
MBL2 mannose binding lectin 2
TNFAIP1 TNF alpha induced protein 1
PSMB9 proteasome subunit beta 9
DDC dopa decarboxylase
ACKR1 atypical chemokine receptor 1
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor)
HMOX1 heme oxygenase 1
CD36 CD36 molecule
TNF tumor necrosis factor
NOS2 nitric oxide synthase 2
IL1B interleukin 1 beta
IRF1 interferon regulatory factor 1
ICAM1 intercellular adhesion molecule 1
HMOX2 heme oxygenase 2
NANOS3 nanos C2HC-type zinc finger 3
NANOS1 nanos C2HC-type zinc finger 1
DDTL D-dopachrome tautomerase-like
SCARB1 scavenger receptor class B member 1
HMX3 H6 family homeobox 3
DDT D-dopachrome tautomerase
CXCL1 C-X-C motif chemokine ligand 1
HBD hemoglobin subunit delta
HBG1 hemoglobin subunit gamma 1
FREM2 FRAS1 related extracellular matrix protein 2
APCS amyloid P component, serum
IL10RA interleukin 10 receptor subunit alpha
IL1R2 interleukin 1 receptor type 2
Continued on next page
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Table A1 – continued from previous page
Gene Description
HBG2 hemoglobin subunit gamma 2
SELT selenoprotein T
CR2 complement component 3d receptor 2
SCARB2 scavenger receptor class B member 2
GYPC glycophorin C (Gerbich blood group)
MGP matrix Gla protein
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